0001375151-18-000085.txt : 20181108 0001375151-18-000085.hdr.sgml : 20181108 20181108170835 ACCESSION NUMBER: 0001375151-18-000085 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181108 DATE AS OF CHANGE: 20181108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZOGENIX, INC. CENTRAL INDEX KEY: 0001375151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205300780 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34962 FILM NUMBER: 181170534 BUSINESS ADDRESS: STREET 1: 5858 HORTON STREET, #455 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: (510) 550-8300 MAIL ADDRESS: STREET 1: 5858 HORTON STREET, #455 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: ZOGENIX INC DATE OF NAME CHANGE: 20060911 10-Q 1 zgnx-20180930.htm 10-Q Document
falseSeptember 30, 20182018Q3ZGNXZOGENIX, INC.Accelerated FilerFALSEFALSE0001375151--12-310.0010.00150,00050,00041,9253480841,92534,8080.0010.00110,00010,000————P5Y2.801.902.301.902.902.102.902.303.56.13.55.16.16.16.16.179.975.179.975.183.275.585.276.600013751512018-01-012018-09-30xbrli:shares00013751512018-10-31iso4217:USD00013751512018-09-3000013751512017-12-31iso4217:USDxbrli:shares00013751512018-07-012018-09-3000013751512017-07-012017-09-3000013751512017-01-012017-09-3000013751512016-12-3100013751512017-09-300001375151us-gaap:CommercialPaperMember2018-09-300001375151us-gaap:CorporateDebtSecuritiesMember2018-09-300001375151us-gaap:MoneyMarketFundsMember2018-09-300001375151us-gaap:BankTimeDepositsMember2018-09-300001375151us-gaap:USTreasurySecuritiesMember2018-09-300001375151us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2018-09-300001375151us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2018-09-300001375151us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2018-09-300001375151us-gaap:CommercialPaperMember2018-09-300001375151us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2018-09-300001375151us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2018-09-300001375151us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2018-09-300001375151us-gaap:CorporateDebtSecuritiesMember2018-09-300001375151us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2018-09-300001375151us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2018-09-300001375151us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2018-09-300001375151us-gaap:MoneyMarketFundsMember2018-09-300001375151us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Member2018-09-300001375151us-gaap:FairValueInputsLevel2Memberus-gaap:BankTimeDepositsMember2018-09-300001375151us-gaap:FairValueInputsLevel3Memberus-gaap:BankTimeDepositsMember2018-09-300001375151us-gaap:BankTimeDepositsMember2018-09-300001375151us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2018-09-300001375151us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2018-09-300001375151us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2018-09-300001375151us-gaap:USTreasurySecuritiesMember2018-09-300001375151us-gaap:FairValueInputsLevel1Member2018-09-300001375151us-gaap:FairValueInputsLevel2Member2018-09-300001375151us-gaap:FairValueInputsLevel3Member2018-09-300001375151us-gaap:FairValueInputsLevel1Memberzgnx:CommonStockWarrantLiabilityMember2018-09-300001375151us-gaap:FairValueInputsLevel2Memberzgnx:CommonStockWarrantLiabilityMember2018-09-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:CommonStockWarrantLiabilityMember2018-09-300001375151zgnx:CommonStockWarrantLiabilityMember2018-09-300001375151zgnx:ContingentPurchaseConsiderationMemberus-gaap:FairValueInputsLevel1Member2018-09-300001375151zgnx:ContingentPurchaseConsiderationMemberus-gaap:FairValueInputsLevel2Member2018-09-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:ContingentPurchaseConsiderationMember2018-09-300001375151zgnx:ContingentPurchaseConsiderationMember2018-09-300001375151us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2017-12-310001375151us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2017-12-310001375151us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2017-12-310001375151us-gaap:MoneyMarketFundsMember2017-12-310001375151us-gaap:FairValueInputsLevel1Memberzgnx:CommonStockWarrantLiabilityMember2017-12-310001375151us-gaap:FairValueInputsLevel2Memberzgnx:CommonStockWarrantLiabilityMember2017-12-310001375151us-gaap:FairValueInputsLevel3Memberzgnx:CommonStockWarrantLiabilityMember2017-12-310001375151zgnx:CommonStockWarrantLiabilityMember2017-12-310001375151zgnx:ContingentPurchaseConsiderationMemberus-gaap:FairValueInputsLevel1Member2017-12-310001375151zgnx:ContingentPurchaseConsiderationMemberus-gaap:FairValueInputsLevel2Member2017-12-310001375151us-gaap:FairValueInputsLevel3Memberzgnx:ContingentPurchaseConsiderationMember2017-12-310001375151zgnx:ContingentPurchaseConsiderationMember2017-12-310001375151us-gaap:FairValueInputsLevel1Member2017-12-310001375151us-gaap:FairValueInputsLevel2Member2017-12-310001375151us-gaap:FairValueInputsLevel3Member2017-12-310001375151zgnx:ZX008Member2018-09-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:ContingentPurchaseConsiderationMember2018-06-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:ContingentPurchaseConsiderationMember2018-07-012018-09-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:ContingentPurchaseConsiderationMember2017-06-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:ContingentPurchaseConsiderationMember2017-07-012017-09-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:ContingentPurchaseConsiderationMember2017-09-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:CommonStockWarrantLiabilityMember2018-06-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:CommonStockWarrantLiabilityMember2018-07-012018-09-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:CommonStockWarrantLiabilityMember2017-06-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:CommonStockWarrantLiabilityMember2017-07-012017-09-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:CommonStockWarrantLiabilityMember2017-09-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:ContingentPurchaseConsiderationMember2018-01-012018-09-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:ContingentPurchaseConsiderationMember2016-12-310001375151us-gaap:FairValueInputsLevel3Memberzgnx:ContingentPurchaseConsiderationMember2017-01-012017-09-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:CommonStockWarrantLiabilityMember2018-01-012018-09-300001375151us-gaap:FairValueInputsLevel3Memberzgnx:CommonStockWarrantLiabilityMember2016-12-310001375151us-gaap:FairValueInputsLevel3Memberzgnx:CommonStockWarrantLiabilityMember2017-01-012017-09-30zgnx:lease0001375151us-gaap:SubsequentEventMember2018-10-310001375151us-gaap:ScenarioForecastMember2019-01-012019-09-300001375151us-gaap:CommonStockMember2018-01-012018-09-30xbrli:pure0001375151us-gaap:CommonStockMember2018-04-012018-06-300001375151us-gaap:CommonStockMember2018-08-012018-08-310001375151zgnx:NonemployeeDirectorMember2018-03-310001375151zgnx:NonemployeeDirectorMember2018-02-280001375151us-gaap:PerformanceSharesMember2018-09-300001375151us-gaap:PerformanceSharesMember2018-07-012018-09-300001375151us-gaap:RestrictedStockUnitsRSUMember2017-12-310001375151us-gaap:RestrictedStockUnitsRSUMember2018-01-012018-09-300001375151us-gaap:RestrictedStockUnitsRSUMember2018-09-300001375151us-gaap:RestrictedStockUnitsRSUMemberzgnx:EmployeesandExecutivesMember2018-09-300001375151us-gaap:EmployeeStockOptionMember2018-07-012018-09-300001375151us-gaap:EmployeeStockOptionMember2017-07-012017-09-300001375151us-gaap:EmployeeStockOptionMember2018-01-012018-09-300001375151us-gaap:EmployeeStockOptionMember2017-01-012017-09-300001375151us-gaap:CostOfSalesMember2018-07-012018-09-300001375151us-gaap:CostOfSalesMember2017-07-012017-09-300001375151us-gaap:CostOfSalesMember2018-01-012018-09-300001375151us-gaap:CostOfSalesMember2017-01-012017-09-300001375151us-gaap:ResearchAndDevelopmentExpenseMember2018-07-012018-09-300001375151us-gaap:ResearchAndDevelopmentExpenseMember2017-07-012017-09-300001375151us-gaap:ResearchAndDevelopmentExpenseMember2018-01-012018-09-300001375151us-gaap:ResearchAndDevelopmentExpenseMember2017-01-012017-09-300001375151us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-07-012018-09-300001375151us-gaap:SellingGeneralAndAdministrativeExpensesMember2017-07-012017-09-300001375151us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-01-012018-09-300001375151us-gaap:SellingGeneralAndAdministrativeExpensesMember2017-01-012017-09-300001375151srt:MinimumMemberus-gaap:EmployeeStockOptionMember2018-07-012018-09-300001375151srt:MinimumMemberus-gaap:EmployeeStockOptionMember2017-07-012017-09-300001375151srt:MinimumMemberus-gaap:EmployeeStockOptionMember2018-01-012018-09-300001375151srt:MinimumMemberus-gaap:EmployeeStockOptionMember2017-01-012017-09-300001375151us-gaap:EmployeeStockOptionMembersrt:MaximumMember2018-07-012018-09-300001375151us-gaap:EmployeeStockOptionMembersrt:MaximumMember2017-07-012017-09-300001375151us-gaap:EmployeeStockOptionMembersrt:MaximumMember2018-01-012018-09-300001375151us-gaap:EmployeeStockOptionMembersrt:MaximumMember2017-01-012017-09-300001375151us-gaap:StockOptionMember2018-07-012018-09-300001375151us-gaap:StockOptionMember2017-07-012017-09-300001375151us-gaap:StockOptionMember2018-01-012018-09-300001375151us-gaap:StockOptionMember2017-01-012017-09-300001375151us-gaap:RestrictedStockUnitsRSUMember2018-07-012018-09-300001375151us-gaap:RestrictedStockUnitsRSUMember2017-07-012017-09-300001375151us-gaap:RestrictedStockUnitsRSUMember2018-01-012018-09-300001375151us-gaap:RestrictedStockUnitsRSUMember2017-01-012017-09-300001375151us-gaap:WarrantMember2018-07-012018-09-300001375151us-gaap:WarrantMember2017-07-012017-09-300001375151us-gaap:WarrantMember2018-01-012018-09-300001375151us-gaap:WarrantMember2017-01-012017-09-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
___________________________________________
FORM 10-Q
___________________________________________
(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2018 
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             
Commission file number: 001-34962 
___________________________________________
Zogenix, Inc.
(Exact Name of Registrant as Specified in its Charter)
____________________________________________ 
Delaware
20-5300780
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer
Identification No.)
5858 Horton Street, Suite 455
Emeryville, California
94608 
(Address of Principal Executive Offices)
(Zip Code)
510-550-8300
(Registrant’s Telephone Number, Including Area Code)
 ____________________________________________
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    x  Yes    ¨  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
¨
Accelerated filer
x
Non-accelerated filer
¨
Smaller reporting company
¨
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    ¨  Yes    x  No
The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of October 31, 2018 was  41,968,019.


ZOGENIX, INC.
FORM 10-Q
For the Quarterly Period Ended September 30, 2018 
Table of Contents
 
Page

2

PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
Zogenix, Inc.

Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except par value)
 
September 30, 2018December 31, 2017
Assets: 
Current assets: 
Cash and cash equivalents $163,038 $293,503 
Marketable securities 376,087 — 
Prepaid expenses 6,861 5,994 
Other current assets 1,286 5,206 
Total current assets 547,272 304,703 
Property and equipment, net 244 245 
Intangible assets 102,500 102,500 
Goodwill 6,234 6,234 
Other assets 3,380 3,931 
Total assets $659,630 $417,613 
Liabilities and stockholders’ equity: 
Current liabilities: 
Accounts payable $4,110 $3,356 
Accrued clinical trial expenses 10,674 8,657 
Accrued compensation 5,039 6,616 
Other accrued liabilities 2,413 1,842 
Current portion of contingent consideration 32,500 — 
Common stock warrant liabilities 607 512 
Total current liabilities 55,343 20,983 
Contingent consideration, net of current portion 47,600 76,900 
Deferred income taxes 17,425 17,425 
Other long-term liabilities 482 784 
Total liabilities 120,850 116,092 
Commitments and contingencies 
Stockholders’ equity: 
Preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding — — 
Common stock, $0.001 par value; 50,000 shares authorized; 41,925 and 34,808 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively 42 35 
Additional paid-in capital 1,212,305 873,526 
Accumulated deficit (673,521)(572,040)
Accumulated other comprehensive loss (46)— 
Total stockholders’ equity 538,780 301,521 
Total liabilities and stockholders’ equity $659,630 $417,613 
See accompanying notes to the unaudited condensed consolidated financial statements.
3

Zogenix, Inc.

Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except per share amounts)
Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Contract manufacturing revenue $— $— $— $9,821 
Costs and expenses: 
Cost of contract manufacturing — — — 10,729 
Research and development 27,608 21,178 77,329 49,369 
Selling, general and administrative 11,016 6,073 27,663 18,129 
Loss on contract termination — 478 — 478 
Asset impairment charges — 196 — 1,116 
Change in fair value of contingent consideration 5,700 10,500 3,200 11,600 
Total costs and expenses 44,324 38,425 108,192 91,421 
Loss from operations (44,324)(38,425)(108,192)(81,600)
Other income (expense): 
Interest income 2,133 121 3,995 332 
Interest expense — (702)(6)(2,065)
Loss on extinguishment of debt — (3,378)— (3,378)
Change in fair value of common stock warrant liabilities (64)(380)(95)360 
Other (expense) income, net (9)62 3,015 71 
Total other income (expense) 2,060 (4,277)6,909 (4,680)
Loss from continuing operations before income taxes (42,264)(42,702)(101,283)(86,280)
Income tax benefit — 42 — 41 
Net loss from continuing operations (42,264)(42,660)(101,283)(86,239)
Loss from discontinued operations, net of taxes — (134)(198)(870)
Net loss $(42,264)$(42,794)$(101,481)$(87,109)
Net loss per share, basic and diluted: 
Continuing operations $(1.08)$(1.68)$(2.78)$(3.45)
Discontinued operations — — — (0.03)
Total $(1.08)$(1.68)$(2.78)$(3.48)
Weighted average common shares used in the calculation of basic and diluted net loss per common share 39,242 25,431 36,485 25,024 
See accompanying notes to the unaudited condensed consolidated financial statements.
4

Zogenix, Inc.

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)
(in thousands)
Three Months Ended September 30,Nine Months Ended September 30,
2018201720182017
Net loss $(42,264)$(42,794)$(101,481)$(87,109)
Other comprehensive income (loss): 
Change in unrealized losses on marketable securities, net of tax (46)— (46)— 
Comprehensive loss $(42,310)$(42,794)$(101,527)$(87,109)
See accompanying notes to the unaudited condensed consolidated financial statements.
5

Zogenix, Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
 
Nine Months Ended September 30, 
20182017
Cash flow from operating activities: 
Net loss $(101,481)$(87,109)
Adjustments to reconcile net loss to net cash used in operating activities: 
Stock-based compensation 11,952 4,066 
Depreciation and amortization 76 408 
Amortization of debt issuance costs and debt discount — 753 
Net accretion and amortization of investments in marketable securities
(521)— 
Loss on extinguishment of debt — 3,378 
Inventory write-down — 2,232 
Asset impairment charges — 1,116 
Change in fair value of common stock warrant liabilities 95 (360)
Change in fair value of contingent consideration 3,200 11,600 
Changes in operating assets and liabilities: 
Trade accounts receivable — 9,356 
Inventory — 2,583 
Prepaid expenses and other current assets 1,429 4,996 
Other assets 551 (2,413)
Accounts payable, accrued and other liabilities 1,463 4,204 
Deferred revenue — (1,245)
Net cash used in operating activities (83,236)(46,435)
Cash flows from investing activities: 
Purchases of marketable securities (375,612)— 
Purchases of property and equipment (75)(35)
Net cash used in investing activities (375,687)(35)
Cash flows from financing activities: 
Proceeds from issuance of common stock under equity incentive plans 6,749 271 
Taxes paid related to net share settlement of equity awards (1,426)— 
Proceeds from issuance of common stock, net of issuance costs 323,135 19,378 
Net cash provided by financing activities 328,458 19,649 
Net decrease in cash and cash equivalents (130,465)(26,821)
Cash and cash equivalents, beginning of the period 293,503 91,551 
Cash and cash equivalents, end of the period $163,038 $64,730 
Noncash financing activities: 
Extinguishment of Endo working capital advance note payable through net settlement of balances owed to the Company $— $7,000 
See accompanying notes to the unaudited condensed consolidated financial statements.
6

Zogenix, Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)
 
Note 1 – Organization and Basis of Presentation
Zogenix, Inc., including its wholly-owned subsidiaries (the “Company”), is a pharmaceutical company developing and commercializing innovative central nervous system (“CNS”) therapies for people living with serious and life-threatening rare CNS disorders and medical conditions. The Company’s current primary area of therapeutic focus is rare, or “orphan” childhood-onset epilepsy disorders and its lead product candidate is ZX008. ZX008 is currently being developed for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut Syndrome. The Company operates in one business segment—the research, development and commercialization of pharmaceutical products and its headquarters are located in Emeryville, California.
Basis of Presentation
The accompanying condensed consolidated financial statements include the accounts of Zogenix, Inc. and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. In the opinion of management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. Certain reclassifications have been made to the prior period amounts to conform to the current year presentation. “Accrued clinical trial expenses” and “Other accrued liabilities”, which previously were reported as “Accrued expenses” on the condensed consolidated balance sheet, are now reported as separate line items. Additionally, previously reported “Interest expense, net” has been reclassified to present interest income and interest expense separately in the accompanying condensed consolidated statements of operations. The results of operations for any interim period are not necessarily indicative of results of operations for any future period. Certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted. Accordingly, these unaudited interim condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on March 6, 2018.
Future Funding Requirements
Excluding gains from two discrete business divestitures, the Company has incurred significant net losses and negative cash flows from operating activities since inception resulting in an accumulated deficit of $673.5 million at September 30, 2018. The Company expects to continue to incur significant operating losses and negative cash flows from operations to advance its product candidates through development and commercialization. Additionally, upon acceptance of the Company’s regulatory submissions for ZX008 by the U.S. Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”) and regulatory approval of ZX008 by the FDA or EMA, if at all, each a milestone event, the Company will owe milestone payments under an existing agreement in connection with the Company’s prior acquisition of ZX008. To date, the Company has relied primarily on the proceeds from equity offerings to finance its operations. See Note 6 for the Company's recent equity offerings.
Until the Company can generate a sufficient amount of revenue to finance its cash requirements, if ever, the Company may need to continue to rely on additional financing to achieve its business objectives. However, if such financing is not available at adequate levels when needed, the Company may be required to significantly delay, scale back or discontinue one or more of the product development programs or commercialization efforts or other aspects of its business plans, and its operating results and financial condition would be adversely affected.
7

Note 2 – Summary of Significant Accounting Policies
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Significant Accounting Policies
There have been no material changes to the Company’s significant accounting policies from those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, other than as set forth below.
Cash Equivalents and Marketable Securities
The Company considers cash equivalents to be only those investments which are highly liquid, readily convertible to cash and have an original maturity of three months or less at the date of purchase.
The Company invests its excess cash in marketable securities with high credit ratings that are classified as Level 1 and Level 2 within the fair value hierarchy. These marketable securities consists of money market funds and certificate of deposits, securities issued by the U.S. government and its agencies, corporate debt securities and commercial paper, which are all classified as “available-for-sale”. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and, therefore, classifies all securities with maturity dates beyond three months at the date of purchase as current assets on the condensed consolidated balance sheets. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the condensed consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on marketable securities are included in interest income (expense), net. The cost of securities sold is determined using the specific identification method.
The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and management’s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value.
Concentration of Credit Risk
Cash, cash equivalents and marketable securities are financial instruments that potentially subject the Company to concentration of credit risk. The Company invests its excess cash primarily in money market funds and certificate of deposits, securities issued by the U.S. government and its agencies, corporate debt securities and commercial paper. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe it is exposed to any significant credit risk related to these instruments. 
Accounting Pronouncements Recently Adopted
Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) and subsequent amendments to the initial guidance (collectively, “Topic 606”) amended the existing accounting standards for revenue recognition. The core principle of Topic 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. The Company adopted Topic 606 effective January 1, 2018 using the modified retrospective approach. The adoption of Topic 606 did not have a material impact on the Company’s condensed consolidated financial statements as the Company does not have any contracts with customers.
ASU 2016-15, Statement of Cash Flows (Topic 230) provides guidance on eight specific cash flow issues, thereby reducing the diversity in practice in how certain transactions are classified in the statement of cash flows. The amendments in this ASU are applied using a retrospective transition method to each period presented. The Company adopted ASU 2016-15
8

effective January 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.
ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business narrows the definition of a business and provides additional guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This accounting standards update is required to be applied prospectively to transactions occurring after the date of adoption. The Company adopted ASU 2017-09 effective January 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.
ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting provides guidance on determining changes to the terms and conditions of share-based payment awards and require an entity to apply modification accounting under Topic 718 unless all of the following conditions are met: (1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification; (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The amendments should be applied prospectively to an award modified on or after the adoption date. The Company adopted ASU 2017-09 effective January 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.
On December 22, 2017, the U.S. federal government enacted the Tax Cuts and Jobs Act (“the Act”). The Tax Act contains, among other things, significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% for tax years beginning after December 31, 2017, limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, implementing a territorial tax system, and requiring a mandatory one-time tax on U.S. owned undistributed foreign earnings and profits known as the transition tax. In December 2017, SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) to address the accounting implications of recently enacted U.S. federal tax reform. SAB 118 allows companies to record provisional amounts during a measurement period not to extend beyond one year of the enactment date to address ongoing guidance and tax interpretations that are expected over the next 12 months. The Company has adopted SAB 118 and currently considers its accounting of the impact of U.S. federal tax reform to be incomplete but continues to make a reasonable estimate of the effects on our existing deferred tax assets. The Company expects to complete the remainder of the analysis within the measurement period in accordance with SAB 118. Adjustments, if any, are not expected to impact the condensed consolidated statement of operations and comprehensive loss due to the full valuation allowance on the Company’s deferred tax assets.
ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting simplifies the accounting for share-based payment awards issued to nonemployees for goods and services, including fixing the estimated fair value of the stock award at the date of grant. ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The adoption of ASU 2018-07 requires a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year. ASU 2018-07 is effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company early adopted ASU 2018-07 effective July 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.
In August 2018, the SEC adopted amendments to certain disclosure requirements in Securities Act Release No. 33-10532, Disclosure Update and Simplification. These amendments eliminate, modify, or integrate into other SEC requirements certain disclosure rules. Among the amendments is the requirement to present an analysis of changes in stockholders’ equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments became effective for all filings made on or after November 5, 2018. In light of the anticipated timing of effectiveness of the amendments and expected proximity of effectiveness to the filing date for most filers’ quarterly reports, the SEC’s Division of Corporate Finance issued a Compliance and Disclosure Interpretation related to Exchange Act Forms, or CDI – Question 105.09, that provides transition guidance related to this disclosure requirement. CDI – Question 105.09 states that the SEC would not object if the filer’s first presentation of the changes in shareholders’ equity is included in its Form 10-Q for the quarter that begins after the effective date of the amendments. Except for the requirement to provide the annual disclosure
9

changes in stockholders’ equity for interim periods, which will be included beginning with the Company's quarterly report on Form 10-Q ending March 31, 2019, the Company has adopted all relevant disclosure requirements.
Accounting Pronouncements Issued But Not Yet Effective
ASU 2016-02, Leases (Topic 842) establishes a right-of-use model (“ROU”) that requires all lessees to recognize ROU assets and liabilities for leases with a duration greater than one year on the balance sheet as well as provide disclosures with respect to certain qualitative and quantitative information regarding the amount, timing and uncertainty of cash flows arising from leases. Both a ROU asset and liability will initially be measured at the present value of the future minimum lease payments over the lease term. Subsequent measurement, including the presentation of expenses and cash flows, will depend on the classification of the lease as either a finance or an operating lease. Initial costs directly attributable to negotiating and arranging the lease will be included in the asset. The new standard is effective for fiscal years beginning after December 15, 2018, and interim periods therein. Early adoption is permitted. Originally, entities were required to adopt ASU 2016-02 using a modified retrospective approach, which required prior periods to be presented under this new standard with various practical expedients allowed. In July 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption (January 1, 2019) while continuing to present all prior periods under previous lease accounting guidance. The Company intends to adopt the standard on January 1, 2019 by recognizing a cumulative effect adjustment to the opening balance of retained earnings and utilizing the practical expedient that allows the Company to not reassess whether an expired or existing contract contains a lease, the classification of leases or initial direct costs. The Company is in the process of inventorying and scoping its existing lease contracts. While the Company is currently evaluating the impact of adopting this accounting standard update on its condensed consolidated financial statements and related disclosures, the Company anticipates that ROU assets and corresponding liabilities will be recognized in its condensed consolidated balance sheets related to its lease arrangements. The adoption of these standards are also expected to impact the Company’s condensed consolidated financial statement disclosures.
ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. Under the amendments in ASU 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds its fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The updated guidance requires a prospective adoption. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the timing and impact of adopting this ASU on its condensed consolidated financial statements and related disclosures.
ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement modifies the disclosure requirements in Topic 820, Fair Value Measurement, by removing certain disclosure requirements related to the fair value hierarchy, modifying existing disclosure requirements related to measurement uncertainty and adding new disclosure requirements, such as disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and disclosing the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for public companies for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year. Early adoption is permitted for any removed or modified disclosures. The Company is currently evaluating the timing and impact of adopting this ASU on its condensed consolidated financial statements and related disclosures.
Note 3 – Cash, Cash Equivalents and Marketable Securities
The following table summarizes the amortized cost and fair value of the Company's cash, cash equivalents and marketable securities as of September 30, 2018 (in thousands):

10

Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value 
(in thousands)
Current assets: 
Cash $4,747 $— $— $4,747 
Cash equivalents: 
Commercial paper 58,127 — — 58,127 
Corporate debt securities 1,624 — — 1,624 
Money market funds 97,686 — — 97,686 
Certificate of deposits 854 — — 854 
Total cash equivalents 158,291 — — 158,291 
Total cash and cash equivalents 163,038 — — 163,038 
Marketable securities: 
Commercial paper 174,769 1 (1)174,769 
Corporate debt securities 47,416 — (30)47,386 
Certificate of deposits 118,775 — — 118,775 
U.S. Treasuries 35,173 — (16)35,157 
Total marketable securities 376,133 1 (47)376,087 
Total cash, cash equivalents and marketable securities $539,171 $1 $(47)$539,125 
The following table summarizes the cost and fair value of marketable securities based on stated effective maturities as of September 30, 2018 (in thousands):
Amortized Cost Fair Value 
Due within one year $345,678 $345,644 
Due between one and two years 30,455 30,443 
Total $376,133 $376,087 
The Company did not hold any marketable securities as of December 31, 2017.
There have been no significant realized gains or losses on available-for-sale securities for the periods presented. Available-for-sale debt securities that were in a continuous loss position but were not deemed to be other than temporarily impaired were immaterial at September 30, 2018.
See Note 4 for further information regarding the fair value of the Company's financial instruments.
Note 4 – Fair Value Measurements
The carrying amount of the Company’s financial instruments, including cash and cash equivalents, other current assets, accounts payable, accrued and other current liabilities approximate their fair value due to their short maturities.
Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
Level 1: 
Observable inputs such as quoted prices in active markets;
Level 2: 
Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3: 
Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
The following tables summarize assets and liabilities recognized or disclosed at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 (in thousands):

11

Level 1 Level 2 Level 3 Total 
September 30, 2018
Assets: 
Cash equivalents: 
Commercial paper $— $58,127 $— $58,127 
Corporate debt securities — 1,624 — 1,624 
Money market funds 97,686 — — 97,686 
Certificate of deposits — 854 — 854 
Marketable securities 
Commercial paper — 174,769 — 174,769 
Corporate debt securities — 47,386 — 47,386 
Certificate of deposits — 118,775 — 118,775 
U.S. Treasuries — 35,157 — 35,157 
Total assets(1) $97,686 $436,692 $— $534,378 
Liabilities: 
Common stock warrant liabilities(2) $— $— $607 $607 
Contingent consideration liabilities(3) — — 80,100 80,100 
Total liabilities $— $— $80,707 $80,707 

Level 1 Level 2 Level 3 Total 
December 31, 2017
Assets: 
Cash equivalents consisting of money market funds(1) $289,782 $— $— $289,782 
Total assets $289,782 $— $— $289,782 
Liabilities: 
Common stock warrant liabilities(2) $— $— $512 $512 
Contingent consideration liabilities(3) — — 76,900 76,900 
Total liabilities $— $— $77,412 $77,412 

(1) Fair value is determined by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry standard valuation models, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.
(2) Represents the fair value of common stock warrants outstanding that may require cash settlement under certain circumstances. The Company estimated the fair value of the warrant liabilities using the Black-Scholes valuation model. As of December 31, 2017 and September 30, 2018, common stock warrant liabilities relate to warrants issued in July 2011 in connection with a debt financing arrangement. The warrants entitle the holder to purchase up to 28,125 shares of common stock at an exercise price of $72.00 per share. The warrants will expire in July 2021.
(3) In connection with a prior acquisition, the Company may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. The Company estimated the fair value of the contingent consideration liabilities on the acquisition date using a probability-weighted income approach, which reflects the probability and timing of future payments. This fair value measurement is based on significant Level 3 inputs such as the anticipated timelines and probability of achieving development, regulatory approval or sales-based milestone events and projected revenues. The resulting probability-weighted cash flows are discounted at risk-adjusted rates. Subsequent to the acquisition date, at each reporting period prior to settlement, the Company revalues these liabilities by performing a review of the assumptions listed above and record increases or decreases in the fair value of these contingent consideration liabilities. In the absence of any significant changes in key assumptions, the quarterly determination of fair values of these contingent consideration liabilities would primarily reflect the passage of time and
12

risk-adjusted interest rates. Significant judgment is used in determining Level 3 inputs and fair value measurements as of the acquisition date and for each subsequent reporting period. Updates to assumptions could have a significant impact on the Company’s results of operations in any given period and actual results may differ from estimates. For example, significant increases in the probability of achieving a milestone or projected revenues would result in a significantly higher fair value measurement while significant decreases in the estimated probability of achieving a milestone or projected revenues would result in a significantly lower fair value measurement. Significant increases in the discount rate or in the anticipated timelines would result in a significantly lower fair value measurement while significant decreases in the discount rate or anticipated timelines would result in a significantly higher fair value measurement. The potential contingent consideration payments required upon achievement of development, regulatory approval and sales-based milestones related to the Company’s acquisition of ZX008 range from zero if none of the milestones are achieved to a maximum of $95.0 million (undiscounted). As of September 30, 2018, the Company has classified $32.5 million of the total contingent consideration liabilities of $80.1 million as current liabilities. The classification was based upon the Company’s reasonable expectation as to the timing of settlement of certain specified milestones.
The following table provides a reconciliation of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and nine months ended September 30, 2018 and 2017 (in thousands):

June 30, 2018Change in Fair Value September 30, 2018June 30, 2017Change in Fair Value September 30, 2017
Contingent consideration liabilities $74,400 $5,700 $80,100 $53,900 $10,500 $64,400 
Common stock warrant liabilities 543 64 607 69 380 449 

December 31, 2017Change in Fair Value September 30, 2018December 31, 2016Change in Fair Value September 30, 2017
Contingent consideration liabilities 76,900 $3,200 $80,100 $52,800 $11,600 $64,400 
Common stock warrant liabilities 512 95 607 809 (360)449 

The changes in fair value of the liabilities shown in the table above are recorded through change in fair value of contingent consideration liabilities within operating expense and the change in fair value of common stock warrant liabilities within other income (expense) in the condensed consolidated statements of operations.

There were no transfers between levels during the periods presented. See Note 3 for further information regarding the amortized cost of the Company's financial instruments.
Note 5 – Commitments and Contingencies
Leases
The Company has two noncancellable operating leases consisting of administrative and research and development office space for its Emeryville, California headquarters and former headquarters in San Diego, California that expire in November 2022 and March 2020, respectively. The former headquarters has been subleased to an unrelated third party for the remainder of the Company’s original lease term. Future minimum lease payments under our non-cancellable operating leases at September 30, 2018, net of sublease income, were as follows (in thousands):
Gross Lease
Payments
Sublease
Income
Net Lease
Payments
2018 (remaining 3 months) $481 $(136)$345 
20191,955 (576)1,379 
20201,234 (148)1,086 
20211,004 — 1,004 
2022946 — 946 
Total $5,620 $(860)$4,760 

13

In October 2018, the Company executed a lease for new headquarters with its current landlord to move to a facility nearby its current headquarters in Emeryville, California. The lease has an initial term that expires on June 30, 2027 and provides for one five-year renewal option. Concurrent with the new lease, the landlord agreed to terminate the Company's existing lease once it completes the move to the new headquarters. The cash expected to be paid for rent over the term of the new lease of eight years is approximately $15.3 million beginning in June 2019, partially offset by a reduction in the commitments under its existing headquarter lease.
Legal Matters
The Company is not currently involved in any material legal proceedings. The Company may become involved in various legal proceedings and claims that arise in the ordinary course of business. Such matters are subject to uncertainty and there can be no assurance that such legal proceedings will not have a material adverse effect on its business, results of operations, financial position or cash flows.
Note 6 – Sale of Common Stock
The Company has an at-the-market offering program (“ATM Program”) with Cantor Fitzgerald & Co. (“Cantor”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its common stock having an aggregate offering price of up to $75.0 million under a previously filed and effective registration statement on Form S-3 (File No. 333-220759) and a prospectus supplement filed in December 2017. Cantor is entitled to a commission at a fixed commission rate of up to 3% of the gross proceeds of the sales price of all common stock sold under the ATM program. The Company and Cantor may each terminate the ATM program at any time upon ten days’ prior notice.
In the second quarter of 2018, the Company sold a total of 740,417 shares of its common stock under the ATM program and received net proceeds of approximately $30.3 million, after deducting commissions and other offering expenses of $1.1 million.
In August 2018, the Company completed an underwritten public offering for the sale of 6,000,000 shares of its common stock. Net proceeds raised from the offering were approximately $292.9 million, after deducting underwriting discounts and commissions and other offering expenses of $19.1 million.
Note 7 – Stock-Based Compensation
The Company has adopted certain equity incentive and stock purchase plans as described in the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
In March 2018, our board of directors approved an amendment and restatement of our non-employee director compensation policy, pursuant to which any non-employee director who is first elected to the board of directors is granted an option to purchase 20,000 shares of our common stock on the date of his or her initial election to the board of directors. In addition, on the date of each annual meeting of our stockholders, commencing with the 2018 annual meeting, each non-employee director is eligible to receive an option to purchase 15,000 shares of common stock. Prior to March 2018, under our non-employee director compensation policy, any non-employee director who was first elected to the board of directors was granted an option to purchase 30,000 shares of our common stock on the date of his or her initial election to the board of directors. In addition, on the date of each annual meeting of our stockholders, each non-employee director was eligible to receive an option to purchase 20,000 shares of common stock.
Performance Stock Options
In October 2015, the Company granted employees certain performance-based stock options for retention purposes. The stock options would vest upon satisfaction of a specified regulatory milestone within three years of the date of grant. In 2017, management determined the achievement of the performance condition was no longer probable and the cumulative compensation expense previously recognized was reversed. In September 2018, these awards were modified to allow for 90% of such options outstanding at the modification date to vest immediately. The remaining 10% of the awards were canceled in October 2018 since the performance condition was not met. This improbable to probable modification resulted in the calculation and recognition of incremental stock-based compensation expense of $3.5 million during the third quarter of 2018.
14

Equity Incentive Awards Activity

Stock Options
The following is a summary of stock option activity for the nine months ended September 30, 2018 (in thousands, except per share data):
Shares
(in thousands)
Weighted-
Average
Exercise
Price per Share
Outstanding at December 31, 20173,392 $14.41 
Granted
842 43.13 
Exercised
(290)16.45 
Canceled
(59)26.10 
Outstanding at September 30, 20183,885 $20.30 

Restricted Stock Units
The following is a summary of restricted stock unit activity for the nine months ended September 30, 2018 (in thousands, except per share data):
Shares
(in thousands)
Weighted- Average Fair Value per Share at Grant Date 
Outstanding at December 31, 2017259 $10.43 
Granted
146 42.76 
Vested
(98)10.74 
Canceled
(8)29.74 
Outstanding at September 30, 2018299 $25.58 
As of September 30, 2018, outstanding restricted stock units included 159,000 granted in March 2017 with performance-based conditions to employees and executives. The restricted stock units vest upon the approval of the Company’s new drug application for ZX008 by the FDA, provided such approval occurs within five years following the grant date. Due to the uncertainties associated with the FDA approval process, approval is not yet probable, as such term is used for accounting purposes, prior to the occurrence of the event. Accordingly, no compensation expense has been recognized to date for these performance-based awards.
Valuation of Equity Awards
The fair value of the stock options granted or modified during the periods indicated was estimated using the Black-Scholes option pricing model, based on the following assumptions:

Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Risk free interest rate 2.8% to 2.9% 1.9% to 2.1% 2.3% to 2.9% 1.9% to 2.3% 
Expected term 3.5 to 6.1 years 6.1 years 3.5 to 6.1 years 5.1 to 6.1 years 
Expected volatility 79.9% to 83.2% 75.1% to 75.5% 79.9% to 85.2% 75.1% to 76.6% 
Expected dividend yield — %— %— %— %
The fair value of restricted stock units granted is determined based on the price of the Company's common stock on the date of grant.
15

Stock-Based Compensation Expense
The following table summarizes the components of total stock-based compensation expense included in the condensed consolidated statements of operations (in thousands):
 
Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Cost of contract manufacturing $— $— $— $71 
Research and development 3,275 294 5,018 1,313 
Selling, general and administrative 3,706 968 6,934 2,682 
Total $6,981 $1,262 $11,952 $4,066 

Note 8 – Net Loss Per Share
Basic net loss from continuing operations per share is calculated by dividing net loss from continuing operations by the weighted average number of shares outstanding for the period. Diluted net loss from continuing operations per share is calculated by dividing net loss from continuing operations by the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period if the effect is dilutive. The Company’s potentially dilutive shares of common stock include outstanding stock options, restricted stock units and warrants to purchase common stock.
A reconciliation of the numerators and denominators used in computing net loss from continuing operations per share is as follows (in thousands, except per share amounts):
Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Numerator: 
Net loss from continuing operations $(42,264)$(42,660)$(101,283)$(86,239)
Denominator: 
Shares used in per share calculation 39,242 25,431 36,485 25,024 
Net loss from continuing operations per share, basic and diluted $(1.08)$(1.68)$(2.78)$(3.45)
The following table presents the potential shares of common stock outstanding that were excluded from the computation of diluted net loss from continuing operations per share for the periods presented because including them would have been anti-dilutive (in thousands):
Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Shares subject to outstanding common stock options 3,957 4,121 3,752 3,879 
Shares subject to outstanding restricted stock units 303 271 287 228 
Shares subject to outstanding warrants to purchase common stock 28 1,251 35 1,522 
Total 4,288 5,643 4,074 5,629 

Note 9 – United Kingdom (U.K.) Research and Development Incentives
The Company carries out extensive research and development activities that benefit from the U.K.’s small and medium-sized enterprise (“SME”) research and development tax credit regime, whereby the Company may either receive an enhanced U.K. tax deduction on its eligible research and development activities or, when an SME entity is in a net operating loss position, elect to surrender net operating losses that arise from its eligible research and development activities in exchange for a cash
16

payment from the U.K. tax authorities. These refundable cash credits, which may be received without regard to actual tax liability, are not subject to accounting for income taxes and have been recorded as a component of other income.
In December 2017, the Company filed a claim as an SME for a $3.0 million refundable cash credit for its 2015 tax year, which was received in July 2018. The Company recorded this amount as a component of other income for the nine months ended September 30, 2018. As of the date hereof, the Company has not filed claims for any refundable cash credit for its 2016 or 2017 tax years, nor has it recorded any balances related to claims for these years or for the 2018 tax year, as collectability is deemed not probable or reasonably assured.
17

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. These forward-looking statements include, but are not limited to, statements about:
• the progress and timing of clinical trials of ZX008;
• the safety and efficacy of our product candidates;
• the timing of submissions to, and decisions made by, the U.S. Food and Drug Administration (“FDA”) and other regulatory agencies, including foreign regulatory agencies, with respect to our product candidates and our ability to demonstrate the safety and efficacy of our product candidates to the satisfaction of the FDA and such other regulatory agencies;
• the goals of our development activities and estimates of the potential markets for our product candidates, and our ability to compete within those markets; and
• projected cash needs and our expected future revenues, operations and expenditures.
The forward-looking statements are contained principally in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements relate to future events or our future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. We discuss many of these risks, uncertainties and other factors in this Quarterly Report on Form 10-Q in greater detail under the heading “Item 1A – Risk Factors.”
Given these risks, uncertainties and other factors, we urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. You should read this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. We undertake no obligation to revise or update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.
DosePro® and Zogenix™ are our trademarks. All other trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. Use or display by us of other parties’ trademarks, trade dress or products is not intended to and does not imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owner.
Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “Zogenix,” “we,” “us” and “our” refer to Zogenix, Inc., including its consolidated subsidiaries.
The condensed consolidated financial statements and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2017 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2017.
Overview
We are a pharmaceutical company developing and commercializing innovative central nervous system (“CNS”) therapies for people living with serious and life-threatening rare CNS disorders and medical conditions. Our current primary area of therapeutic focus is rare, or “orphan” childhood-onset epilepsy disorders.
We currently own and control worldwide development and commercialization rights to ZX008, our lead Phase 3 product candidate. ZX008 is low-dose fenfluramine for the treatment of seizures associated with two rare and catastrophic forms of childhood-onset epilepsy: Dravet syndrome and Lennox-Gastaut syndrome (“LGS”).
ZX008 for Patients with Dravet Syndrome
Dravet syndrome is a rare form of pediatric-onset epilepsy with life threatening consequences for patients and for which current treatment options are very limited. ZX008 has received orphan drug designation in the United States and the European
18

Union (the “EU”) for the treatment of Dravet syndrome. In addition, ZX008 for the treatment of Dravet syndrome received Fast Track designation from the FDA in January 2016 and Breakthrough Therapy designation in February 2018.
Study 1501 and 1502 (“Study 1”)
We initiated our Phase 3 clinical trials in North America (“Study 1501”) in January 2016 and in Europe and Australia in June 2016 (“Study 1502”). Study 1501 and Study 1502 are each identical randomized, double-blind placebo-controlled studies of ZX008 as adjunctive therapy for patients with uncontrolled seizures who have Dravet syndrome. In January 2017, we announced our plan to report top-line results from Study 1501 and Study 1502 via a prospective merged study analysis approach whereby top-line results from the first approximately 120 subjects randomized into either Study 1501 or 1502 would have their study results analyzed and be reported initially as “Study 1”. In April 2017, we completed enrollment of Study 1 and, in September 2017, we announced positive top-line results for the 119 patients included in the Study 1 Phase 3 trial. The Study 1 trial met its primary objective of demonstrating that ZX008, at a dose of 0.8 mg/kg/day (30mg/day maximum), is superior to placebo as adjunctive therapy in the treatment of Dravet syndrome in children and young adults based on change in the frequency of convulsive seizures between the 6-week baseline observation period and the 14-week treatment period (p<0.001). In the trial, ZX008 at a dose of 0.8 mg/kg/day also demonstrated statistically significant improvements versus placebo in all key secondary measures, including the proportion of patients with clinically meaningful reductions in seizure frequency (50% or greater) and longest seizure-free interval. The same analyses comparing a 0.2 mg/kg/day ZX008 dose versus placebo also demonstrated statistically significant improvement compared with placebo. ZX008 was generally well tolerated without any signs or symptoms of valvulopathy or pulmonary hypertension.
Study 1504
In September 2016, we initiated Part 1 of Study 1504, a two-part, double blind, randomized, two arm pivotal Phase 3 clinical trial of ZX008 in Dravet syndrome patients who are taking stiripentol, valproate and/or clobazam as part of their baseline standard care. Part 1 investigated the pharmacokinetic profile and safety of ZX008 when co-administered with the stiripentol regimen (stiripentol, valproate and/or clobazam). Based on the results of the pharmacokinetic and safety portion of the trial, in February 2017 we initiated the safety and efficacy portion of Study 1504 utilizing a dose of ZX008 0.5mg/kg/day (20mg/day maximum). Study 1504, a two-arm study compared ZX008 versus placebo across the titration and 12-week maintenance periods at multiple sites, which included sites in France, the Netherlands, United States, Canada, Germany, the United Kingdom and Spain. In January 2018, patient enrollment was completed at 87 patients and randomized between the ZX008-arm (n=43) or placebo (n=44).
Announcement of Top-line Clinical Trial Results for Study 1504
On July 12, 2018, we reported positive top-line results from Study 1504. The study results, which are consistent with those reported in Study 1, successfully met the primary objective of demonstrating that ZX008, at a dose of 0.5 mg/kg/day, when co-administered with stiripentol regimen (stiripentol, valproate and/or clobazam), is superior to placebo as adjunctive therapy in the treatment of Dravet syndrome in children and young adults based on change in the frequency of convulsive seizures between the 6-week baseline observation period and the 15-week treatment period (p<0.001). In the trial, ZX008 at a dose of 0.5 mg/kg/day also demonstrated statistically significant improvements versus placebo in both key secondary measures, the proportion of patients with clinically meaningful reductions in seizure frequency (50% or greater) and longest seizure-free interval. ZX008 was generally well-tolerated in this study, with the adverse events consistent with those observed in Study 1 and the known safety profile of fenfluramine without any signs or symptoms of valvulopathy or pulmonary hypertension. We believe we are on track to submit applications for regulatory approvals for ZX008 in the United States and Europe in the first quarter of 2019.
ZX008 for Patients with LGS
LGS is another rare, refractory, debilitating pediatric-onset epilepsy with life threatening consequences for patients and for which current treatment options are very limited. Beginning in first quarter of 2016, we funded an open-label, dose-finding, investigator-initiated study of the effectiveness and tolerability of ZX008 as an adjunctive therapy in patients with LGS. The results of this pilot study of 13 refractory LGS patients were recently published in a peer review journal (Epilepsia) and reported an overall 53% median reduction in convulsive seizures,8 patients (62%) had a ≥50% convulsive seizure reduction and 3 patients (23%) had a ≥75% reduction. In addition, ZX008 was generally well tolerated without any signs or symptoms or echocardiographic findings of valvulopathy or pulmonary hypertension. We believe these data indicate that ZX008 has the potential to be a safe and effective adjunctive treatment of major motor and drop seizures for patients with LGS. Based on the strength of the LGS data generated, in the first quarter of 2017, we submitted an investigational new drug (“IND”) application to the FDA to initiate a Phase 3 program of ZX008 in LGS, which became effective in April 2017. In the first half of 2017, ZX008 received orphan drug designation for the treatment of LGS from the FDA in the United States and the European Medicines Agency (“EMA”) in the EU.
19

Study 1601
In November 2017, we announced the initiation of our multicenter global Phase 3 clinical trial of ZX008 as an adjunctive treatment for seizures in patients with LGS (“Study 1601”). Study 1601 is planned for up to 85 sites in North America, Europe, Asia-Pacific, South America, South Africa and Australia and is divided in two parts. Part 1 is a double-blind, placebo-controlled investigation to assess the safety, tolerability and efficacy of ZX008, low-dose fenfluramine, when added to a patient’s current anti-epileptic therapy. The trial will include two dose levels of ZX008 (0.2 mg/kg/day and 0.8 mg/kg/day, up to a maximum daily dose of 30 mg), as well as placebo. After establishing baseline seizure frequency for 4 weeks, randomized patients will be titrated to their dose over a 2-week titration period, followed by a 12-week fixed dose maintenance period. We are targeting a total of 225 randomized patients (75 per treatment arm) in the trial. The primary endpoint of the clinical trial is change in the number of seizures that result in drops between baseline and the combined titration and maintenance periods at the 0.8 mg/kg/day dose. The key secondary endpoints include change in the number of seizures that result in drops between baseline and the combined titration and maintenance periods at the 0.2 mg/kg/day dose, and the proportion of patients achieving a 50 percent reduction in drop seizures. Part 2 of the clinical trial will be a 12-month open-label extension to evaluate the long-term safety, tolerability and effectiveness of ZX008.
Critical Accounting Policies and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in conformity with GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosures. We evaluate our estimates and assumptions on an ongoing basis. Our estimates are based on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.
We believe that the assumptions and estimates associated with revenue recognition, the impairment assessments related to goodwill and indefinite-lived intangible assets, estimated fair value of contingent consideration, accrued clinical trial expenses and the related prepaid expenses, stock-based compensation and income taxes have the greatest potential impact on our consolidated financial statements. Therefore, we consider these to be our critical accounting policies and estimates.
There have been no significant changes in our critical accounting policies and estimates during the nine months ended September 30, 2018, as compared to the critical accounting policies and estimates disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2017.
Recent Accounting Pronouncements
For information with respect to recent accounting pronouncements that are of significance or potential significance to us, see Note 2 “Summary of Significant Accounting Policies” in the notes to condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Results of Operations
Comparison of Three and Nine Months Ended September 30, 2018 and 2017 
Contract Manufacturing Revenue
Three Months Ended September 30, Nine Months Ended September 30, 
(in thousands) 20182017Change 20182017Change 
Contract manufacturing revenue $— $— $— $— $9,821 $(9,821)
Through April 2017, we generated contract manufacturing revenue from supplying Sumavel DosePro to Endo International plc (“Endo”), who purchased our Sumavel DosePro business in May 2014. In September 2017, we and Endo terminated the supply agreement. As a result, we did not generate any contract manufacturing revenue in the three and nine months ended September 30, 2018 and no longer have any contracts with customers.
20

Cost of Contract Manufacturing 
Three Months Ended September 30, Nine Months Ended September 30, 
(in thousands) 20182017Change 20182017Change 
Cost of contract manufacturing $— $— $— $— $10,729 $(10,729)
We did not incur contract manufacturing costs during the three and nine months ended September 30, 2018 as a result of the aforementioned termination of the supply agreement to manufacture and supply Sumavel DosePro to Endo.
Research and Development Expenses
Three Months Ended September 30, Nine Months Ended September 30, 
(in thousands) 20182017Change 20182017Change 
Research and development $27,608 $21,178 $6,430 $77,329 $49,369 $27,960 
Research and development expenses consist of expenses incurred in developing, testing and seeking marketing approval of our product candidates, including: license and milestone payments; payments made to third-party clinical research organizations (“CROs”) and investigational sites, which conduct our clinical trials on our behalf, and consultants; expenses associated with regulatory submissions, pre-clinical development and clinical trials; payments to third-party manufacturers, which produce our active pharmaceutical ingredient and finished product; personnel related expenses, such as salaries, benefits, travel and other related expenses, including stock-based compensation; and facility, maintenance, depreciation and other related expenses.
We utilize contract manufacturing organizations, CROs, contract laboratories and independent contractors to produce product candidate material and for the conduct of our pre-clinical studies and clinical trials. We track third-party costs by program. We recognize the expenses associated with the services provided by CROs based on estimated progress toward completion at the end of each reporting period. We coordinate clinical trials through a number of contracted investigational sites and recognize the associated expense based on a number of factors, including actual and estimated subject enrollment and visits, direct pass-through costs and other clinical site fees. The table below sets forth information regarding our research and development costs for our major development programs.
Three Months Ended September 30, Nine Months Ended September 30, 
(in thousands) 20182017Change 20182017Change 
ZX008 $16,564 $16,520 $44 $52,547 $35,111 $17,436 
Other(1) 11,044 4,658 6,386 24,782 14,258 10,524 
Total $27,608 $21,178 $6,430 $77,329 $49,369 $27,960 
(1) Other research and development expenses include employee and infrastructure resources that are not tracked on a program-by-program basis, as well as development costs incurred for other product candidates.
We acquired ZX008 in October 2014 and have since incurred significant expenditures related to conducting clinical trials of ZX008. Research and development expenses related to ZX008 remained flat for the three months ended September 30, 2018 compared to the same period in 2017 as a decrease in activity within Study 1504 was offset by an increase in activity within Study 1601, which was initiated in November 2017. Research and development expenses related to ZX008 increased by $17.4 million for the nine months ended September 30, 2018 compared to the same period in 2017 reflecting the progression and expansion of our clinical trial activities within Study 1504 as well as Study 1601. Other research and development expenses increased by $6.4 million and $10.5 million for the three and nine months ended September 30, 2018, respectively, compared to the same periods in 2017. The increase was primarily attributable to personnel-related costs from additions to headcount as well as increased stock-based compensation due to modification of stock options. 
Selling, General and Administrative Expenses
Three Months Ended September 30, Nine Months Ended September 30, 
(in thousands) 20182017Change 20182017Change 
Selling $4,200 $648 $3,552 $8,911 $3,071 $5,840 
General and administrative 6,816 5,425 1,391 18,752 15,058 3,694 
Total selling, general and administrative $11,016 $6,073 $4,943 $27,663 $18,129 $9,534 
21

Selling expense consists primarily of salaries and benefits of sales and marketing management and market research expenses for product candidates that are in development. General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, accounting, business development and internal support functions. In addition, general and administrative expenses include professional fees for legal, consulting and accounting services.
Selling expense increased by $3.6 million and $5.8 million for the three and nine months ended September 30, 2018, respectively, compared to the same periods in 2017. The increase was primarily attributable to costs incurred for market research and commercialization planning as we prepare for the potential commercialization of ZX008 for Dravet syndrome.
General and administrative expense increased by $1.4 million and $3.7 million for the three and nine months ended September 30, 2018, respectively, compared to the same periods in 2017 and was primarily attributable to personnel-related costs, including stock-based compensation due to incremental expense from modification of stock options.
Loss on Contract Termination
Three Months Ended September 30, Nine Months Ended September 30, 
(in thousands) 20182017Change 20182017Change 
Loss on contract termination $— $478 $(478)$— $478 $(478)
For the three and nine months ended September 30, 2017, we entered into a termination agreement of the Supply Agreement with Endo related to Sumavel DosePro. The loss on contract termination represents costs incurred by us to terminate agreements with our third-party manufacturers and suppliers of Sumavel DosePro that were in excess of reimbursements received from Endo for such costs.

Impairment Charges
Three Months Ended September 30, Nine Months Ended September 30, 
(in thousands) 20182017Change 20182017Change 
Asset impairment charges $— $196 $(196)$— $1,116 $(1,116)
Asset impairment charges for the three and nine months ended September 30, 2017 primarily resulted from the wind down of our contract manufacturing operations.
Change in Fair Value of Contingent Consideration
Three Months Ended September 30, Nine Months Ended September 30, 
(in thousands) 2018201720182017
Change in fair value of contingent consideration $5,700 $10,500 $3,200 $11,600 
The contingent consideration liability relates to milestone payments under an existing agreement in connection with our prior acquisition of ZX008. At each reporting period, the estimated fair value of the liability is determined by applying the income approach which utilizes variable inputs, such as the probability of success for achieving regulatory/commercial milestones, anticipated future cash flows, risk-free adjusted discount rates, and nonperformance risk. Any change in the fair value is recorded as contingent consideration (income) expense.
For the three and nine months ended September 30, 2018, the estimated fair value of our contingent consideration liabilities increased by $5.7 million and $3.2 million, respectively, due to the positive top-line results announced in July 2018 from our second confirmatory Phase 3 study (Study 1504) of ZX008 for the treatment of Dravet syndrome. For the three and nine months ended September 30, 2017, the estimated fair value of our contingent consideration liabilities increased by $10.5 million and $11.6 million, respectively, due to the positive top-line results announced in September 2017 from our first Phase 3 trial (Study 1) of ZX008 for the treatment of Dravet syndrome. As a result of the positive top-line data from clinical trials for the reporting periods presented, the probability of success used to calculate the specified milestone payments increased.
22

Other Income (Expense)
Three Months Ended September 30, Nine Months Ended September 30, 
(in thousands) 2018201720182017
Other income (expense): 
Interest income $2,133 $121 $3,995 $332 
Interest expense — (702)(6)(2,065)
Loss on extinguishment of debt — (3,378)— (3,378)
Change in fair value of common stock warrant liabilities (64)(380)(95)360 
Other income, net (9)62 3,015 71 
Total other income (expense) $2,060 $(4,277)$6,909 $(4,680)
Total other income for the three months ended September 30, 2018 of $2.1 million primarily consisted of interest income attributable to higher average cash and investment balances resulting from our recent capital raising activities described below. Total other income for the nine months ended September 30, 2018 of $6.9 million primarily consisted of interest income and a $3.0 million claim for cash payment under the U.K.’s small and medium-sized enterprise and research and development tax credit regime for qualifying expenditures incurred in the 2015 tax year.
Total other expense for the three and nine months ended September 30, 2017 of $4.3 million and $4.7 million, respectively, primarily consisted of interest expense recognized under a term loan and its related loss upon early repayment in full.
Liquidity and Capital Resources
Excluding gains from two discrete business divestitures, we have incurred significant net losses and negative cash flows from operating activities since inception. We had an accumulated deficit of $673.5 million at September 30, 2018. We expect to continue to incur significant operating losses and negative cash flows from operations to advance our product candidates through development and commercialization. Additionally, upon acceptance of our regulatory submissions for ZX008 by the FDA or the EMA and regulatory approval of ZX008 by the FDA or EMA, if at all, each a milestone event, we will owe milestone payments under an existing agreement in connection with our prior acquisition of ZX008. We currently do not engage in any revenue-generating activities. We do not know when, or if, we will generate any revenue from product sales and do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize ZX008. To date, the Company has relied primarily on the proceeds from equity offerings to finance its operations. The Company's recent equity offerings include the following transactions.
In the third quarter of 2017, we sold a total of 1,550,880 shares of our common stock under the ATM Program with Cantor resulting in net proceeds of approximately $19.4 million.
In October 2017, we completed an underwritten public offering for the sale of 7,700,000 shares of our common stock. Net proceeds raised from the offering amounted to approximately $271.3 million, after deducting underwriting discounts and commissions and other offering expenses.
In the second quarter of 2018, we sold a total of 740,417 shares of our common stock under the ATM Program and received net proceeds of approximately $30.3 million, after deducting commissions and other offering expenses of $1.1 million.
In August 2018, we completed an underwritten public offering for the sale of 6,000,000 shares of our common stock. Net proceeds raised from the offering were approximately $292.9 million, after deducting underwriting discounts and commissions and other offering expenses of $19.1 million.
As of September 30, 2018, our cash, cash equivalents and marketable securities totaled $539.1 million. Our principal uses of cash are research and development expenses, selling, general and administrative expenses and other working capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:
• the rate of progress and cost of our clinical trials and other product development programs for ZX008 and our other product candidates and any other product candidates that we may develop, in-license or acquire;
• the timing of regulatory approval for any of our other product candidates and the commercial success of any approved products;
23

• the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights associated with ZX008 and any of our other product candidates;
• the costs of establishing or outsourcing sales, marketing and distribution capabilities, should we elect to do so;
• the costs, terms and timing of completion of outsourced commercial manufacturing supply arrangements for any product candidate; and
• the effect of competing technological and market developments.
Until we can generate a sufficient amount of revenue to finance our cash requirements, if ever, we may need to continue to rely on additional financing to achieve our business objectives. However, we may not be able to secure such financing in a timely manner or on favorable terms, if at all. If future funds are raised through issuance of equity or debt securities, these securities may have rights, preferences and privileges senior to those of our existing stockholders. If we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to our potential products or proprietary technologies, or grant licenses on terms that are not favorable to us. Without additional funds at the time we need such funding, we may be forced to delay, scale back or eliminate some of our research and development activities, or other operations and potentially delay product development in an effort to provide sufficient funds to continue its operations. If any of these events occurs, our ability to achieve the development and commercialization goals could be adversely affected.
The following table presents selected information from our statements of cash flows (in thousands):
Nine Months Ended September 30, 
20182017
Cash and cash equivalents, beginning of the period $293,503 $91,551 
Net cash used in operating activities (83,236)(46,435)
Net cash used in investing activities (375,687)(35)
Net cash provided by financing activities 328,458 19,649 
Net decrease in cash and cash equivalents (130,465)(26,821)
Cash and cash equivalents, end of the period $163,038 $64,730 
Operating Activities 
For the nine months ended September 30, 2018, net cash used in operating activities of $83.2 million was primarily attributable to a net loss of $101.5 million, plus the net effect of non-cash items of $14.8 million, primarily from stock-based compensation and changes in the estimated fair value of contingent consideration, and a net cash inflow from changes in operating assets and liabilities of $3.4 million. Cash inflows from changes in operating assets and liabilities was primarily attributable to the timing of payments for prepaid and accrued clinical trial costs.
For the nine months ended September 30, 2017, net cash used in operating activities consisted of a net loss of $87.1 million, offset by non-cash charges of $23.2 million and a net cash inflow from changes in operating assets and liabilities of $17.5 million.
Investing Activities
For the nine months ended September 30, 2018, net cash used in investing activities was attributable to purchases of marketable securities. There were no sales/maturities of marketable securities for the nine months ended September 30, 2018 as our initial investments were made in July 2018.
For the nine months ended September 30, 2017, net cash used in investing activities was attributable to purchases of property and equipment.
Financing Activities
For the nine months ended September 30, 2018, net cash provided by financing activities of $328.5 million consisted of net proceeds from sales of common stock of $323.1 million in connection with the equity offerings described above and $6.7 million in proceeds received from the issuance of common stock under equity incentive plans. These cash inflows were offset by cash used to remit withholding taxes of $1.4 million related to the vesting of restricted stock units that were net share-settled by us to cover the required withholding tax. 
For the nine months ended September 30, 2017, net cash provided by financing activities was due to proceeds from issuance of common stock under employee equity incentive plans.
24

Contractual Obligations
There were no material changes outside the ordinary course of our business during the nine months ended September 30, 2018 to the information regarding our contractual obligations that was disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2017.
In October 2018, we executed a lease for new headquarters with our current landlord to move to a facility nearby our current headquarters in Emeryville, California. The lease has an initial term that expires on June 30, 2027 and provides for one five-year renewal option. Concurrent with the new lease, the landlord agreed to terminate our existing lease once we complete the move to our new headquarters. The cash expected to be paid for rent over the eight-year term of the new lease is approximately $15.3 million beginning in June 2019, partially offset by a reduction in the commitments under our existing headquarter lease.
Off-Balance Sheet Arrangements
As of September 30, 2018, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K.
25

Item 3. Quantitative and Qualitative Disclosures About Market Risk
As part of our investment portfolio, we own financial instruments that are sensitive to market risks. The primary objective of our investment activities is to preserve our capital until it is required to fund operations, including our research and development activities.
Interest Rate Risk
We place our investments with high quality credit issuers and, by policy, limit the amount of credit exposure to any one issuer. We invest our excess cash primarily in money market funds and certificate of deposits, securities issued by the U.S. government and its agencies, corporate debt securities and commercial paper. These investments are denominated in U.S. Dollars. A portion of our investments consisting of interest-bearing securities are subject to interest rate risk and could decline in value if interest rates fluctuate. The portfolio includes cash equivalents and investments in marketable securities with active secondary or resale markets to ensure portfolio liquidity. Due to the conservative nature of these instruments, we do not believe that we have a material exposure to interest rate risk. A 100 basis points change in interest rates would not have a significant impact on the total value of our portfolio. We had no debt outstanding as of September 30, 2018.

Foreign Exchange Risk
As a result of our U.K operations, we face exposure to movements in foreign currency exchange rates, primarily the British Pound Sterling and the Euro against the U.S. Dollar. The current exposures arise primarily from cash and payables and accruals denominated in the British Pound Sterling and the Euro. We have not hedged our foreign currency since the exposure has not been material to our historical operating results. Based on our foreign currency exchange rate exposures at September 30, 2018, a hypothetical 10% adverse fluctuation in the average exchange rate of the Euro or the British Pound Sterling would not have had a material impact on our condensed consolidated financial statements. We will continue to monitor and evaluate our exposure to foreign exchange risk as a result of entering into transactions denominated in currencies other than the U.S. Dollar.
Item 4. Controls and Procedures
Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2018 at the reasonable assurance level.
Changes in Disclosure Controls and Procedures
There were no changes in our internal control over financial reporting during the nine months ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
26

PART II – OTHER INFORMATION
Item 1. Legal Proceedings
There have been no material updates to the legal proceedings as set forth in “Item 3. Legal Proceedings” in our Annual Report on Form 10-K for the year ended December 31, 2017.
Item 1A. Risk Factors
There have been no material changes in our risk factors from those disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017, other than as set forth below.
We are exposed to fluctuations in the market values of our investments.
As of September 30, 2018, our cash, cash equivalents and marketable securities totaled $539.1 million. Our cash equivalents and marketable securities include money market funds and certificate of deposits, securities issued by the U.S. government and its agencies, corporate debt securities and commercial paper meeting the criteria of our investment policy, which prioritizes the preservation of capital. These investments are subject to general credit, liquidity, market and interest rate risks, instability in the global financial markets, or other factors. As a result, the value or liquidity of our investments could decline and result in a material impairment, which could have a material adverse effect on our financial results and the availability of cash to fund our operations.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Unregistered Sales of Equity Securities
None.
Use of Proceeds
Not applicable.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Erle T. Mast, a member of our Board of Directors and chair of our Audit Committee, served as Executive Vice President and Chief Financial Officer of Clovis Oncology, Inc., a public biopharmaceutical company, from its inception in April 2009 until his retirement in March 2016. As previously disclosed, the U.S. Securities and Exchange Commission, or SEC, had an ongoing investigation to determine whether Clovis violated federal securities laws in connection with its regulatory update announced in November 2015 that the FDA had requested additional clinical data on the efficacy and safety of a product under development by Clovis. On September 18, 2018, the SEC announced that it had reached an agreement with Clovis and certain of its executive officers, including Mr. Mast, to settle this matter on negligence based charges. Pursuant to the settlement, without admitting or denying the SEC’s allegations, Mr. Mast paid a civil penalty and disgorgement and agreed to a standard injunction against future violations of those provisions of the federal securities laws. The settlement agreement does not allege that Clovis or any of its current or former officers, including Mr. Mast, engaged in any intentional fraud or misconduct and it does not preclude Mr. Mast from continuing to serve as a director or officer of a public company.
27

Item 6. Exhibits
EXHIBIT INDEX 
Exhibit
Number
Description
3.1(1) 
3.2(4) 
3.3(5) 
3.4(1) 
4.1(2) 
4.5(3) 
10.1†  
31.1 
31.2 
32.1* 
32.2* 
101.INS
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 
101.SCH
XBRL Taxonomy Extension Schema Document. 
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document. 
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document. 
101.LAB
XBRL Taxonomy Extension Label Linkbase Document. 
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document. 
 
1. Filed with Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 on October 27, 2010.
2. Filed with Amendment No. 3 to the Registrant’s Registration Statement on Form S-1 on November 4, 2010.
3. Filed with the Registrant’s Quarterly Report on Form 10-Q on August 12, 2011.
4. Filed with the Registrant’s Quarterly Report on Form 10-Q on November 8, 2012.
5. Filed with the Registrant’s Quarterly Report on Form 10-Q on August 10, 2015.
† Indicates management contract or compensatory plan.
∗ These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not subject to the liability of that section. These certifications are not to be incorporated by reference into any filing of Zogenix, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

28

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
ZOGENIX, INC. 
Date: November 8, 2018By: /s/ Stephen J. Farr 
President and Chief Executive Officer 
(Principal Executive Officer) 
Date: November 8, 2018By: /s/ Michael P. Smith 
Executive Vice President, Chief Financial Officer, Treasurer and Secretary 
(Principal Financial and Accounting Officer) 

 EX-10.1 2 ex10120180930.htm EXHIBIT 10.1 Document

Exhibit 10.1
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Zogenix, Inc., a Delaware corporation (the “Company”), and Ashish Sagrolikar (“Executive”), and shall be effective as of July 2, 2018 (the “Effective Date”).
WHEREAS, the Company desires to employ Executive, and Executive desires to accept employment with the Company, on the terms and conditions set forth in this Agreement.
NOW, THEREFORE, in consideration of the mutual promises herein contained, the parties agree as follows:
1. Definitions. As used in this Agreement, the following terms shall have the following meanings:
a. “Board” means the Board of Directors of the Company.
b. “Bonus” means an amount equal to the average of the bonuses awarded to Executive for each of the three (3) fiscal years prior to the date of Executive’s termination of employment, or such lesser number of years as may be applicable if Executive has not been employed for three (3) full years on the date of Executive’s termination of employment; provided, that to the extent Executive has not received any bonus prior to the date of his termination of employment due to the fact that his employment commenced during the fiscal year in which his termination of employment occurs, his “Bonus” for purposes of Section 4 shall be equal to his target bonus for the fiscal year in which such termination occurs (calculated by reference to the target bonus level in effect on the date of termination). For purposes of determining Executive’s “Bonus,” (i) to the extent Executive received no bonus in any year due to a failure to meet the applicable performance objectives, such year will still be taken into account (using zero (0) as the applicable bonus) in determining Executive’s “Bonus,” and (ii) to the extent Executive was not employed for an entire fiscal year, the bonus received by Executive for such fiscal year for purposes of the preceding calculation shall be annualized. If any portion of the bonuses awarded to Executive consisted of securities or other property, the fair market value thereof shall be determined in good faith by the Board.
c. “California WARN Act” means California Labor Code Sections 1400 et seq.
d. “Cause” means any of the following:
i. the commission of an act of fraud, embezzlement or dishonesty by Executive, or the commission of some other illegal act by Executive, that has a material adverse impact on the Company or any successor or affiliate thereof;


ii. a conviction of, or plea of “guilty” or “no contest” to, a felony by Executive;
iii. any unauthorized use or disclosure by Executive of confidential information or trade secrets of the Company or any successor or affiliate thereof that has, or may reasonably be expected to have, a material adverse impact on any such entity;
iv. Executive’s gross negligence, insubordination or material violation of any duty of loyalty to the Company or any successor or affiliate thereof, or any other material misconduct on the part of Executive;
v. Executive’s ongoing and repeated failure or refusal to perform or neglect of Executive’s duties as required by this Agreement, which failure, refusal or neglect continues for fifteen (15) days following Executive’s receipt of written notice from the Board or the Company’s Chief Executive Officer (the “CEO”) stating with specificity the nature of such failure, refusal or neglect; or
vi. Executive’s breach of any Company policy or any material provision of this Agreement; provided, however, that prior to the determination that “Cause” under this Section 1(d) has occurred, the Company shall (A) provide to Executive in writing, in reasonable detail, the reasons for the determination that such “Cause” exists, (B) other than with respect to clause (v) above which specifies the applicable period of time for Executive to remedy his breach, afford Executive a reasonable opportunity to remedy any such breach, (C) provide Executive an opportunity to be heard prior to the final decision to terminate Executive’s employment hereunder for such “Cause” and (D) make any decision that such “Cause” exists in good faith.
The foregoing definition shall not in any way preclude or restrict the right of the Company or any successor or affiliate thereof to discharge or dismiss Executive for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of this Agreement, to constitute grounds for termination for Cause.
a. “Change in Control” means and includes each of the following:


i. a transaction or series of transactions (other than an offering of the Company’s common stock to the general public through a registration statement filed with the Securities and Exchange Commission) whereby any “person” or related “group” of “persons” (as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (other than the Company, any of its subsidiaries, an employee benefit plan maintained by the Company or any of its subsidiaries or a “person” that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act), of securities of the Company possessing more than fifty percent (50%) of the total combined voting power of the Company’s securities outstanding immediately after such acquisition; or
ii. the consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (A) a merger, consolidation, reorganization, or business combination or (B) a sale or other disposition of all or substantially all of the Company’s assets in any single transaction or series of related transactions or (C) the acquisition of assets or stock of another entity, in each case other than a transaction:
1. which results in the Company’s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company’s assets or otherwise succeeds to the business of the Company (the Company or such person, the “Successor Entity”) directly or indirectly, at least a majority of the combined voting power of the Successor Entity’s outstanding voting securities immediately after the transaction, and
2. after which no person or group beneficially owns voting securities representing fifty percent (50%) or more of the combined voting power of the Successor Entity; provided, however, that no person or group shall be treated for purposes of this clause (2) as beneficially owning fifty percent (50%) or more of combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction.


Notwithstanding the foregoing, a transaction shall not constitute a “Change in Control” if: (i) its sole purpose is to change the state of the Company’s incorporation; (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transaction; (iii) it constitutes the Company’s initial public offering of its securities; or (iv) it is a transaction effected primarily for the purpose of financing the Company with cash (as determined by the Board in its discretion and without regard to whether such transaction is effectuated by a merger, equity financing or otherwise). The Board shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control of the Company has occurred pursuant to the above definition, and the date of the occurrence of such Change in Control and any incidental matters thereto.
a. “Code” means the Internal Revenue Code of 1986, as amended from time to time, and the Treasury Regulations and other interpretive guidance issued thereunder.
b. “Good Reason” means the occurrence of any of the following events or conditions without Executive’s written consent:
i. a material diminution in Executive’s authority, duties or responsibilities;
ii. a material diminution in Executive’s base compensation, unless such a reduction is imposed across-the-board to senior management of the Company;
iii. a material change in the geographic location at which Executive must perform his duties (and the parties agree that any involuntary change in the geographic location at which Executive must perform his duties to a location that requires a one-way drive from Executive’s principal residence as of the Effective Date in excess of forty (40) miles shall constitute a material change); or
iv. any other action or inaction that constitutes a material breach by the Company or any successor or affiliate of its obligations to Executive under this Agreement.
Executive must provide written notice to the Company of the occurrence of any of the foregoing events or conditions without Executive’s written consent within ninety (90) days of the occurrence of such event. The Company or any successor or affiliate shall have a period of thirty (30) days to cure such event or condition after receipt of written notice of such event from Executive.


a. “Involuntary Termination” means (i) Executive’s Separation from Service by reason of Executive’s discharge by the Company other than for Cause, or (ii) Executive’s Separation from Service by reason of Executive’s resignation of employment with the Company for Good Reason. Executive’s Separation from Service by reason of Executive’s death or discharge by the Company following Executive’s Permanent Disability shall not constitute an Involuntary Termination. Executive’s Separation from Service by reason of resignation from employment with the Company for Good Reason shall be an “Involuntary Termination” only if such Separation from Service occurs within two (2) years following the initial existence of the act or failure to act constituting Good Reason. Executive’s Separation from Service by reason of resignation from employment with the Company for Good Reason shall be treated as involuntary.
b. Executive’s “Permanent Disability” shall be deemed to have occurred if Executive shall become physically or mentally incapacitated or disabled or otherwise unable fully to discharge his duties hereunder for a period of ninety (90) consecutive calendar days or for one hundred twenty (120) calendar days in any one hundred eighty (180) calendar-day period. The existence of Executive’s Permanent Disability shall be determined by the Company on the advice of a physician chosen by the Company and the Company reserves the right to have Executive examined by a physician chosen by the Company at the Company’s expense.
c. “Separation from Service,” with respect to Executive, means Executive’s “separation from service,” as defined in Treasury Regulation Section 1.409A-1(h).
d. “Stock Awards” means all stock options, restricted stock and such other awards granted pursuant to the Company’s stock option and equity incentive award plans or agreements and any shares of stock issued upon exercise thereof.
e. “WARN Act” shall mean the Worker Adjustment and Retraining Notification Act, 29 U.S.C. Sections 2101 et seq., and the Department of Labor regulations thereunder.
1. Services to Be Rendered. 


a. Duties and Responsibilities. Executive shall serve as Executive Vice President and Chief Commercial Officer of the Company. In the performance of such duties, Executive shall report directly to the CEO and shall be subject to the direction of the CEO and to such limits upon Executive’s authority as the CEO may from time to time impose. In the event of the CEO’s incapacity or unavailability, Executive shall be subject to the direction of the Board. Executive hereby consents to serve as an officer and/or director of the Company or any subsidiary or affiliate thereof without any additional salary or compensation, if so requested by the CEO. Executive shall be employed by the Company on a full-time basis. Executive’s primary place of work shall be the Company’s facility in Emeryville, California, or such other locations designated by the CEO from time to time. Prior to Executive’s permanent relocation to the San Francisco Bay Area, Executive will be expected to work from the Company’s facility in Emeryville, California, no less than three (3) weeks per month provided that time spent traveling pursuant to Executive’s duties prior to Executive’s permanent relocation to the San Francisco Bay Area shall be considered time spent working from the Company’s Emeryville, California location for purposes of this Section 2(a). Executive shall also render services at such other places within or outside the United States as the CEO may direct from time to time. Executive shall be subject to and comply with the policies and procedures generally applicable to senior executives of the Company to the extent the same are not inconsistent with any term of this Agreement.
b. Exclusive Services. Executive shall at all times faithfully, industriously and to the best of his ability, experience and talent perform to the satisfaction of the Board and the CEO all of the duties that may be assigned to Executive hereunder and shall devote substantially all of his productive time and efforts to the performance of such duties. Subject to the terms of the Proprietary Information and Inventions Agreement referred to in Section 5(b), this shall not preclude Executive from devoting time to personal and family investments or serving on community and civic boards, or participating in industry associations, provided such activities do not interfere with his duties to the Company, as determined in good faith by the CEO. Executive agrees that he will not join any boards, other than community and civic boards (which do not interfere with his duties to the Company), without the prior approval of the CEO.  
2. Compensation and Benefits. The Company shall pay or provide, as the case may be, to Executive the compensation and other benefits and rights set forth in this Section 3.
a. Base Salary. The Company shall pay to Executive a base salary of $385,000 per year, payable in accordance with the Company’s usual pay practices (and in any event no less frequently than monthly). Executive’s base salary shall be subject to review annually by and at the sole discretion of the Compensation Committee of the Board or its designee.
b. Bonus. Commencing in 2018, Executive shall participate in any bonus plan that the Board or its designee may approve for the senior executives of the Company. Executive’s target bonus under the Company’s annual bonus plan shall be forty-five percent (45%) of Executive’s base salary. Executive’s annual bonus for 2018 shall not be pro-rated for partial year service.
c. Benefits. Executive shall be entitled to participate in benefits under the Company’s benefit plans and arrangements, including, without limitation, any employee benefit plan or arrangement made available in the future by the Company to its senior executives, subject to and on a basis consistent with the terms, conditions and overall administration of such plans and arrangements. The Company shall have the right to amend or delete any such benefit plan or arrangement made available by the Company to its senior executives and not otherwise specifically provided for herein; provided, that any reduction of Executive’s benefits such that Executive’s benefits are, in the aggregate, materially less favorable to Executive than those benefits offered to Executive as of the Effective Date shall be considered a material breach of this Agreement by the Company.


d. Expenses. The Company shall reimburse Executive for reasonable out-of-pocket business expenses incurred in connection with the performance of his duties hereunder, subject to (i) such policies as the Company may from time to time establish, (ii) Executive furnishing the Company with evidence in the form of receipts satisfactory to the Company substantiating the claimed expenditures, (iii) Executive receiving advance approval from the CEO in the case of expenses for travel outside of North America, and (iv) Executive receiving advance approval from the CEO in the case of expenses (or a series of related expenses) in excess of $5,000.
e. Paid Time Off. Executive shall be entitled to such periods of paid time off (“PTO”) each year as provided from time to time under the Company’s PTO policy and as otherwise provided for senior executive officers.
f. Equity Awards and Plans.
i. As soon as practicable following the Effective Date, and subject to the approval of the Compensation Committee of the Board, Executive shall receive stock options to purchase 100,000 shares of the Company’s common stock pursuant to the Company’s Employment Inducement Equity Incentive Award Plan (the “Inducement Plan”). Such stock options shall have an exercise price equal to the “Fair Market Value” per share of the Company’s common stock on the date of grant, as determined pursuant to the Inducement Plan. Such stock options shall be non-qualified stock options. The shares subject to such stock options shall vest as follows: one-fourth (1/4 th) of the shares subject to the option shall vest on the first anniversary of the Effective Date, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installment over the three-year period thereafter, subject to Executive’s continued employment or service with the Company on each such date. Such stock options shall have a ten (10) year term and shall be subject to the terms and conditions of the Inducement Plan and the stock option agreement pursuant to which such stock options are granted. The foregoing stock options are being granted to Executive as an inducement material to Executive’s entering into employment with the Company and are intended to constitute an “employment inducement” award under Nasdaq Marketplace Rule 5635(c)(4).


ii. As soon as practicable following the Effective Date, and subject to the approval of the Compensation Committee of the Board, Executive shall receive 15,000 restricted stock units pursuant to the Inducement Plan. The restricted stock units shall vest as follows: one-fourth (1/4) of the restricted stock units shall vest on each of the first four (4) anniversaries of the Effective Date, subject to Executive’s continued employment or service with the Company on each such date. Such restricted stock units shall be subject to the terms and conditions of the Inducement Plan and the restricted stock unit agreement pursuant to which such restricted stock units are granted. The foregoing restricted stock units are being granted to Executive as an inducement material to Executive’s entering into employment with the Company and are intended to constitute an “employment inducement” award under Nasdaq Marketplace Rule 5635(c)(4).
iii. Executive shall be entitled to participate in any equity or other employee benefit plan that is generally available to senior executive officers, as distinguished from general management, of the Company. Except as otherwise provided in this Agreement, Executive’s participation in and benefits under any such plan shall be on the terms and subject to the conditions specified in the governing document of the particular plan.
g. Stock Award Acceleration.
i. In the event of a Change in Control, the vesting and exercisability of fifty percent (50%) of Executive’s outstanding unvested Stock Awards shall be automatically accelerated effective immediately prior to the consummation of such Change in Control.
ii. In the event of Executive’s Involuntary Termination or Executive’s Separation from Service by reason of Executive’s death or discharge by the Company following Executive’s Permanent Disability, the vesting and/or exercisability of each of Executive’s outstanding unvested Stock Awards shall be automatically accelerated on the date of Executive’s Separation from Service as to the number of Stock Awards that would vest over the twelve (12) month period following the date of Executive’s Separation from Service had Executive remained continuously employed by the Company during such period.


iii. In the event of Executive’s Involuntary Termination within three (3) months prior to or twelve (12) months following a Change in Control, the vesting and/or exercisability of any outstanding unvested portions of such Stock Awards shall be automatically accelerated on the later of (A) the date of Executive’s Separation from Service and (B) the date of the Change in Control (provided, however, that unless otherwise expressly provided in a Stock Award Agreement, any Stock Awards that are restricted stock units shall only be eligible for accelerated vesting pursuant to this clause (iii) in the event of an Involuntary Termination within twelve (12) months following a Change in Control and an Involuntary Termination preceding a Change in Control will not trigger acceleration under this clause (iii)). In addition, with respect to Stock Awards granted to Executive on or after the Effective Date, such Stock Awards may be exercised by Executive (or Executive’s legal guardian or legal representative) until the latest of (A) three (3) months after the date of Executive’s Separation from Service, (B) with respect to any portion of the Stock Awards that become exercisable on the date of a Change in Control pursuant to this Section 3(g)(iii), three (3) months after the date of the Change in Control, or (C) such longer period as may be specified in the applicable Stock Award agreement; provided, however, that in no event shall any Stock Award remain exercisable beyond the original outside expiration date of such Stock Award.
iv. The vesting pursuant to clauses (i), (ii) and (iii) of this Section 3(g) shall be cumulative. The foregoing provisions are hereby deemed to be a part of each Stock Award and to supersede any less favorable provision in any agreement or plan regarding such Stock Award.
h. Relocation.
i. The Company expects Executive to relocate his principal place of residence from Cary, North Carolina to the San Francisco Bay Area on or before September 1, 2019. In furtherance of Executive’s relocation, the Company shall pay for or reimburse Executive in accordance with the Company’s written expense reimbursement policies and procedures for (i) the movement of Executive’s reasonable household goods, which includes two automobiles (excluding extraordinary or unusual moving costs such as boat, recreational vehicle, playground equipment), (ii) reimbursement for up to two (2) house hunting trips to the San Francisco Bay Area for Executive, his spouse and his dependent children and (iii) reimbursement for transportation for Executive, his spouse and his dependent children from North Carolina to the San Francisco Bay Area.


ii. In addition, the Company shall pay to Executive a tax gross-up (the “Tax Gross-Up”) for any federal and state income and employment taxes Executive is required to pay resulting from the Relocation Reimbursement and from the Tax Gross-Up, which Tax Gross-Up shall be paid in accordance with Treasury Regulation Section 1.409A-3(i)(1)(v). The Relocation Reimbursement and any Tax Gross-Up shall be subject to an aggregate cap of $220,000. All amounts eligible for the Relocation Reimbursement must be incurred by and paid to Executive during the term of his employment with the Company. The Relocation Reimbursement and the Tax Gross-Up shall be paid to Executive within thirty (30) days following the Company’s receipt of a written request for such reimbursement, but subject to receipt by the Company of supporting receipts and/or documentation and/or receipts in form and substance reasonably acceptable to the Company. If Executive voluntarily terminates his employment without Good Reason prior to the first anniversary of the Effective Date, Executive shall repay to the Company a pro rata portion of the Relocation Reimbursement and any Tax Gross-Up based on the number of days elapsed in the one-year period ending on the first anniversary of the Effective Date. The Company will have the right to offset such amounts against any compensation otherwise payable to Executive on the date of Executive’s termination of employment.
iii. In addition to the foregoing, during the period commencing on the Effective Date and ending on the earlier of (A) the date Executive relocates his primary residence to the San Francisco Bay Area or (B) September 1, 2019, the Company will pay for or reimburse Executive for temporary housing in the San Francisco Bay Area, subject to the Company’s prior approval of Executive’s temporary housing arrangements.
i. Attorneys' Fees. The Company will reimburse Executive for up to $5,000 in attorneys' fees incurred by Executive in connection with the review of this Agreement. Such reimbursement will be paid to Executive within thirty (30) days following the Company’s receipt of a written request for such reimbursement, but subject to receipt by the Company of supporting receipts and/or documentation and/or receipts in form and substance reasonably acceptable to the Company.
3. Severance. Executive shall be entitled to receive benefits upon a Separation from Service only as set forth in this Section 4:
a. At-Will Employment; Termination. The Company and Executive acknowledge that Executive’s employment is and shall continue to be at-will, as defined under applicable law, and that Executive’s employment with the Company may be terminated by either party at any time for any or no reason, with or without notice. If Executive’s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided in this Agreement. Executive’s employment under this Agreement shall be terminated immediately on the death of Executive.


b. Separation from Service by Death or Following Permanent Disability. Subject to Sections 4(e) and 9(o) and Executive’s continued compliance with Section 5, in the event of Executive’s Separation from Service as a result of Executive’s death or discharge by the Company following Executive’s Permanent Disability, Executive or Executive’s estate, as applicable, shall be entitled to receive, in lieu of any severance benefits to which Executive or Executive’s estate may otherwise be entitled under any severance plan or program of the Company, the benefits provided below, which, with respect to clause (ii) below will be payable in a lump sum within ten (10) days following the effective date of Executive’s Release (or, in the event of Executive’s incapacity as a result of his Permanent Disability, the Release executed by Executive’s legal representative) (or, in the event of Executive’s death, within ten (10) days following the date of Executive’s death):
i. the Company shall pay to Executive or Executive’s estate, as applicable, Executive’s fully earned but unpaid base salary, when due, through the date of Executive’s Separation from Service at the rate then in effect, plus all other benefits, if any, under any Company group retirement plan, nonqualified deferred compensation plan, equity award plan or agreement (other than any such plan or agreement pertaining to Stock Awards whose treatment is prescribed by Section 3(g) above), health benefits plan or other Company group benefit plan to which Executive or Executive’s estate may be entitled pursuant to the terms of such plans or agreements at the time of Executive’s Separation from Service;
ii. Executive or Executive’s estate, as applicable, shall be entitled to receive severance pay in an amount equal to twelve (12) multiplied by Executive’s monthly base salary as in effect immediately prior to the date of Executive’s Separation from Service; and


iii. for the period beginning on the date of Executive’s Separation from Service and ending on the date which is twelve (12) full months following the date of Executive’s Separation from Service (or, if earlier, (1) the date on which the applicable continuation period under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) expires or (2) the date Executive becomes eligible to receive the equivalent or increased healthcare coverage from a subsequent employer) (such period, the “COBRA Coverage Period”), if Executive and/or his eligible dependents who were covered under the Company’s health insurance plans as of the date of Executive’s Separation from Service elect to have COBRA coverage and are eligible for such coverage, the Company shall reimburse Executive or his estate, as applicable, on a monthly basis for an amount equal to (A) the monthly premium Executive and/or his covered dependents, as applicable, are required to pay for continuation coverage pursuant to COBRA for Executive and/or his eligible dependents, as applicable, who were covered under the Company’s health plans as of the date of Executive’s Separation from Service (calculated by reference to the premium as of the date of Executive’s Separation from Service) less (B) the amount Executive would have had to pay to receive group health coverage for Executive and/or his covered dependents, as applicable, based on the cost sharing levels in effect on the date of Executive’s Separation from Service. If any of the Company’s health benefits are self-funded as of the date of Executive’s Separation from Service, or if the Company cannot provide the foregoing benefits in a manner that is exempt from Section 409A (as defined below) or that is otherwise compliant with applicable law (including, without limitation, Section 2716 of the Public Health Service Act), instead of providing the reimbursements as set forth above, the Company shall instead pay to Executive or his estate, as applicable, the foregoing monthly amount as a taxable monthly payment for the COBRA Coverage Period (or any remaining portion thereof). Executive or his estate, as applicable, shall be solely responsible for all matters relating to continuation of coverage pursuant to COBRA, including, without limitation, the election of such coverage and the timely payment of premiums.
c. Severance Upon Involuntary Termination. Subject to Sections 4(e) and 9(o) and Executive’s continued compliance with Section 5, if Executive’s employment is Involuntarily Terminated, Executive shall be entitled to receive, in lieu of any severance benefits to which Executive may otherwise be entitled under any severance plan or program of the Company, the benefits provided below, which, with respect to clause (ii) below will be payable in a lump sum within ten (10) days following the effective date of Executive’s Release:
i. the Company shall pay to Executive his fully earned but unpaid base salary, when due, through the date of Executive’s Involuntary Termination at the rate then in effect, plus all other benefits, if any, under any Company group retirement plan, nonqualified deferred compensation plan, equity award plan or agreement (other than any such plan or agreement pertaining to Stock Awards whose treatment is prescribed by Section 3(g) above), health benefits plan or other Company group benefit plan to which Executive may be entitled pursuant to the terms of such plans or agreements at the time of Executive’s Involuntary Termination;
ii. Executive shall be entitled to receive severance pay in an amount equal to twelve (12) multiplied by Executive’s monthly base salary as in effect immediately prior to the date of Executive’s Involuntary Termination; and


iii. for the COBRA Coverage Period, if Executive and his eligible dependents who were covered under the Company’s health insurance plans as of the date of Executive’s Involuntary Termination elect to have COBRA coverage and are eligible for such coverage, the Company shall reimburse Executive on a monthly basis for an amount equal to (A) the monthly premium Executive is required to pay for continuation coverage pursuant to COBRA for Executive and his eligible dependents who were covered under the Company’s health plans as of the date of Executive’s Involuntary Termination (calculated by reference to the premium as of the date of Executive’s Involuntary Termination) less (B) the amount Executive would have had to pay to receive group health coverage for Executive and his covered dependents based on the cost sharing levels in effect on the date of Executive’s Involuntary Termination. If any of the Company’s health benefits are self-funded as of the date of Executive’s Involuntary Termination, or if the Company cannot provide the foregoing benefits in a manner that is exempt from Section 409A (as defined below) or that is otherwise compliant with applicable law (including, without limitation, Section 2716 of the Public Health Service Act), instead of providing the reimbursements as set forth above, the Company shall instead pay to Executive the foregoing monthly amount as a taxable monthly payment for the COBRA Coverage Period (or any remaining portion thereof). Executive shall be solely responsible for all matters relating to continuation of coverage pursuant to COBRA, including, without limitation, the election of such coverage and the timely payment of premiums.
iv. Notwithstanding anything to the contrary in this Section 4(c), and subject to Sections 4(e) and 9(o) and Executive's continued compliance with Section 5, in the event of Executive's Involuntary Termination during the period commencing sixty (60) days prior to a Change in Control and continuing until twelve (12) months following a Change in Control, Executive shall be entitled to receive, in addition to the severance benefits described in clauses (i), (ii) and (iii) above, an amount equal to Executive’s Bonus for the year in which Executive’s Involuntary Termination occurs, which amount shall be payable in a lump sum within ten (10) days following the later of (A) the effective date of Executive’s Release and (B) the date of the Change in Control.


d. Termination for Cause or Voluntary Resignation Without Good Reason. In the event of Executive’s termination of employment as a result of Executive’s discharge by the Company for Cause or Executive’s resignation without Good Reason (other than as a result of Executive’s death or Separation of Service by reason of discharge by the Company following Executive’s Permanent Disability), the Company shall not have any other or further obligations to Executive under this Agreement (including any financial obligations) except that Executive shall be entitled to receive (i) Executive’s fully earned but unpaid base salary, through the date of termination at the rate then in effect, and (ii) all other amounts or benefits to which Executive is entitled under any compensation, retirement or benefit plan or practice of the Company at the time of termination in accordance with the terms of such plans or practices, including, without limitation, any continuation of benefits required by COBRA or applicable law. In addition, in the event of Executive’s Separation from Service as a result of Executive’s discharge by the Company for Cause or Executive’s resignation without Good Reason (other than as a result of Executive’s death or Separation of Service by reason of discharge by the Company following Executive’s Permanent Disability), all vesting of Executive’s unvested Stock Awards previously granted to him by the Company shall cease and none of such unvested Stock Awards shall be exercisable following the date of such termination. The foregoing shall be in addition to, and not in lieu of, any and all other rights and remedies which may be available to the Company under the circumstances, whether at law or in equity.
e. Release. As a condition to Executive’s receipt of any post-termination benefits pursuant to Sections 4(b) and (c) above, Executive (or, in the event of Executive’s incapacity as a result of his Permanent Disability, Executive’s legal representative) shall execute and not revoke a general release of all claims in favor of the Company (the “Release”) in the form attached hereto as Exhibit A. In the event the Release does not become effective within the fifty-five (55) day period following the date of Executive’s Separation from Service, Executive shall not be entitled to the aforesaid payments and benefits.
f. Exclusive Remedy. Except as otherwise expressly required by law (e.g., COBRA) or as specifically provided herein, all of Executive’s rights to salary, severance, benefits, bonuses and other amounts hereunder (if any) accruing after the termination of Executive’s employment shall cease upon such termination. In the event of Executive’s termination of employment with the Company, Executive’s sole remedy shall be to receive the payments and benefits described in this Section 4. In addition, Executive acknowledges and agrees that he is not entitled to any reimbursement by the Company for any taxes payable by Executive as a result of the payments and benefits received by Executive pursuant to this Section 4, including, without limitation, any excise tax imposed by Section 4999 of the Code. Any payments made to Executive under this Section 4 shall be inclusive of any amounts or benefits to which Executive may be entitled pursuant to the WARN Act or the California WARN Act.
g. No Mitigation. Except as otherwise provided in Section 4(b)(iii) or 4(c)(iii) above, Executive shall not be required to mitigate the amount of any payment provided for in this Section 4 by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Section 4 be reduced by any compensation earned by Executive as the result of employment by another employer or self-employment or by retirement benefits; provided, however, that loans, advances or other amounts owed by Executive to the Company may be offset by the Company against amounts payable to Executive under this Section 4.


h. Return of the Company’s Property. In the event of Executive’s termination of employment for any reason, the Company shall have the right, at its option, to require Executive to vacate his offices prior to or on the effective date of separation and to cease all activities on the Company’s behalf. Upon Executive’s termination of employment in any manner, as a condition to Executive’s receipt of any severance benefits described in this Agreement, Executive shall immediately surrender to the Company all lists, books and records of, or in connection with, the Company’s business, and all other property belonging to the Company, it being distinctly understood that all such lists, books and records, and other documents, are the property of the Company. Executive shall deliver to the Company a signed statement certifying compliance with this Section 4(h) prior to the receipt of any severance benefits described in this Agreement.
i. Waiver of the Company’s Liability. Executive recognizes that his employment is subject to termination with or without Cause for any reason and therefore Executive agrees that Executive shall hold the Company harmless from and against any and all liabilities, losses, damages, costs and expenses, including but not limited to, court costs and reasonable attorneys’ fees, which Executive may incur as a result of Executive’s termination of employment. Executive further agrees that Executive shall bring no claim or cause of action against the Company for damages or injunctive relief based on a wrongful termination of employment. Executive agrees that the sole liability of the Company to Executive upon termination of this Agreement shall be that determined by this Section 4. In the event this covenant is more restrictive than permitted by laws of the jurisdiction in which the Company seeks enforcement thereof, this covenant shall be limited to the extent permitted by law.
4. Certain Covenants.
a. Noncompetition. Except as may otherwise be approved by the Board, during the term of Executive’s employment, Executive shall not have any ownership interest (of record or beneficial) in, or have any interest as an employee, salesman, consultant, officer or director in, or otherwise aid or assist in any manner, any firm, corporation, partnership, proprietorship or other business that engages in any county, city or part thereof in the United States and/or any foreign country in a business which competes directly or indirectly with the Company’s business in such county, city or part thereof, so long as the Company, or any successor in interest of the Company to the business and goodwill of the Company, remains engaged in such business in such county, city or part thereof or continues to solicit customers or potential customers therein; provided, however, that Executive may own, directly or indirectly, solely as an investment, securities of any entity which are traded on any national securities exchange if Executive (i) is not a controlling person of, or a member of a group which controls, such entity; or (ii) does not, directly or indirectly, own one percent (1%) or more of any class of securities of any such entity.


b. Confidential Information. Executive and the Company have entered into the Company’s standard employee proprietary information and inventions agreement (the “Employee Proprietary Information and Inventions Agreement”). Executive agrees to perform each and every obligation of Executive therein contained.
c. Solicitation of Employees. Executive shall not during the term of Executive’s employment and for the applicable severance period for which Executive receives severance benefits following any termination hereof pursuant to Section 4(b) or (c) above (regardless of whether Executive receives payment of severance amounts payable thereunder in a lump sum) (the “Restricted Period”), directly or indirectly, solicit or encourage to leave the employment of the Company or any of its affiliates, any employee of the Company or any of its affiliates.
d. Solicitation of Consultants. Executive shall not during the term of Executive’s employment and for the Restricted Period, directly or indirectly, hire, solicit or encourage to cease work with the Company or any of its affiliates any consultant then under contract with the Company or any of its affiliates within one year of the termination of such consultant’s engagement by the Company or any of its affiliates.
e. Rights and Remedies Upon Breach. If Executive breaches or threatens to commit a breach of any of the provisions of this Section 5 (the “Restrictive Covenants”), the Company shall have the following rights and remedies, each of which rights and remedies shall be independent of the other and severally enforceable, and all of which rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity:
i. Specific Performance. The right and remedy to have the Restrictive Covenants specifically enforced by any court having equity jurisdiction, all without the need to post a bond or any other security or to prove any amount of actual damage or that money damages would not provide an adequate remedy, it being acknowledged and agreed that any such breach or threatened breach will cause irreparable injury to the Company and that money damages will not provide adequate remedy to the Company; and
ii. Accounting and Indemnification. The right and remedy to require Executive (A) to account for and pay over to the Company all compensation, profits, monies, accruals, increments or other benefits derived or received by Executive or any associated party deriving such benefits as a result of any such breach of the Restrictive Covenants; and (B) to indemnify the Company against any other losses, damages (including special and consequential damages), costs and expenses, including actual attorneys’ fees and court costs, which may be incurred by them and which result from or arise out of any such breach or threatened breach of the Restrictive Covenants.


f. Severability of Covenants/Blue Pencilling. If any court determines that any of the Restrictive Covenants, or any part thereof, is invalid or unenforceable, the remainder of the Restrictive Covenants shall not thereby be affected and shall be given full effect, without regard to the invalid portions. If any court determines that any of the Restrictive Covenants, or any part thereof, are unenforceable because of the duration of such provision or the area covered thereby, such court shall have the power to reduce the duration or area of such provision and, in its reduced form, such provision shall then be enforceable and shall be enforced. Executive hereby waives any and all right to attack the validity of the Restrictive Covenants on the grounds of the breadth of their geographic scope or the length of their term.
g. Enforceability in Jurisdictions. The Company and Executive intend to and do hereby confer jurisdiction to enforce the Restrictive Covenants upon the courts of any jurisdiction within the geographical scope of such covenants. If the courts of any one or more of such jurisdictions hold the Restrictive Covenants wholly unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the Company and Executive that such determination not bar or in any way affect the right of the Company to the relief provided above in the courts of any other jurisdiction within the geographical scope of such covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants.
h. Definitions. For purposes of this Section 5, the term “Company” means not only Zogenix, Inc., but also any company, partnership or entity which, directly or indirectly, controls, is controlled by or is under common control with Zogenix, Inc.


i. Whistleblower Provision. Nothing herein is intended to or shall prevent Executive from communicating directly with, cooperating with, or providing information to, any federal, state or local government regulator, including, but not limited to, the U.S. Securities and Exchange Commission, the U.S. Commodity Futures Trading Commission, or the U.S. Department of Justice. Executive acknowledges that the Company has provided Executive with the following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act: (i) Executive shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of proprietary information of the Company that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, (ii) Executive shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of proprietary information of the Company that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (iii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the proprietary information to my attorney and use the proprietary information in the court proceeding, if Executive files any document containing the proprietary information under seal, and does not disclose the proprietary information, except pursuant to court order.
5. Insurance; Indemnification.
a. Insurance. The Company shall have the right to take out life, health, accident, “key-man” or other insurance covering Executive, in the name of the Company and at the Company’s expense in any amount deemed appropriate by the Company. Executive shall assist the Company in obtaining such insurance, including, without limitation, submitting to any required examinations and providing information and data required by insurance companies.
b. Indemnification. Executive will be provided with indemnification against third party claims related to his work for the Company as required by Delaware law. The Company shall provide Executive with directors and officers liability insurance coverage at least as favorable as that which the Company may maintain from time to time for members of the Board and other executive officers.


6. Arbitration. Any dispute, claim or controversy based on, arising out of or relating to Executive’s employment or this Agreement shall be settled by final and binding arbitration in Alameda County, California, before a single neutral arbitrator in accordance with the National Rules for the Resolution of Employment Disputes (the “Rules”) of the American Arbitration Association, and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction. The Rules may be found online at www.adr.org. Arbitration may be compelled pursuant to the California Arbitration Act (Code of Civil Procedure §§ 1280 et seq.). If the parties are unable to agree upon an arbitrator, one shall be appointed by the AAA in accordance with its Rules. Each party shall pay the fees of its own attorneys, the expenses of its witnesses and all other expenses connected with presenting its case; however, Executive and the Company agree that, to the extent permitted by law, the arbitrator may, in his or her discretion, award reasonable attorneys’ fees to the prevailing party; provided, further, that the prevailing party shall be reimbursed for such fees, costs and expenses within forty-five (45) days following any such award, but in no event later than the last day of Executive’s taxable year following the taxable year in which the fees, costs and expenses were incurred; provided, further, that the parties’ obligations pursuant to this sentence shall terminate on the tenth (10th) anniversary of the date of Executive’s termination of employment. Other costs of the arbitration, including the cost of any record or transcripts of the arbitration, AAA’s administrative fees, the fee of the arbitrator, and all other fees and costs, shall be borne by the Company. This Section 7 is intended to be the exclusive method for resolving any and all claims by the parties against each other for payment of damages under this Agreement or relating to Executive’s employment; provided, however, that Executive shall retain the right to file administrative charges with or seek relief through any government agency of competent jurisdiction, and to participate in any government investigation, including but not limited to (i) claims for workers’ compensation, state disability insurance or unemployment insurance; (ii) claims for unpaid wages or waiting time penalties brought before the California Division of Labor Standards Enforcement; provided, however, that any appeal from an award or from denial of an award of wages and/or waiting time penalties shall be arbitrated pursuant to the terms of this Agreement; and (iii) claims for administrative relief from the United States Equal Employment Opportunity Commission and/or the California Department of Fair Employment and Housing (or any similar agency in any applicable jurisdiction other than California); provided, further, that Executive shall not be entitled to obtain any monetary relief through such agencies other than workers’ compensation benefits or unemployment insurance benefits. This Agreement shall not limit either party’s right to obtain any provisional remedy, including, without limitation, injunctive or similar relief, from any court of competent jurisdiction as may be necessary to protect their rights and interests pending the outcome of arbitration, including without limitation injunctive relief, in any court of competent jurisdiction pursuant to California Code of Civil Procedure § 1281.8 or any similar statute of an applicable jurisdiction. Seeking any such relief shall not be deemed to be a waiver of such party’s right to compel arbitration. Both Executive and the Company expressly waive their right to a jury trial.
7. General Relationship. Executive shall be considered an employee of the Company within the meaning of all federal, state and local laws and regulations including, but not limited to, laws and regulations governing unemployment insurance, workers’ compensation, industrial accident, labor and taxes.
8. Miscellaneous.
a. Modification; Prior Claims. This Agreement and the Employee Proprietary Information and Inventions Agreement set forth the entire understanding of the parties with respect to the subject matter hereof, supersedes all existing agreements between them concerning such subject matter, including any offer letter provided to Executive by the Company. This Agreement may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances whatsoever.


b. Assignment; Assumption by Successor. The rights of the Company under this Agreement may, without the consent of Executive, be assigned by the Company, in its sole and unfettered discretion, to any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly, acquires all or substantially all of the assets or business of the Company. The Company will require any successor (whether direct or indirect, by purchase, merger or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and to agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place; provided, however, that no such assumption shall relieve the Company of its obligations hereunder.  As used in this Agreement, the “Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law or otherwise.
c. Survival. The covenants, agreements, representations and warranties contained in or made in Sections 3(g), 4, 5, 6, 7 and 9 of this Agreement shall survive any Executive’s termination of employment.
d. Third‑Party Beneficiaries. This Agreement does not create, and shall not be construed as creating, any rights enforceable by any person not a party to this Agreement.
e. Waiver. The failure of either party hereto at any time to enforce performance by the other party of any provision of this Agreement shall in no way affect such party’s rights thereafter to enforce the same, nor shall the waiver by either party of any breach of any provision hereof be deemed to be a waiver by such party of any other breach of the same or any other provision hereof.
f. Section Headings. The headings of the several sections in this Agreement are inserted solely for the convenience of the parties and are not a part of and are not intended to govern, limit or aid in the construction of any term or provision hereof.
g. Notices. Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight courier upon written verification of receipt; (iii) by email, telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to Executive at the address listed on the Company’s personnel records and to the Company at its principal place of business, or such other address as either party may specify in writing.
h. Severability. All Sections, clauses and covenants contained in this Agreement are severable, and in the event any of them shall be held to be invalid by any court, this Agreement shall be interpreted as if such invalid Sections, clauses or covenants were not contained herein.


i. Governing Law and Venue. This Agreement is to be governed by and construed in accordance with the laws of the State of California applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Except as provided in Sections 5 and 7, any suit brought hereon shall be brought in the state or federal courts sitting in Alameda County, California, the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to service of process in any manner authorized by California law.
j. Non-transferability of Interest. None of the rights of Executive to receive any form of compensation payable pursuant to this Agreement shall be assignable or transferable except through a testamentary disposition or by the laws of descent and distribution upon the death of Executive. Any attempted assignment, transfer, conveyance, or other disposition (other than as aforesaid) of any interest in the rights of Executive to receive any form of compensation to be made by the Company pursuant to this Agreement shall be void.
k. Gender. Where the context so requires, the use of the masculine gender shall include the feminine and/or neuter genders and the singular shall include the plural, and vice versa, and the word “person” shall include any corporation, firm, partnership or other form of association.
l. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same Agreement.
m. Construction. The language in all parts of this Agreement shall in all cases be construed simply, according to its fair meaning, and not strictly for or against any of the parties hereto. Without limitation, there shall be no presumption against any party on the ground that such party was responsible for drafting this Agreement or any part thereof.
n. Withholding and other Deductions. All compensation payable to Executive hereunder shall be subject to such deductions as the Company is from time to time required to make pursuant to law, governmental regulation or order.
o. Code Section 409A.


i. This Agreement is not intended to provide for any deferral of compensation subject to Section 409A of the Code, and, accordingly, the severance payments payable under Sections 4(b)(ii) and 4(c)(ii) and (iv) shall be paid no later than the later of: (A) the fifteenth (15th) day of the third month following Executive’s first taxable year in which such amounts are no longer subject to a substantial risk of forfeiture, and (B) the fifteenth (15th) day of the third month following first taxable year of the Company in which such amounts are is no longer subject to substantial risk of forfeiture, as determined in accordance with Code Section 409A and any Treasury Regulations and other guidance issued thereunder. To the extent applicable, this Agreement shall be interpreted in accordance with Code Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder. Each series of installment payments made under this Agreement is hereby designated as a series of “separate payments” within the meaning of Section 409A of the Code. For purposes of this Agreement, all references to Executive’s “termination of employment” shall mean Executive’s Separation from Service.
ii. If Executive is a “specified employee” (as defined in Section 409A of the Code), as determined by the Company in accordance with Section 409A of the Code, on the date of Executive’s Separation from Service, to the extent that the payments or benefits under this Agreement are subject to Section 409A of the Code and the delayed payment or distribution of all or any portion of such amounts to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, then such portion deferred pursuant to this Section 9(o)(ii) shall be paid or distributed to Executive in a lump sum on the earlier of (A) the date that is six (6)-months following Executive’s Separation from Service, (B) the date of Executive’s death or (C) the earliest date as is permitted under Section 409A of the Code. Any remaining payments due under the Agreement shall be paid as otherwise provided herein.
iii. To the extent applicable, this Agreement shall be interpreted in accordance with the applicable exemptions from Section 409A of the Code. If Executive and the Company determine that any payments or benefits payable under this Agreement intended to comply with Sections 409A(a)(2), (3) and (4) of the Code do not comply with Section 409A of the Code, Executive and the Company agree to amend this Agreement, or take such other actions as Executive and the Company deem reasonably necessary or appropriate, to comply with the requirements of Section 409A of the Code and the Treasury Regulations thereunder (and any applicable transition relief) while preserving the economic agreement of the parties. To the extent that any provision in this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner that no payments payable under this Agreement shall be subject to an “additional tax” as defined in Section 409A(a)(1)(B) of the Code.


iv. Any reimbursement of expenses or in-kind benefits payable under this Agreement shall be made in accordance with Treasury Regulation Section 1.409A-3(i)(1)(iv) and shall be paid on or before the last day of Executive’s taxable year following the taxable year in which Executive incurred the expenses. The amount of expenses reimbursed or in-kind benefits payable during any taxable year of Executive’s shall not affect the amount eligible for reimbursement or in-kind benefits payable in any other taxable year of Executive’s, and Executive’s right to reimbursement for such amounts shall not be subject to liquidation or exchange for any other benefit.
v. In the event that the amounts payable under Sections 4(b)(ii) and 4(c)(ii) and (iv) are subject to Section 409A of the Code and the timing of the delivery of Executive’s Release could cause such amounts to be paid in one or another taxable year, then notwithstanding the payment timing set forth in such sections, such amounts shall not be payable until the later of (A) the payment date specified in such section or (B) the first business day of the taxable year following Executive’s Separation from Service.
(Signature Page Follows)




IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above.
ZOGENIX, INC.
By:
/s/ Stephen J. Farr, Ph.D.
Name:
Stephen J. Farr, Ph.D.
Title:
Chief Executive Officer

EXECUTIVE

/s/ Ashish Sagrolikar
Ashish Sagrolikar



EXHIBIT A

GENERAL RELEASE OF CLAIMS

[The language in this Release may change based on legal developments and evolving best practices; this form is provided as an example of what will be included in the final Release document.]

This General Release of Claims (“Release”) is entered into as of this _____ day of ________, ____, between Ashish Sagrolikar (“Executive”), and Zogenix, Inc., a Delaware corporation (the “Company”) (collectively referred to herein as the “Parties”).

WHEREAS, Executive and the Company are parties to that certain Employment Agreement dated as of July 2, 2018 (the “Agreement”);

WHEREAS, the Parties agree that Executive is entitled to certain severance benefits under the Agreement, subject to Executive’s execution of this Release; and

WHEREAS, the Company and Executive now wish to fully and finally to resolve all matters between them.

NOW, THEREFORE, in consideration of, and subject to, the severance benefits payable to Executive pursuant to the Agreement, the adequacy of which is hereby acknowledged by Executive, and which Executive acknowledges that he would not otherwise be entitled to receive, Executive and the Company hereby agree as follows:
1. General Release of Claims by Executive.



a. Executive, on behalf of himself and his executors, heirs, administrators, representatives and assigns, hereby agrees to release and forever discharge the Company and all predecessors, successors and their respective parent corporations, affiliates, related, and/or subsidiary entities, and all of their past and present investors, directors, shareholders, officers, general or limited partners, employees, attorneys, agents and representatives, and the employee benefit plans in which Executive is or has been a participant by virtue of his employment with or service to the Company (collectively, the “Company Releasees”), from any and all claims, debts, demands, accounts, judgments, rights, causes of action, equitable relief, damages, costs, charges, complaints, obligations, promises, agreements, controversies, suits, expenses, compensation, responsibility and liability of every kind and character whatsoever (including attorneys’ fees and costs), whether in law or equity, known or unknown, asserted or unasserted, suspected or unsuspected (collectively, “Claims”), which Executive has or may have had against such entities based on any events or circumstances arising or occurring on or prior to the date hereof or on or prior to the date hereof, arising directly or indirectly out of, relating to, or in any other way involving in any manner whatsoever Executive’s employment by or service to the Company or the termination thereof, including any and all claims arising under federal, state, or local laws relating to employment, including without limitation claims of wrongful discharge, breach of express or implied contract, fraud, misrepresentation, defamation, or liability in tort, and claims of any kind that may be brought in any court or administrative agency including, without limitation, claims under Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. Section 2000, et seq.; the Americans with Disabilities Act, as amended, 42 U.S.C. § 12101 et seq.; the Rehabilitation Act of 1973, as amended, 29 U.S.C. § 701 et seq.; the Civil Rights Act of 1866, and the Civil Rights Act of 1991; 42 U.S.C. Section 1981, et seq.; the Age Discrimination in Employment Act, as amended, 29 U.S.C. Section 621, et seq. (the “ADEA”); the Equal Pay Act, as amended, 29 U.S.C. Section 206(d); regulations of the Office of Federal Contract Compliance, 41 C.F.R. Section 60, et seq.; the Family and Medical Leave Act, as amended, 29 U.S.C. § 2601 et seq.; the Fair Labor Standards Act of 1938, as amended, 29 U.S.C. § 201 et seq.; the Employee Retirement Income Security Act, as amended, 29 U.S.C. § 1001 et seq.; and the California Fair Employment and Housing Act, California Government Code Section 12940, et seq.

Notwithstanding the generality of the foregoing, Executive does not release the following claims:
i. Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law;
ii. Claims for workers’ compensation insurance benefits under the terms of any worker’s compensation insurance policy or fund of the Company;
iii. Claims pursuant to the terms and conditions of the federal law known as COBRA;
iv. Claims for indemnity under the bylaws of the Company, as provided for by California law or under any applicable insurance policy with respect to Executive’s liability as an employee, director or officer of the Company;
v. Claims based on any right Executive may have to enforce the Company’s executory obligations under the Agreement;
vi. Executive’s right to bring to the attention of the Equal Employment Opportunity Commission or the California Department of Fair Employment and Housing or any other federal, state or local government agency claims of discrimination, harassment, interference with leave rights or retaliation; provided, however, that Executive does release his right to secure any damages for such alleged treatment;
vii. Claims Executive may have to vested or earned compensation and benefits; and
viii. Executive’s right to communicate or cooperate with any governmental agency.


a. EXECUTIVE ACKNOWLEDGES THAT HE HAS BEEN ADVISED OF AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS:

“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM OR HER, MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.”

BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS HE MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.
[Note: Clauses (c), (d) and (e) apply only if Executive is age 40 or older at time of termination]

a. Executive acknowledges that this Release was presented to him on the date indicated above and that Executive is entitled to have [twenty-one (21)][forty-five (45)] days’ time in which to consider it. Executive further acknowledges that the Company has advised him that he is waiving her rights under the ADEA, and that Executive should consult with an attorney of his choice before signing this Release, and Executive has had sufficient time to consider the terms of this Release. Executive represents and acknowledges that if Executive executes this Release before [twenty-one (21)][forty-five (45)] days have elapsed, Executive does so knowingly, voluntarily, and upon the advice and with the approval of Executive’s legal counsel (if any), and that Executive voluntarily waives any remaining consideration period.
b. Executive understands that after executing this Release, Executive has the right to revoke it within seven (7) days after his execution of it. Executive understands that this Release will not become effective and enforceable unless the seven (7) day revocation period passes and Executive does not revoke the Release in writing. Executive understands that this Release may not be revoked after the seven (7) day revocation period has passed. Executive also understands that any revocation of this Release must be made in writing and delivered to the Company at its principal place of business within the seven (7) day period.
c. Executive understands that this Release shall become effective, irrevocable, and binding upon Executive on the eighth (8th) day after his execution of it, so long as Executive has not revoked it within the time period and in the manner specified in clause (d) above.
d. Executive further understands that Executive will not be given any severance benefits under the Agreement unless this Release is effective on or before the date that is fifty-five (55) days following the date of Executive’s termination of employment.



1. Whistleblower Provision. Nothing herein shall be construed to prohibit Executive from communicating directly with, cooperating with, or providing information to, any government regulator, including, but not limited to, the U.S. Securities and Exchange Commission, the U.S. Commodity Futures Trading Commission, or the U.S. Department of Justice. Executive acknowledges that the Company has provided Executive with the following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act: (i) Executive shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of proprietary information of the Company that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, (ii) Executive shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of proprietary information of the Company that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (iii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the proprietary information to my attorney and use the proprietary information in the court proceeding, if Executive files any document containing the proprietary information under seal, and does not disclose the proprietary information, except pursuant to court order.
2. No Assignment. Executive represents and warrants to the Company Releasees that there has been no assignment or other transfer of any interest in any Claim that Executive may have against the Company Releasees. Executive agrees to indemnify and hold harmless the Company Releasees from any liability, claims, demands, damages, costs, expenses and attorneys’ fees incurred as a result of any such assignment or transfer from Executive.
3. Severability. In the event any provision of this Release is found to be unenforceable by an arbitrator or court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being intended that the parties shall receive the benefit contemplated herein to the fullest extent permitted by law. If a deemed modification is not satisfactory in the judgment of such arbitrator or court, the unenforceable provision shall be deemed deleted, and the validity and enforceability of the remaining provisions shall not be affected thereby.


4. Interpretation; Construction. The headings set forth in this Release are for convenience only and shall not be used in interpreting this Agreement. This Release has been drafted by legal counsel representing the Company, but Executive has participated in the negotiation of its terms. Furthermore, Executive acknowledges that Executive has had an opportunity to review and revise the Release and have it reviewed by legal counsel, if desired, and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Release. Either party’s failure to enforce any provision of this Release shall not in any way be construed as a waiver of any such provision, or prevent that party thereafter from enforcing each and every other provision of this Release.
5. Governing Law and Venue. This Release will be governed by and construed in accordance with the laws of the United States of America and the State of California applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Any suit brought hereon shall be brought in the state or federal courts sitting in Alameda County, California, the Parties hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to service of process in any manner authorized by California law.
6. Entire Agreement. This Release and the Agreement constitute the entire agreement of the Parties in respect of the subject matter contained herein and therein and supersede all prior or simultaneous representations, discussions, negotiations and agreements, whether written or oral. This Release may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances whatsoever.
7. Counterparts. This Release may be executed in multiple counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.
(Signature Page Follows)





IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed the foregoing Release as of the date first written above.

EXECUTIVE
ZOGENIX, INC.
By:
Name: Ashish Sagrolikar
Name:
Title:


 EX-31.1 3 ex31120180930.htm EXHIBIT 31.1 Document

Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Stephen J. Farr, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Zogenix, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
/s/ Stephen J. Farr
Stephen J. Farr
President and Chief Executive Officer
(Principal Executive Officer)
Date: November 8, 2018 

 EX-31.2 4 ex31220180930.htm EXHIBIT 31.2 Document

Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Michael P. Smith, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Zogenix, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
/s/ Michael P. Smith
Michael P. Smith
Executive Vice President, Chief Financial Officer, Treasurer and Secretary
(Principal Financial Officer)
Date: November 8, 2018 

 EX-32.1 5 ex32120180930.htm EXHIBIT 32.1 Document

Exhibit 32.1
CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
In connection with the Quarterly Report on Form 10-Q of Zogenix, Inc. (the “Company”) for the period ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen J. Farr, as Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 8, 2018 
 
/s/ Stephen J. Farr
Stephen J. Farr
President and Chief Executive Officer
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-32.2 6 ex32220180930.htm EXHIBIT 32.2 Document

Exhibit 32.2
CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
In connection with the Quarterly Report on Form 10-Q of Zogenix, Inc. (the “Company”) for the period ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael P. Smith, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: November 8, 2018 
/s/ Michael P. Smith
Michael P. Smith
Executive Vice President, Chief Financial Officer, Treasurer and Secretary

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-101.SCH 7 zgnx-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Organization and Basis of Presentation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2105103 - Disclosure - Cash, Cash Equivalents and Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2108104 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 2112105 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2313303 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2116106 - Disclosure - Sale of Common Stock link:presentationLink link:calculationLink link:definitionLink 2417407 - Disclosure - Sale of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2118107 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2319304 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2420408 - Disclosure - Stock-Based Compensation - Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2421409 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2422410 - Disclosure - Stock-Based Compensation - Assumptions used in Black-Scholes Option-Pricing Model (Detail) link:presentationLink link:calculationLink link:definitionLink 2423411 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 2424412 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2125108 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2326305 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2427413 - Disclosure - Net Loss Per Share - Reconciliation of Numerator and Denominators in Computing Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2428414 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2129109 - Disclosure - United Kingdom (U.K.) Research and Development Incentives link:presentationLink link:calculationLink link:definitionLink 2430415 - Disclosure - United Kingdom (U.K.) Research and Development Incentives (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 zgnx-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 zgnx-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 zgnx-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Common Stock Common Stock [Member] Other Income and Expenses [Abstract] Range [Domain] Range [Domain] Common stock par value (usd per share) Common Stock, Par or Stated Value Per Share Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Number of lease renewal options Lessee, Operating Lease, Number of Renewal Options Lessee, Operating Lease, Number of Renewal Options Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Net loss per share, basic and diluted: Earnings Per Share, Basic [Abstract] Accounts payable Accounts Payable, Current Antidilutive Securities [Axis] Antidilutive Securities [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Accounting Policies [Abstract] Current portion of contingent consideration Fair value of contingent consideration Business Combination, Contingent Consideration, Liability, Current Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Amortization of debt issuance costs and debt discount Amortization of Debt Issuance Costs and Discounts Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Performance stock options Performance Shares [Member] Total cash, cash equivalents and marketable securities Cash, Cash Equivalents, and Short-term Investments Non-employee Director NonemployeeDirector [Member] Award Type [Domain] Equity Award [Domain] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Costs and expenses: Operating Expenses [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Additional number of options available for grant annually (shares) SharebasedCompensationArrangementbySharebasedPaymentAwardAdditionalNumberofSharesAvailableforGrantAnnually Number of options granted upon initial election to board (shares) SharebasedCompensationArrangementbySharebasedPaymentAwardInitialNumberofSharesGranted Contingent consideration, net of current portion Business Combination, Contingent Consideration, Liability, Noncurrent Granted - Weighted average fair value per share at grant date (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Additional paid-in capital Additional Paid in Capital, Common Stock Claim for refundable cash credit Income Taxes Receivable Marketable securities, estimated fair value Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value Liabilities measured at fair value on a recurring basis Financial and Nonfinancial Liabilities, Fair Value Disclosure Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Common stock outstanding (shares) Common Stock, Shares, Outstanding Level 1 Fair Value, Inputs, Level 1 [Member] Marketable securities, amortized cost Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost Marketable securities, amortized cost Debt Securities, Available-for-sale, Amortized Cost Cash Equivalents Cash and Cash Equivalents, Fair Value Disclosure Proceeds from issuance of common stock under equity incentive plans Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Weighted- Average Exercise Price per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Fair Value Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract] Liabilities Measured at Fair Value on Recurring Basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Goodwill Goodwill Percentage of outstanding options that vested (percent) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Percentage of Shares Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Percentage of Shares Outstanding Income Statement Location [Axis] Income Statement Location [Axis] Other assets Increase (Decrease) in Other Operating Assets Risk free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Change in fair value of common stock warrant liabilities Derivative, Gain (Loss) on Derivative, Net Canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Interest income Interest Income, Domestic Deposits Property and equipment, net Property, Plant and Equipment, Net Level 2 Fair Value, Inputs, Level 2 [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Preferred stock outstanding (shares) Preferred Stock, Shares Outstanding Schedule of Cash and Cash Equivalents [Table] Schedule of Cash and Cash Equivalents [Table] Vested - Weighted average fair value per share at grant date (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Number of Noncancelable Leases NumberofNoncancelableLeases December 31, 2017 (in shares) March 31, 2018 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Stock Options Employee Stock Option [Member] Due within one year, amortized cost Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost Expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Loss from operations Operating Income (Loss) Canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Changes in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Commitments and Contingencies Disclosure [Abstract] Noncash financing activities Noncash Investing and Financing Items [Abstract] Inventory Increase (Decrease) in Inventories Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Total (in dollars per share) Earnings Per Share, Basic and Diluted Outstanding at December 31, 2017 (in shares) Outstanding at March 31, 2018 (in shares) Outstanding RSUs at March 31, 2018 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Subsequent event Subsequent Event [Member] Shares subject to outstanding warrants to purchase common stock Warrant [Member] Change in unrealized losses on marketable securities, net of tax Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Accrued compensation Employee-related Liabilities, Current Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Asset impairment charges Asset Impairment Charges Expected payment for rent Payments for Rent Contract manufacturing revenue Revenue from Contract with Customer, Including Assessed Tax Expected volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Proceeds from stock issuance Stock Issued During Period, Value, New Issues Schedule of Future Minimum Payments Under Non-cancelable Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Total assets Cash Equivalents and Debt Securities, Available-for-sale Cash and Cash Equivalents [Abstract] Commitments and contingencies Commitments and Contingencies Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Underwriting discounts and commissions and other offering expenses Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Total net lease payments OperatingLeasesFutureMinimumPaymentsDueNet Research and development Research and Development Expense Other (expense) income, net Other Nonoperating Income (Expense) Total liabilities Liabilities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] 2020 gross lease payment due Operating Leases, Future Minimum Payments, Due in Three Years Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] U.S. Treasuries US Treasury Securities [Member] Trading Symbol Trading Symbol Amortized Cost and Fair Value of Cash, Cash Equivalents and Marketable Securities Cash, Cash Equivalents and Investments [Table Text Block] Warrants exercise price per share (usd per share) CommonStockWarrantExercisePricePerShare Document Period End Date Document Period End Date Cost and Fair Value of Marketable Securities Investments Classified by Contractual Maturity Date [Table Text Block] Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Stock-based compensation expense Allocated Share-based Compensation Expense Financial Instruments [Domain] Financial Instruments [Domain] Total sublease income Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals Potential contingent consideration payment, minimum Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Common stock, $0.001 par value; 50,000 shares authorized; 35,827 and 34,808 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively Common Stock, Value, Issued Assets Assets [Abstract] Research and development Research and Development Expense [Member] Cost of contract manufacturing Cost of Sales [Member] Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Organization, Consolidation and Presentation of Financial Statements [Abstract] Range [Axis] Range [Axis] Preferred stock authorized (shares) Preferred Stock, Shares Authorized Cash and cash equivalents Cash and cash equivalents, beginning of the period Cash and cash equivalents, end of the period Total cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Business Acquisition [Axis] Business Acquisition [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Prepaid expenses Prepaid Expense, Current Cost of contract manufacturing Cost of Goods and Services Sold Loss on extinguishment of debt Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Document Fiscal Year Focus Document Fiscal Year Focus Sale of Common Stock Stockholders' Equity Note Disclosure [Text Block] Revenue: Revenues [Abstract] Total assets Assets Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Marketable securities, estimated fair value Short-term fixed income securities Debt Securities, Available-for-sale Common stock warrant liabilities Warrants and Rights Outstanding 2020 sublease income OperatingLeasesFutureMinimumSubleaseIncomeDueinThreeYears Scenario [Axis] Scenario [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Schedule of Restricted Stock Unit Activity Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Document Type Document Type Other assets Other Assets, Noncurrent 2019 net lease payments OperatingLeasesFutureMinimumPaymentsNetDueinTwoYears Preferred stock issued (shares) Preferred Stock, Shares Issued Entity Emerging Growth Company Entity Emerging Growth Company Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Loss on contract termination Gain (Loss) on Contract Termination Income Statement [Abstract] Stock issued (in shares) Stock Issued During Period, Shares, New Issues Other income (expense): Nonoperating Income (Expense) [Abstract] Corporate debt securities Corporate Debt Securities [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Income tax benefit Income Tax Expense (Benefit) Common stock warrant liabilities CommonStockWarrantLiability [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] 2022 sublease income OperatingLeasesFutureMinimumSubleaseIncomeDueinFiveYears Total current assets Assets, Current 2018 (remaining 6 months) gross lease payment due Operating Leases, Future Minimum Payments, Remainder of Fiscal Year Net decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Anti-dilutive securities excluded from computation of earnings per share amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Statement of Financial Position [Abstract] Total current liabilities Liabilities, Current Length of each lease renewal Lessee, Operating Lease, Renewal Term Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] 2018 (remaining 6 months) sublease income OperatingLeasesFutureMinimumSubleaseIncomeRemainderofFiscalYear Risk free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 2022 gross lease payment due Operating Leases, Future Minimum Payments, Due in Five Years Restricted stock units Shares subject to outstanding restricted stock units Restricted Stock Units (RSUs) [Member] Total liabilities and stockholders’ equity Liabilities and Equity Summary of Stock Option Activity Share-based Compensation, Stock Options, Activity [Table Text Block] Continuing operations (in dollars per share) Net loss from continuing operations per share, basic and diluted (in dollars per share) Income (Loss) from Continuing Operations, Per Basic and Diluted Share 2019 gross lease payment due Operating Leases, Future Minimum Payments, Due in Two Years Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Class of Stock [Line Items] Class of Stock [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Equity Components [Axis] Equity Components [Axis] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period United Kingdom (U.K.) Research and Development Incentives Other Income and Other Expense Disclosure [Text Block] Canceled - Weighted average fair value per share at grant date (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Assumptions used in the Black-Scholes Option-Pricing Model Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Net loss from continuing operations Net loss from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Award Type [Axis] Award Type [Axis] Intangible assets Intangible Assets, Net (Excluding Goodwill) Counterparty Name [Domain] Counterparty Name [Domain] Proceeds from issuance of common stock under an at-the-market offering, net of issuance costs Proceeds from Issuance of Common Stock Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Organization and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Shares of common stock exercisable through warrants AggregateNumberOfCommonStockSharesExercisableFromWarrantsIssued Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 2020 net lease payments OperatingLeasesFutureMinimumPaymentsNetDueinThreeYears Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Common stock issued (shares) Common Stock, Shares, Issued Taxes paid related to net share settlement of equity awards Payments Related to Tax Withholding for Share-based Compensation Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-sale Shares subject to outstanding common stock options Equity Option [Member] ZX008 ZX008 [Member] Total costs and expenses Operating Expenses Preferred stock par value (usd per share) Preferred Stock, Par or Stated Value Per Share 2018 (remaining 6 months) net lease payments OperatingLeasesFutureMinimumPaymentsDueNetRemainderofFiscalYear Granted weighted average exercise price (in usd per share Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Cash Cash Outstanding weighted average exercise price, beginning balance (in usd per share) Outstanding weighted average exercise price, ending balance (in usd per share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Percentage of outstanding options that were canceled (percent) Share-based Compensation Arrangement by Share-based Payment Award, Options, Canceled, Percentage of Shares Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Canceled, Percentage of Shares Outstanding Stock-based compensation Share-based Compensation Net loss Net loss Net Income (Loss) Attributable to Parent 2022 net lease payments OperatingLeasesFutureMinimumPaymentsNetDueinFiveYears Employees and Executives EmployeesandExecutives [Member] Canceled weighted average exercise price (in usd per share Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Loss from continuing operations before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Net accretion and amortization of investments in marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Trade accounts receivable Increase (Decrease) in Accounts Receivable Entity Small Business Entity Small Business Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Level 3 Fair Value, Inputs, Level 3 [Member] Expected Scenario, Forecast [Member] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Total contingent consideration Business Combination, Contingent Consideration, Liability Entity Filer Category Entity Filer Category Total gross lease payment due Operating Leases, Future Minimum Payments Due Equity [Abstract] Inventory write-down Inventory Write-down Commercial paper Commercial Paper [Member] Liability Class [Axis] Liability Class [Axis] Counterparty Name [Axis] Counterparty Name [Axis] Stock-Based Compensation Expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] 2021 sublease income OperatingLeasesFutureMinimumSubleaseIncomeDueinFourYears Financial Instrument [Axis] Financial Instrument [Axis] Subsequent Event [Table] Subsequent Event [Table] Depreciation and amortization Depreciation, Depletion and Amortization Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Other current assets Other Assets, Current Total cash, cash equivalents and marketable securities Cash, Cash Equivalents, and Short-term Investments, Fair Value Entity Registrant Name Entity Registrant Name Asset Class [Axis] Asset Class [Axis] 2019 sublease income OperatingLeasesFutureMinimumSubleaseIncomeDueinTwoYears Total other income (expense) Nonoperating Income (Expense) Deferred revenue Increase (Decrease) in Contract with Customer, Liability Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Current liabilities: Liabilities, Current [Abstract] Selling, general and administrative Selling, General and Administrative Expenses [Member] Accrued clinical trial expenses AccruedClinicalExpenseCurrent Assets Measured at Fair Value on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Loss from discontinued operations, net of taxes Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Amendment Flag Amendment Flag Marketable securities, gross unrealized gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Selling, general and administrative Selling, General and Administrative Expense Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Potential contingent consideration payment, maximum Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Contingent consideration liabilities ContingentPurchaseConsideration [Member] Deferred income taxes Deferred Income Tax Liabilities, Net Nonvested at December 31, 2017 - Weighted average fair value per share at grant date (in usd per share) Nonvested at March 31, 2018 - Weighted average fair value per share at grant date (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Cash equivalents Cash Equivalents, at Carrying Value Money market funds Money market funds Money Market Funds [Member] Beginning Balance Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Asset impairment charges Impairment of Long-Lived Assets to be Disposed of 2021 gross lease payment due Operating Leases, Future Minimum Payments, Due in Four Years Entity Central Index Key Entity Central Index Key Term of new lease Lessee, Operating Lease, Term of Contract Certificate of deposits Bank Time Deposits [Member] Other accrued liabilities Other Accrued Liabilities, Current Statement of Cash Flows [Abstract] Interest expense Interest Expense Marketable securities, gross unrealized losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Weighted average common shares used in the calculation of basic and diluted net loss per common share (shares) Shares used in per share calculation (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Aggregate offering price Sale of Stock, Aggregate Offer Price Sale of Stock, Aggregate Offer Price Due between one and two years, amortized cost Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Two Years, Amortized Cost Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through second fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date. Shares (in thousands) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Net Loss per Share Earnings Per Share, Policy [Policy Text Block] Common stock authorized (shares) Common Stock, Shares Authorized Earnings Per Share [Abstract] Earnings Per Share [Abstract] Change in fair value of common stock warrant liabilities Fair Value Adjustment of Warrants Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Exercised weighted average exercise price (in usd per share Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Discontinued operations (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic and Diluted Share Minimum Minimum [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Extinguishment of Endo working capital advance note payable through net settlement of balances owed to the Company Notes Reduction Fair Value Disclosures [Abstract] Current assets: Assets, Current [Abstract] Marketable securities Debt Securities, Available-for-sale, Current Expected volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Cash Equivalents and Marketable Securities Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents, and Marketable Securities Cash, Cash Equivalents, and Short-term Investments [Text Block] Statements of Comprehensive Income (Loss) Statement of Comprehensive Income [Abstract] Stock-based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Other long-term liabilities Other Liabilities, Noncurrent Total stockholders’ equity Stockholders' Equity Attributable to Parent Due within one year, estimated fair value Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value Net Loss per Share Earnings Per Share [Text Block] 2021 net lease payments OperatingLeasesFutureMinimumPaymentsNetDueinFourYears Accounts payable, accrued and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Commission rate (percent) Sale of Stock, Commission, Percent Sale of Stock, Commission, Percent Amortized Cost Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Due between one and two years, estimated fair value Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Two Years, Fair Value Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through second fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date. Asset Class [Domain] Asset Class [Domain] Equity Component [Domain] Equity Component [Domain] Maximum Maximum [Member] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] EX-101.PRE 11 zgnx-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 zgnx-20180930_htm.xml IDEA: XBRL DOCUMENT 0001375151 2018-01-01 2018-09-30 0001375151 2017-01-01 2017-09-30 0001375151 us-gaap:CostOfSalesMember 2018-07-01 2018-09-30 0001375151 us-gaap:CostOfSalesMember 2017-07-01 2017-09-30 0001375151 us-gaap:CostOfSalesMember 2018-01-01 2018-09-30 0001375151 us-gaap:CostOfSalesMember 2017-01-01 2017-09-30 0001375151 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001375151 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0001375151 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001375151 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0001375151 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2018-09-30 0001375151 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-07-01 2017-09-30 0001375151 2016-12-31 0001375151 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-09-30 0001375151 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-09-30 0001375151 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001375151 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0001375151 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001375151 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001375151 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001375151 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0001375151 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001375151 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001375151 2017-09-30 0001375151 us-gaap:StockOptionMember 2018-07-01 2018-09-30 0001375151 us-gaap:StockOptionMember 2017-07-01 2017-09-30 0001375151 us-gaap:StockOptionMember 2018-01-01 2018-09-30 0001375151 us-gaap:StockOptionMember 2017-01-01 2017-09-30 0001375151 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2018-09-30 0001375151 us-gaap:RestrictedStockUnitsRSUMember 2017-07-01 2017-09-30 0001375151 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001375151 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-09-30 0001375151 us-gaap:WarrantMember 2018-07-01 2018-09-30 0001375151 us-gaap:WarrantMember 2017-07-01 2017-09-30 0001375151 us-gaap:CommercialPaperMember 2018-09-30 0001375151 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001375151 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001375151 us-gaap:CorporateDebtSecuritiesMember 2018-09-30 0001375151 us-gaap:MoneyMarketFundsMember 2018-09-30 0001375151 us-gaap:BankTimeDepositsMember 2018-09-30 0001375151 us-gaap:USTreasurySecuritiesMember 2018-09-30 0001375151 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member 2018-09-30 0001375151 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2018-09-30 0001375151 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member 2018-09-30 0001375151 us-gaap:CommercialPaperMember 2018-09-30 0001375151 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2018-09-30 0001375151 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-09-30 0001375151 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member 2018-09-30 0001375151 us-gaap:CorporateDebtSecuritiesMember 2018-09-30 0001375151 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2018-09-30 0001375151 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2018-09-30 0001375151 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2018-09-30 0001375151 us-gaap:MoneyMarketFundsMember 2018-09-30 0001375151 2018-10-31 0001375151 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member 2018-09-30 0001375151 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member 2018-09-30 0001375151 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member 2018-09-30 0001375151 us-gaap:BankTimeDepositsMember 2018-09-30 0001375151 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2018-09-30 0001375151 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-09-30 0001375151 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member 2018-09-30 0001375151 us-gaap:USTreasurySecuritiesMember 2018-09-30 0001375151 us-gaap:FairValueInputsLevel1Member 2018-09-30 0001375151 us-gaap:FairValueInputsLevel2Member 2018-09-30 0001375151 us-gaap:FairValueInputsLevel3Member 2018-09-30 0001375151 us-gaap:FairValueInputsLevel1Member zgnx:CommonStockWarrantLiabilityMember 2018-09-30 0001375151 us-gaap:FairValueInputsLevel2Member zgnx:CommonStockWarrantLiabilityMember 2018-09-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:CommonStockWarrantLiabilityMember 2018-09-30 0001375151 zgnx:CommonStockWarrantLiabilityMember 2018-09-30 0001375151 us-gaap:FairValueInputsLevel1Member zgnx:ContingentPurchaseConsiderationMember 2018-09-30 0001375151 us-gaap:FairValueInputsLevel2Member zgnx:ContingentPurchaseConsiderationMember 2018-09-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:ContingentPurchaseConsiderationMember 2018-09-30 0001375151 zgnx:ContingentPurchaseConsiderationMember 2018-09-30 0001375151 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0001375151 2018-09-30 0001375151 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0001375151 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0001375151 us-gaap:MoneyMarketFundsMember 2017-12-31 0001375151 us-gaap:FairValueInputsLevel1Member zgnx:CommonStockWarrantLiabilityMember 2017-12-31 0001375151 us-gaap:FairValueInputsLevel2Member zgnx:CommonStockWarrantLiabilityMember 2017-12-31 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:CommonStockWarrantLiabilityMember 2017-12-31 0001375151 zgnx:CommonStockWarrantLiabilityMember 2017-12-31 0001375151 us-gaap:FairValueInputsLevel1Member zgnx:ContingentPurchaseConsiderationMember 2017-12-31 0001375151 us-gaap:FairValueInputsLevel2Member zgnx:ContingentPurchaseConsiderationMember 2017-12-31 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:ContingentPurchaseConsiderationMember 2017-12-31 0001375151 2017-12-31 0001375151 zgnx:ContingentPurchaseConsiderationMember 2017-12-31 0001375151 us-gaap:FairValueInputsLevel1Member 2017-12-31 0001375151 us-gaap:FairValueInputsLevel2Member 2017-12-31 0001375151 us-gaap:FairValueInputsLevel3Member 2017-12-31 0001375151 zgnx:ZX008Member 2018-09-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:ContingentPurchaseConsiderationMember 2018-06-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:ContingentPurchaseConsiderationMember 2018-07-01 2018-09-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:ContingentPurchaseConsiderationMember 2017-06-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:ContingentPurchaseConsiderationMember 2017-07-01 2017-09-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:ContingentPurchaseConsiderationMember 2017-09-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:CommonStockWarrantLiabilityMember 2018-06-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:CommonStockWarrantLiabilityMember 2018-07-01 2018-09-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:CommonStockWarrantLiabilityMember 2017-06-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:CommonStockWarrantLiabilityMember 2017-07-01 2017-09-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:CommonStockWarrantLiabilityMember 2017-09-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:ContingentPurchaseConsiderationMember 2018-01-01 2018-09-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:ContingentPurchaseConsiderationMember 2016-12-31 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:ContingentPurchaseConsiderationMember 2017-01-01 2017-09-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:CommonStockWarrantLiabilityMember 2018-01-01 2018-09-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:CommonStockWarrantLiabilityMember 2016-12-31 0001375151 2018-07-01 2018-09-30 0001375151 us-gaap:FairValueInputsLevel3Member zgnx:CommonStockWarrantLiabilityMember 2017-01-01 2017-09-30 0001375151 us-gaap:SubsequentEventMember 2018-10-31 0001375151 us-gaap:ScenarioForecastMember 2019-01-01 2019-09-30 0001375151 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001375151 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001375151 us-gaap:CommonStockMember 2018-08-01 2018-08-31 0001375151 zgnx:NonemployeeDirectorMember 2018-03-31 0001375151 zgnx:NonemployeeDirectorMember 2018-02-28 0001375151 2017-07-01 2017-09-30 0001375151 us-gaap:PerformanceSharesMember 2018-09-30 0001375151 us-gaap:PerformanceSharesMember 2018-07-01 2018-09-30 0001375151 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0001375151 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001375151 us-gaap:RestrictedStockUnitsRSUMember 2018-09-30 0001375151 zgnx:EmployeesandExecutivesMember us-gaap:RestrictedStockUnitsRSUMember 2018-09-30 0001375151 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001375151 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0001375151 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001375151 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 shares iso4217:USD iso4217:USD shares zgnx:lease pure false 2018-09-30 2018 Q3 ZGNX ZOGENIX, INC. Accelerated Filer false false 0001375151 --12-31 0.001 0.001 50000000 50000000 41925000 34808000 41925000 34808000 0.001 0.001 10000000 10000000 0 0 0 0 P5Y 0.0280 0.0190 0.0230 0.0190 0.0290 0.0210 0.0290 0.0230 P3Y6M P6Y1M6D P3Y6M P5Y1M6D P6Y1M6D P6Y1M6D P6Y1M6D P6Y1M6D 0.799 0.751 0.799 0.751 0.832 0.755 0.852 0.766 10-Q 41968019 163038000 293503000 376087000 0 6861000 5994000 1286000 5206000 547272000 304703000 244000 245000 102500000 102500000 6234000 6234000 3380000 3931000 659630000 417613000 4110000 3356000 10674000 8657000 5039000 6616000 2413000 1842000 32500000 0 607000 512000 55343000 20983000 47600000 76900000 17425000 17425000 482000 784000 120850000 116092000 0 0 42000 35000 1212305000 873526000 -673521000 -572040000 -46000 0 538780000 301521000 659630000 417613000 0 0 0 9821000 0 0 0 10729000 27608000 21178000 77329000 49369000 11016000 6073000 27663000 18129000 0 -478000 0 -478000 0 196000 0 1116000 5700000 10500000 3200000 11600000 44324000 38425000 108192000 91421000 -44324000 -38425000 -108192000 -81600000 2133000 121000 3995000 332000 0 702000 6000 2065000 0 -3378000 0 -3378000 -64000 -380000 -95000 360000 -9000 62000 3015000 71000 2060000 -4277000 6909000 -4680000 -42264000 -42702000 -101283000 -86280000 0 -42000 0 -41000 -42264000 -42660000 -101283000 -86239000 0 -134000 -198000 -870000 -42264000 -42794000 -101481000 -87109000 -1.08 -1.68 -2.78 -3.45 0 0 0 -0.03 -1.08 -1.68 -2.78 -3.48 39242000 25431000 36485000 25024000 -42264000 -42794000 -101481000 -87109000 -46000 0 -46000 0 -42310000 -42794000 -101527000 -87109000 -101481000 -87109000 11952000 4066000 76000 408000 0 753000 521000 0 0 -3378000 0 2232000 0 1116000 95000 -360000 3200000 11600000 0 -9356000 0 -2583000 -1429000 -4996000 -551000 2413000 1463000 4204000 0 -1245000 -83236000 -46435000 375612000 0 75000 35000 -375687000 -35000 6749000 271000 1426000 0 323135000 19378000 328458000 19649000 -130465000 -26821000 293503000 91551000 163038000 64730000 0 7000000 Organization and Basis of Presentation<div style="text-indent:27pt;margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Zogenix, Inc., including its wholly-owned subsidiaries (the “Company”), is a pharmaceutical company developing and commercializing innovative central nervous system (“CNS”) therapies for people living with serious and life-threatening rare CNS disorders and medical conditions. The Company’s current primary area of therapeutic focus is rare, or “orphan” childhood-onset epilepsy disorders and its lead product candidate is ZX008. ZX008 is currently being developed for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut Syndrome. The Company operates in one business segment—the research, development and commercialization of pharmaceutical products and its headquarters are located in Emeryville, California.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:27pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The accompanying condensed consolidated financial statements include the accounts of Zogenix, Inc. and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. In the opinion of management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. Certain reclassifications have been made to the prior period amounts to conform to the current year presentation. “Accrued clinical trial expenses” and “Other accrued liabilities”, which previously were reported as “Accrued expenses” on the condensed consolidated balance sheet, are now reported as separate line items. Additionally, previously reported “Interest expense, net” has been reclassified to present interest income and interest expense separately in the accompanying condensed consolidated statements of operations. The results of operations for any interim period are not necessarily indicative of results of operations for any future period. Certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted. Accordingly, these unaudited interim condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on March 6, 2018.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Future Funding Requirements</span></div><div style="text-indent:27pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Excluding gains from two discrete business divestitures, the Company has incurred significant net losses and negative cash flows from operating activities since inception resulting in an accumulated deficit of $673.5 million at September 30, 2018. The Company expects to continue to incur significant operating losses and negative cash flows from operations to advance its product candidates through development and commercialization. Additionally, upon acceptance of the Company’s regulatory submissions for ZX008 by the U.S. Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”) and regulatory approval of ZX008 by the FDA or EMA, if at all, each a milestone event, the Company will owe milestone payments under an existing agreement in connection with the Company’s prior acquisition of ZX008. To date, the Company has relied primarily on the proceeds from equity offerings to finance its operations. See Note 6 for the Company's recent equity offerings.</span></div><div style="text-indent:27pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Until the Company can generate a sufficient amount of revenue to finance its cash requirements, if ever, the Company may need to continue to rely on additional financing to achieve its business objectives. However, if such financing is not available at adequate levels when needed, the Company may be required to significantly delay, scale back or discontinue one or more of the product development programs or commercialization efforts or other aspects of its business plans, and its operating results and financial condition would be adversely affected.</span></div> -673500000 Summary of Significant Accounting Policies<div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Significant Accounting Policies</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">There have been no material changes to the Company’s significant accounting policies from those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, other than as set forth below.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Equivalents and Marketable Securities</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company considers cash equivalents to be only those investments which are highly liquid, readily convertible to cash and have an original maturity of three months or less at the date of purchase.</span></div><div style="text-indent:22pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company invests its excess cash in marketable securities with high credit ratings that are classified as Level 1 and Level 2 within the fair value hierarchy. These marketable securities consists of money market funds and certificate of deposits, securities issued by the U.S. government and its agencies, corporate debt securities and commercial paper, which are all classified as “available-for-sale”. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and, therefore, classifies all securities with maturity dates beyond three months at the date of purchase as current assets on the condensed consolidated balance sheets. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the condensed consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on marketable securities are included in interest income (expense), net. The cost of securities sold is determined using the specific identification method.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and management’s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk</span></div><div style="text-indent:22pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cash, cash equivalents and marketable securities are financial instruments that potentially subject the Company to concentration of credit risk. The Company invests its excess cash primarily in money market funds and certificate of deposits, securities issued by the U.S. government and its agencies, corporate debt securities and commercial paper. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe it is exposed to any significant credit risk related to these instruments. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Accounting Pronouncements Recently Adopted</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Accounting Standards Update (“ASU”) 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Revenue from Contracts with Customers (Topic 606) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">and subsequent amendments to the initial guidance (collectively, “Topic 606”) amended the existing accounting standards for revenue recognition. The core principle of Topic 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. The Company adopted Topic 606 effective January 1, 2018 using the modified retrospective approach. The adoption of Topic 606 did not have a material impact on the Company’s condensed consolidated financial statements as the Company does not have any contracts with customers.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ASU 2016-15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Statement of Cash Flows (Topic 230) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">provides guidance on eight specific cash flow issues, thereby reducing the diversity in practice in how certain transactions are classified in the statement of cash flows. The amendments in this ASU are applied using a retrospective transition method to each period presented. The Company adopted ASU 2016-15</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> effective January 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ASU 2017-01, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Business Combinations (Topic 805): Clarifying the Definition of a Business </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">narrows the definition of a business and provides additional guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This accounting standards update is required to be applied prospectively to transactions occurring after the date of adoption. The Company adopted ASU 2017-09 effective January 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ASU 2017-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> provides guidance on determining changes to the terms and conditions of share-based payment awards and require an entity to apply modification accounting under Topic 718 unless all of the following conditions are met: (1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification; (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The amendments should be applied prospectively to an award modified on or after the adoption date. The Company adopted ASU 2017-09 effective January 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On December 22, 2017, the U.S. federal government enacted the Tax Cuts and Jobs Act (“the Act”). The Tax Act contains, among other things, significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% for tax years beginning after December 31, 2017, limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, implementing a territorial tax system, and requiring a mandatory one-time tax on U.S. owned undistributed foreign earnings and profits known as the transition tax. In December 2017, SEC staff issued Staff Accounting Bulletin No. 118, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Income Tax Accounting Implications of the Tax Cuts and Jobs Act</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (“SAB 118”) to address the accounting implications of recently enacted U.S. federal tax reform. SAB 118 allows companies to record provisional amounts during a measurement period not to extend beyond one year of the enactment date to address ongoing guidance and tax interpretations that are expected over the next 12 months. The Company has adopted SAB 118 and currently considers its accounting of the impact of U.S. federal tax reform to be incomplete but continues to make a reasonable estimate of the effects on our existing deferred tax assets. The Company expects to complete the remainder of the analysis within the measurement period in accordance with SAB 118. Adjustments, if any, are not expected to impact the condensed consolidated statement of operations and comprehensive loss due to the full valuation allowance on the Company’s deferred tax assets.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ASU 2018-07, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Compensation—Stock Compensation (Topic 718):</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Improvements to Nonemployee Share-Based Payment Accounting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> simplifies the accounting for share-based payment awards issued to nonemployees for goods and services, including fixing the estimated fair value of the stock award at the date of grant. ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The adoption of ASU 2018-07 requires a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year. ASU 2018-07 is effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company early adopted ASU 2018-07 effective July 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In August 2018, the SEC adopted amendments to certain disclosure requirements in Securities Act Release No. 33-10532, Disclosure Update and Simplification. These amendments eliminate, modify, or integrate into other SEC requirements certain disclosure rules. Among the amendments is the requirement to present an analysis of changes in stockholders’ equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments became effective for all filings made on or after November 5, 2018. In light of the anticipated timing of effectiveness of the amendments and expected proximity of effectiveness to the filing date for most filers’ quarterly reports, the SEC’s Division of Corporate Finance issued a Compliance and Disclosure Interpretation related to Exchange Act Forms, or CDI – Question 105.09, that provides transition guidance related to this disclosure requirement. CDI – Question 105.09 states that the SEC would not object if the filer’s first presentation of the changes in shareholders’ equity is included in its Form 10-Q for the quarter that begins after the effective date of the amendments. Except for the requirement to provide the annual disclosure </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> changes in stockholders’ equity for interim periods, which will be included beginning with the Company's quarterly report on Form 10-Q ending March 31, 2019, the Company has adopted all relevant disclosure requirements.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Accounting Pronouncements Issued But Not Yet Effective</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ASU 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Leases (Topic 842) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">establishes a right-of-use model (“ROU”) that requires all lessees to recognize ROU assets and liabilities for leases with a duration greater than one year on the balance sheet as well as provide disclosures with respect to certain qualitative and quantitative information regarding the amount, timing and uncertainty of cash flows arising from leases. Both a ROU asset and liability will initially be measured at the present value of the future minimum lease payments over the lease term. Subsequent measurement, including the presentation of expenses and cash flows, will depend on the classification of the lease as either a finance or an operating lease. Initial costs directly attributable to negotiating and arranging the lease will be included in the asset. The new standard is effective for fiscal years beginning after December 15, 2018, and interim periods therein. Early adoption is permitted. Originally, entities were required to adopt ASU 2016-02 using a modified retrospective approach, which required prior periods to be presented under this new standard with various practical expedients allowed. In July 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Leases (Topic 842): Targeted Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">, which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption (January 1, 2019) while continuing to present all prior periods under previous lease accounting guidance. The Company intends to adopt the standard on January 1, 2019 by recognizing a cumulative effect adjustment to the opening balance of retained earnings and utilizing the practical expedient that allows the Company to not reassess whether an expired or existing contract contains a lease, the classification of leases or initial direct costs. The Company is in the process of inventorying and scoping its existing lease contracts. While the Company is currently evaluating the impact of adopting this accounting standard update on its condensed consolidated financial statements and related disclosures, the Company anticipates that ROU assets and corresponding liabilities will be recognized in its condensed consolidated balance sheets related to its lease arrangements. The adoption of these standards are also expected to impact the Company’s condensed consolidated financial statement disclosures.</span></div><div style="text-indent:24pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ASU 2017-04,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"> Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. Under the amendments in ASU 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds its fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The updated guidance requires a prospective adoption. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the timing and impact of adopting this ASU on its condensed consolidated financial statements and related disclosures.</span></div><div style="text-indent:24pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ASU 2018-13,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"> Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">modifies the disclosure requirements in Topic 820, Fair Value Measurement, by removing certain disclosure requirements related to the fair value hierarchy, modifying existing disclosure requirements related to measurement uncertainty and adding new disclosure requirements, such as disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and disclosing the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for public companies for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year. Early adoption is permitted for any removed or modified disclosures. The Company is currently evaluating the timing and impact of adopting this ASU on its condensed consolidated financial statements and related disclosures.</span></div> <div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.</span></div> <div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Equivalents and Marketable Securities</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company considers cash equivalents to be only those investments which are highly liquid, readily convertible to cash and have an original maturity of three months or less at the date of purchase.</span></div><div style="text-indent:22pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company invests its excess cash in marketable securities with high credit ratings that are classified as Level 1 and Level 2 within the fair value hierarchy. These marketable securities consists of money market funds and certificate of deposits, securities issued by the U.S. government and its agencies, corporate debt securities and commercial paper, which are all classified as “available-for-sale”. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and, therefore, classifies all securities with maturity dates beyond three months at the date of purchase as current assets on the condensed consolidated balance sheets. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the condensed consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on marketable securities are included in interest income (expense), net. The cost of securities sold is determined using the specific identification method.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and management’s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value.</span></div> Concentration of Credit RiskCash, cash equivalents and marketable securities are financial instruments that potentially subject the Company to concentration of credit risk. The Company invests its excess cash primarily in money market funds and certificate of deposits, securities issued by the U.S. government and its agencies, corporate debt securities and commercial paper. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe it is exposed to any significant credit risk related to these instruments. <div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Accounting Pronouncements Recently Adopted</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Accounting Standards Update (“ASU”) 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Revenue from Contracts with Customers (Topic 606) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">and subsequent amendments to the initial guidance (collectively, “Topic 606”) amended the existing accounting standards for revenue recognition. The core principle of Topic 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. The Company adopted Topic 606 effective January 1, 2018 using the modified retrospective approach. The adoption of Topic 606 did not have a material impact on the Company’s condensed consolidated financial statements as the Company does not have any contracts with customers.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ASU 2016-15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Statement of Cash Flows (Topic 230) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">provides guidance on eight specific cash flow issues, thereby reducing the diversity in practice in how certain transactions are classified in the statement of cash flows. The amendments in this ASU are applied using a retrospective transition method to each period presented. The Company adopted ASU 2016-15</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> effective January 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ASU 2017-01, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Business Combinations (Topic 805): Clarifying the Definition of a Business </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">narrows the definition of a business and provides additional guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This accounting standards update is required to be applied prospectively to transactions occurring after the date of adoption. The Company adopted ASU 2017-09 effective January 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ASU 2017-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> provides guidance on determining changes to the terms and conditions of share-based payment awards and require an entity to apply modification accounting under Topic 718 unless all of the following conditions are met: (1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification; (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The amendments should be applied prospectively to an award modified on or after the adoption date. The Company adopted ASU 2017-09 effective January 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On December 22, 2017, the U.S. federal government enacted the Tax Cuts and Jobs Act (“the Act”). The Tax Act contains, among other things, significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% for tax years beginning after December 31, 2017, limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, implementing a territorial tax system, and requiring a mandatory one-time tax on U.S. owned undistributed foreign earnings and profits known as the transition tax. In December 2017, SEC staff issued Staff Accounting Bulletin No. 118, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Income Tax Accounting Implications of the Tax Cuts and Jobs Act</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (“SAB 118”) to address the accounting implications of recently enacted U.S. federal tax reform. SAB 118 allows companies to record provisional amounts during a measurement period not to extend beyond one year of the enactment date to address ongoing guidance and tax interpretations that are expected over the next 12 months. The Company has adopted SAB 118 and currently considers its accounting of the impact of U.S. federal tax reform to be incomplete but continues to make a reasonable estimate of the effects on our existing deferred tax assets. The Company expects to complete the remainder of the analysis within the measurement period in accordance with SAB 118. Adjustments, if any, are not expected to impact the condensed consolidated statement of operations and comprehensive loss due to the full valuation allowance on the Company’s deferred tax assets.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ASU 2018-07, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Compensation—Stock Compensation (Topic 718):</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Improvements to Nonemployee Share-Based Payment Accounting</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> simplifies the accounting for share-based payment awards issued to nonemployees for goods and services, including fixing the estimated fair value of the stock award at the date of grant. ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The adoption of ASU 2018-07 requires a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year. ASU 2018-07 is effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company early adopted ASU 2018-07 effective July 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In August 2018, the SEC adopted amendments to certain disclosure requirements in Securities Act Release No. 33-10532, Disclosure Update and Simplification. These amendments eliminate, modify, or integrate into other SEC requirements certain disclosure rules. Among the amendments is the requirement to present an analysis of changes in stockholders’ equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments became effective for all filings made on or after November 5, 2018. In light of the anticipated timing of effectiveness of the amendments and expected proximity of effectiveness to the filing date for most filers’ quarterly reports, the SEC’s Division of Corporate Finance issued a Compliance and Disclosure Interpretation related to Exchange Act Forms, or CDI – Question 105.09, that provides transition guidance related to this disclosure requirement. CDI – Question 105.09 states that the SEC would not object if the filer’s first presentation of the changes in shareholders’ equity is included in its Form 10-Q for the quarter that begins after the effective date of the amendments. Except for the requirement to provide the annual disclosure </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> changes in stockholders’ equity for interim periods, which will be included beginning with the Company's quarterly report on Form 10-Q ending March 31, 2019, the Company has adopted all relevant disclosure requirements.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Accounting Pronouncements Issued But Not Yet Effective</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ASU 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Leases (Topic 842) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">establishes a right-of-use model (“ROU”) that requires all lessees to recognize ROU assets and liabilities for leases with a duration greater than one year on the balance sheet as well as provide disclosures with respect to certain qualitative and quantitative information regarding the amount, timing and uncertainty of cash flows arising from leases. Both a ROU asset and liability will initially be measured at the present value of the future minimum lease payments over the lease term. Subsequent measurement, including the presentation of expenses and cash flows, will depend on the classification of the lease as either a finance or an operating lease. Initial costs directly attributable to negotiating and arranging the lease will be included in the asset. The new standard is effective for fiscal years beginning after December 15, 2018, and interim periods therein. Early adoption is permitted. Originally, entities were required to adopt ASU 2016-02 using a modified retrospective approach, which required prior periods to be presented under this new standard with various practical expedients allowed. In July 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-11, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Leases (Topic 842): Targeted Improvements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">, which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption (January 1, 2019) while continuing to present all prior periods under previous lease accounting guidance. The Company intends to adopt the standard on January 1, 2019 by recognizing a cumulative effect adjustment to the opening balance of retained earnings and utilizing the practical expedient that allows the Company to not reassess whether an expired or existing contract contains a lease, the classification of leases or initial direct costs. The Company is in the process of inventorying and scoping its existing lease contracts. While the Company is currently evaluating the impact of adopting this accounting standard update on its condensed consolidated financial statements and related disclosures, the Company anticipates that ROU assets and corresponding liabilities will be recognized in its condensed consolidated balance sheets related to its lease arrangements. The adoption of these standards are also expected to impact the Company’s condensed consolidated financial statement disclosures.</span></div><div style="text-indent:24pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ASU 2017-04,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"> Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. Under the amendments in ASU 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds its fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The updated guidance requires a prospective adoption. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the timing and impact of adopting this ASU on its condensed consolidated financial statements and related disclosures.</span></div><div style="text-indent:24pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">ASU 2018-13,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"> Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">modifies the disclosure requirements in Topic 820, Fair Value Measurement, by removing certain disclosure requirements related to the fair value hierarchy, modifying existing disclosure requirements related to measurement uncertainty and adding new disclosure requirements, such as disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and disclosing the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for public companies for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year. Early adoption is permitted for any removed or modified disclosures. The Company is currently evaluating the timing and impact of adopting this ASU on its condensed consolidated financial statements and related disclosures.</span></div> Cash, Cash Equivalents and Marketable SecuritiesThe following table summarizes the amortized cost and fair value of the Company's cash, cash equivalents and marketable securities as of September 30, 2018 (in thousands):<div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:36.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets: </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,747 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,747 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents: </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,127 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,127 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,624 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,624 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">97,686 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">97,686 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificate of deposits </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">854 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">854 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">158,291 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">158,291 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">163,038 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">163,038 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">174,769 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">174,769 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">47,416 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(30)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">47,386 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificate of deposits </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">118,775 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">118,775 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35,173 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(16)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35,157 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">376,133 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(47)</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">376,087 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and marketable securities </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">539,171 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(47)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">539,125 </span></td></tr></table></div><div style="text-indent:24pt;margin-top:15pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the cost and fair value of marketable securities based on stated effective maturities as of September 30, 2018 (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:67.298246%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Due within one year </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">345,678 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">345,644 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Due between one and two years </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">30,455 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">30,443 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">376,133 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">376,087 </span></td></tr></table></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company did not hold any marketable securities as of December 31, 2017.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">There have been no significant realized gains or losses on available-for-sale securities for the periods presented. Available-for-sale debt securities that were in a continuous loss position but were not deemed to be other than temporarily impaired were immaterial at September 30, 2018.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">See Note 4 for further information regarding the fair value of the Company's financial instruments.</span></div> The following table summarizes the amortized cost and fair value of the Company's cash, cash equivalents and marketable securities as of September 30, 2018 (in thousands):<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:36.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets: </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,747 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,747 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents: </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,127 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,127 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,624 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,624 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">97,686 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">97,686 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificate of deposits </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">854 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">854 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">158,291 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">158,291 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and cash equivalents </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">163,038 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">163,038 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">174,769 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">174,769 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">47,416 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(30)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">47,386 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificate of deposits </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">118,775 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">118,775 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35,173 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(16)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35,157 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">376,133 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(47)</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">376,087 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and marketable securities </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">539,171 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(47)</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">539,125 </span></td></tr></table> 4747000 4747000 58127000 58127000 1624000 1624000 97686000 97686000 854000 854000 158291000 158291000 163038000 163038000 174769000 1000 1000 174769000 47416000 0 30000 47386000 118775000 0 0 118775000 35173000 0 16000 35157000 376133000 1000 47000 376087000 539171000 1000 47000 539125000 <div style="text-indent:24pt;margin-top:15pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the cost and fair value of marketable securities based on stated effective maturities as of September 30, 2018 (in thousands):</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:67.298246%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Due within one year </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">345,678 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">345,644 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Due between one and two years </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">30,455 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">30,443 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">376,133 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">376,087 </span></td></tr></table></div> 345678000 345644000 30455000 30443000 376133000 376087000 Fair Value Measurements<div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The carrying amount of the Company’s financial instruments, including cash and cash equivalents, other current assets, accounts payable, accrued and other current liabilities approximate their fair value due to their short maturities. </span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="padding-left:36pt;margin-top:9pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.982456%;"><tr><td style="width:1.0%;"/><td style="width:7.591195%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:88.408805%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1: </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Observable inputs such as quoted prices in active markets;</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2: </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3: </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></div></td></tr></table></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following tables summarize assets and liabilities recognized or disclosed at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:36.742690%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384795%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">September 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets: </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents: </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,127 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,127 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,624 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,624 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">97,686 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">97,686 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificate of deposits </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">854 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">854 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">174,769 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">174,769 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">47,386 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">47,386 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificate of deposits </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">118,775 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">118,775 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35,157 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35,157 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:30pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets(1) </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">97,686 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">436,692 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">534,378 </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liabilities(2) </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">607 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">607 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liabilities(3) </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,100 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,100 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:30pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,707 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,707 </span></td></tr></table></div><div style="margin-top:9pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:41.274854%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384795%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384795%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384795%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384795%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">December 31, 2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets: </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents consisting of money market funds(1) </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">289,782 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">289,782 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:30pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">289,782 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">289,782 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liabilities(2) </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">512 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">512 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liabilities(3) </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">76,900 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">76,900 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:30pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">77,412 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">77,412 </span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(1) Fair value is determined by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry standard valuation models, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs. </span></div><div style="text-indent:-13.5pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(2) Represents the fair value of common stock warrants outstanding that may require cash settlement under certain circumstances. The Company estimated the fair value of the warrant liabilities using the Black-Scholes valuation model. As of December 31, 2017 and September 30, 2018, common stock warrant liabilities relate to warrants issued in July 2011 in connection with a debt financing arrangement. The warrants entitle the holder to purchase up to 28,125 shares of common stock at an exercise price of $72.00 per share. The warrants will expire in July 2021.</span></div><div style="text-indent:-13.5pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(3) In connection with a prior acquisition, the Company may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. The Company estimated the fair value of the contingent consideration liabilities on the acquisition date using a probability-weighted income approach, which reflects the probability and timing of future payments. This fair value measurement is based on significant Level 3 inputs such as the anticipated timelines and probability of achieving development, regulatory approval or sales-based milestone events and projected revenues. The resulting probability-weighted cash flows are discounted at risk-adjusted rates. Subsequent to the acquisition date, at each reporting period prior to settlement, the Company revalues these liabilities by performing a review of the assumptions listed above and record increases or decreases in the fair value of these contingent consideration liabilities. In the absence of any significant changes in key assumptions, the quarterly determination of fair values of these contingent consideration liabilities would primarily reflect the passage of time and</span></div><div style="padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> risk-adjusted interest rates. Significant judgment is used in determining Level 3 inputs and fair value measurements as of the acquisition date and for each subsequent reporting period. Updates to assumptions could have a significant impact on the Company’s results of operations in any given period and actual results may differ from estimates. For example, significant increases in the probability of achieving a milestone or projected revenues would result in a significantly higher fair value measurement while significant decreases in the estimated probability of achieving a milestone or projected revenues would result in a significantly lower fair value measurement. Significant increases in the discount rate or in the anticipated timelines would result in a significantly lower fair value measurement while significant decreases in the discount rate or anticipated timelines would result in a significantly higher fair value measurement. The potential contingent consideration payments required upon achievement of development, regulatory approval and sales-based milestones related to the Company’s acquisition of ZX008 range from zero if none of the milestones are achieved to a maximum of $95.0 million (undiscounted). As of September 30, 2018, the Company has classified $32.5 million of the total contingent consideration liabilities of $80.1 million as current liabilities. The classification was based upon the Company’s reasonable expectation as to the timing of settlement of certain specified milestones.</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table provides a reconciliation of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and nine months ended September 30, 2018 and 2017 (in thousands): </span></div><div style="text-indent:24pt;margin-top:9pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:29.323529%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.176471%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.147059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.176471%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.176471%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.147059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.176471%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in Fair Value </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in Fair Value </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liabilities </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">74,400 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,700 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,100 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">53,900 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10,500 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">64,400 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liabilities </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">543 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">64 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">607 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">69 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">380 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">449 </span></td></tr></table></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:27.239766%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.087719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.111111%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.111111%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.087719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.111111%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in Fair Value </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2016</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in Fair Value </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liabilities </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">76,900 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,200 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,100 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">52,800 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,600 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">64,400 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liabilities </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">512 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">95 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">607 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">809 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(360)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">449 </span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The changes in fair value of the liabilities shown in the table above are recorded through change in fair value of contingent consideration liabilities within operating expense and the change in fair value of common stock warrant liabilities within other income (expense) in the condensed consolidated statements of operations.</span></div><div style="text-indent:24pt;"><span><br/></span></div><div style="text-indent:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">There were no transfers between levels during the periods presented. See Note 3 for further information regarding the amortized cost of the Company's financial instruments.</span></div> The carrying amount of the Company’s financial instruments, including cash and cash equivalents, other current assets, accounts payable, accrued and other current liabilities approximate their fair value due to their short maturities. The following tables summarize assets and liabilities recognized or disclosed at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 (in thousands):<div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:36.742690%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384795%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">September 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets: </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents: </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,127 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,127 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,624 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,624 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">97,686 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">97,686 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificate of deposits </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">854 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">854 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">174,769 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">174,769 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">47,386 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">47,386 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificate of deposits </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">118,775 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">118,775 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35,157 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35,157 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:30pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets(1) </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">97,686 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">436,692 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">534,378 </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liabilities(2) </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">607 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">607 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liabilities(3) </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,100 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,100 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:30pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,707 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,707 </span></td></tr></table></div><div style="margin-top:9pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:41.274854%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384795%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384795%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384795%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384795%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">December 31, 2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets: </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents consisting of money market funds(1) </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">289,782 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">289,782 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:30pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">289,782 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">289,782 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liabilities(2) </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">512 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">512 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liabilities(3) </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">76,900 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">76,900 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:30pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">77,412 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">77,412 </span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(1) Fair value is determined by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry standard valuation models, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs. </span></div><div style="text-indent:-13.5pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(2) Represents the fair value of common stock warrants outstanding that may require cash settlement under certain circumstances. The Company estimated the fair value of the warrant liabilities using the Black-Scholes valuation model. As of December 31, 2017 and September 30, 2018, common stock warrant liabilities relate to warrants issued in July 2011 in connection with a debt financing arrangement. The warrants entitle the holder to purchase up to 28,125 shares of common stock at an exercise price of $72.00 per share. The warrants will expire in July 2021.</span></div><div style="text-indent:-13.5pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(3) In connection with a prior acquisition, the Company may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. The Company estimated the fair value of the contingent consideration liabilities on the acquisition date using a probability-weighted income approach, which reflects the probability and timing of future payments. This fair value measurement is based on significant Level 3 inputs such as the anticipated timelines and probability of achieving development, regulatory approval or sales-based milestone events and projected revenues. The resulting probability-weighted cash flows are discounted at risk-adjusted rates. Subsequent to the acquisition date, at each reporting period prior to settlement, the Company revalues these liabilities by performing a review of the assumptions listed above and record increases or decreases in the fair value of these contingent consideration liabilities. In the absence of any significant changes in key assumptions, the quarterly determination of fair values of these contingent consideration liabilities would primarily reflect the passage of time and</span></div> risk-adjusted interest rates. Significant judgment is used in determining Level 3 inputs and fair value measurements as of the acquisition date and for each subsequent reporting period. Updates to assumptions could have a significant impact on the Company’s results of operations in any given period and actual results may differ from estimates. For example, significant increases in the probability of achieving a milestone or projected revenues would result in a significantly higher fair value measurement while significant decreases in the estimated probability of achieving a milestone or projected revenues would result in a significantly lower fair value measurement. Significant increases in the discount rate or in the anticipated timelines would result in a significantly lower fair value measurement while significant decreases in the discount rate or anticipated timelines would result in a significantly higher fair value measurement. The potential contingent consideration payments required upon achievement of development, regulatory approval and sales-based milestones related to the Company’s acquisition of ZX008 range from zero if none of the milestones are achieved to a maximum of $95.0 million (undiscounted). As of September 30, 2018, the Company has classified $32.5 million of the total contingent consideration liabilities of $80.1 million as current liabilities. The classification was based upon the Company’s reasonable expectation as to the timing of settlement of certain specified milestones The following tables summarize assets and liabilities recognized or disclosed at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 (in thousands):<div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:36.742690%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384795%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">September 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets: </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents: </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,127 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,127 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,624 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,624 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">97,686 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">97,686 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificate of deposits </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">854 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">854 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">174,769 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">174,769 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">47,386 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">47,386 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificate of deposits </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">118,775 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">118,775 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35,157 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35,157 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:30pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets(1) </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">97,686 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">436,692 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">534,378 </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liabilities(2) </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">607 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">607 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liabilities(3) </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,100 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,100 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:30pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,707 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,707 </span></td></tr></table></div><div style="margin-top:9pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:41.274854%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384795%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384795%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384795%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384795%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">December 31, 2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets: </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents consisting of money market funds(1) </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">289,782 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">289,782 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:30pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">289,782 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">289,782 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liabilities(2) </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">512 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">512 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liabilities(3) </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">76,900 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">76,900 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:30pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">77,412 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">77,412 </span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:-13.5pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(1) Fair value is determined by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry standard valuation models, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs. </span></div><div style="text-indent:-13.5pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(2) Represents the fair value of common stock warrants outstanding that may require cash settlement under certain circumstances. The Company estimated the fair value of the warrant liabilities using the Black-Scholes valuation model. As of December 31, 2017 and September 30, 2018, common stock warrant liabilities relate to warrants issued in July 2011 in connection with a debt financing arrangement. The warrants entitle the holder to purchase up to 28,125 shares of common stock at an exercise price of $72.00 per share. The warrants will expire in July 2021.</span></div><div style="text-indent:-13.5pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(3) In connection with a prior acquisition, the Company may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. The Company estimated the fair value of the contingent consideration liabilities on the acquisition date using a probability-weighted income approach, which reflects the probability and timing of future payments. This fair value measurement is based on significant Level 3 inputs such as the anticipated timelines and probability of achieving development, regulatory approval or sales-based milestone events and projected revenues. The resulting probability-weighted cash flows are discounted at risk-adjusted rates. Subsequent to the acquisition date, at each reporting period prior to settlement, the Company revalues these liabilities by performing a review of the assumptions listed above and record increases or decreases in the fair value of these contingent consideration liabilities. In the absence of any significant changes in key assumptions, the quarterly determination of fair values of these contingent consideration liabilities would primarily reflect the passage of time and</span></div> risk-adjusted interest rates. Significant judgment is used in determining Level 3 inputs and fair value measurements as of the acquisition date and for each subsequent reporting period. Updates to assumptions could have a significant impact on the Company’s results of operations in any given period and actual results may differ from estimates. For example, significant increases in the probability of achieving a milestone or projected revenues would result in a significantly higher fair value measurement while significant decreases in the estimated probability of achieving a milestone or projected revenues would result in a significantly lower fair value measurement. Significant increases in the discount rate or in the anticipated timelines would result in a significantly lower fair value measurement while significant decreases in the discount rate or anticipated timelines would result in a significantly higher fair value measurement. The potential contingent consideration payments required upon achievement of development, regulatory approval and sales-based milestones related to the Company’s acquisition of ZX008 range from zero if none of the milestones are achieved to a maximum of $95.0 million (undiscounted). As of September 30, 2018, the Company has classified $32.5 million of the total contingent consideration liabilities of $80.1 million as current liabilities. The classification was based upon the Company’s reasonable expectation as to the timing of settlement of certain specified milestones 0 58127000 0 58127000 0 1624000 0 1624000 97686000 0 0 97686000 0 854000 0 854000 0 174769000 0 174769000 0 47386000 0 47386000 0 118775000 0 118775000 0 35157000 0 35157000 97686000 436692000 0 534378000 0 0 607000 607000 0 0 80100000 80100000 0 0 80707000 80707000 289782000 0 0 289782000 289782000 0 0 289782000 0 0 512000 512000 0 0 76900000 76900000 0 0 77412000 77412000 28125 72.00 0 95000000.0 32500000 80100000 <div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table provides a reconciliation of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and nine months ended September 30, 2018 and 2017 (in thousands): </span></div><div style="text-indent:24pt;margin-top:9pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:29.323529%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.176471%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.147059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.176471%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.176471%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.147059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.176471%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in Fair Value </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in Fair Value </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liabilities </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">74,400 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,700 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,100 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">53,900 </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10,500 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">64,400 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liabilities </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">543 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">64 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">607 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">69 </span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">380 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">449 </span></td></tr></table></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:27.239766%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596491%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.087719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.111111%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.111111%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.087719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.111111%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in Fair Value </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2016</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in Fair Value </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liabilities </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">76,900 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,200 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,100 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">52,800 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,600 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">64,400 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liabilities </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">512 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">95 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">607 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">809 </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(360)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">449 </span></td></tr></table></div> 74400000 5700000 80100000 53900000 10500000 64400000 543000 64000 607000 69000 380000 449000 76900000 3200000 80100000 52800000 11600000 64400000 512000 95000 607000 809000 -360000 449000 Commitments and Contingencies<div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:24pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company has two noncancellable operating leases consisting of administrative and research and development office space for its Emeryville, California headquarters and former headquarters in San Diego, California that expire in November 2022 and March 2020, respectively. The former headquarters has been subleased to an unrelated third party for the remainder of the Company’s original lease term. Future minimum lease payments under our non-cancellable operating leases at September 30, 2018, net of sublease income, were as follows (in thousands): </span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:58.588235%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.647059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.647059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.647059%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Gross Lease </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Payments</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Sublease</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Income</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Net Lease</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Payments</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018 (remaining 3 months) </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">481 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(136)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">345 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,955 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(576)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,379 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,234 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(148)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,086 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,004 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,004 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">946 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">946 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,620 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(860)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,760 </span></td></tr></table></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In October 2018, the Company executed a lease for new headquarters with its current landlord to move to a facility nearby its current headquarters in Emeryville, California. The lease has an initial term that expires on June 30, 2027 and provides for one <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEwYzExNTQ5MjExMzQxMDNhZGZkNzU1MWEwNzdlYjgwL3NlYzphMGMxMTU0OTIxMTM0MTAzYWRmZDc1NTFhMDc3ZWI4MF8yMDMvZnJhZzoyNDE2M2I2NGU0ZDk0YTE3YThmZjU2ZDE3NmVkMTE2Mi90ZXh0cmVnaW9uOjI0MTYzYjY0ZTRkOTRhMTdhOGZmNTZkMTc2ZWQxMTYyXzM4NDgyOTA3MDA5OTM_75a8dd19-df5a-475a-8b58-3ca5f5d82a14">five</span>-year renewal option. Concurrent with the new lease, the landlord agreed to terminate the Company's existing lease once it completes the move to the new headquarters. The cash expected to be paid for rent over the term of the new lease of eight years is approximately $15.3 million beginning in June 2019, partially offset by a reduction in the commitments under its existing headquarter lease.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Legal Matters</span></div><div style="text-indent:24pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company is not currently involved in any material legal proceedings. The Company may become involved in various legal proceedings and claims that arise in the ordinary course of business. Such matters are subject to uncertainty and there can be no assurance that such legal proceedings will not have a material adverse effect on its business, results of operations, financial position or cash flows.</span></div> 2 Future minimum lease payments under our non-cancellable operating leases at September 30, 2018, net of sublease income, were as follows (in thousands): <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:58.588235%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.647059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.647059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.647059%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Gross Lease </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Payments</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Sublease</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Income</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Net Lease</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Payments</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018 (remaining 3 months) </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">481 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(136)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">345 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,955 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(576)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,379 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,234 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(148)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,086 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,004 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,004 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">946 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">946 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,620 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(860)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,760 </span></td></tr></table> 481000 136000 345000 1955000 576000 1379000 1234000 148000 1086000 1004000 0 1004000 946000 0 946000 5620000 860000 4760000 1 P8Y 15300000 Sale of Common Stock<div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company has an at-the-market offering program (“ATM Program”) with Cantor Fitzgerald &amp; Co. (“Cantor”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its common stock having an aggregate offering price of up to $75.0 million under a previously filed and effective registration statement on Form S-3 (File No. 333-220759) and a prospectus supplement filed in December 2017. Cantor is entitled to a commission at a fixed commission rate of up to 3% of the gross proceeds of the sales price of all common stock sold under the ATM program. The Company and Cantor may each terminate the ATM program at any time upon ten days’ prior notice.</span></div><div style="text-indent:27pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In the second quarter of 2018, the Company sold a total of 740,417 shares of its common stock under the ATM program and received net proceeds of approximately $30.3 million, after deducting commissions and other offering expenses of $1.1 million.</span></div><div style="text-indent:27pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In August 2018, the Company completed an underwritten public offering for the sale of 6,000,000 shares of its common stock. Net proceeds raised from the offering were approximately $292.9 million, after deducting underwriting discounts and commissions and other offering expenses of $19.1 million.</span></div> 75000000.0 0.03 740417 30300000 1100000 6000000 292900000 19100000 Stock-Based Compensation<div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company has adopted certain equity incentive and stock purchase plans as described in the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.</span></div><div style="text-indent:24pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In March 2018, our board of directors approved an amendment and restatement of our non-employee director compensation policy, pursuant to which any non-employee director who is first elected to the board of directors is granted an option to purchase 20,000 shares of our common stock on the date of his or her initial election to the board of directors. In addition, on the date of each annual meeting of our stockholders, commencing with the 2018 annual meeting, each non-employee director is eligible to receive an option to purchase 15,000 shares of common stock. Prior to March 2018, under our non-employee director compensation policy, any non-employee director who was first elected to the board of directors was granted an option to purchase 30,000 shares of our common stock on the date of his or her initial election to the board of directors. In addition, on the date of each annual meeting of our stockholders, each non-employee director was eligible to receive an option to purchase 20,000 shares of common stock. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Performance Stock Options</span></div><div style="text-indent:24pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In October 2015, the Company granted employees certain performance-based stock options for retention purposes. The stock options would vest upon satisfaction of a specified regulatory milestone within three years of the date of grant. In 2017, management determined the achievement of the performance condition was no longer probable and the cumulative compensation expense previously recognized was reversed. In September 2018, these awards were modified to allow for 90% of such options outstanding at the modification date to vest immediately. The remaining 10% of the awards were canceled in October 2018 since the performance condition was not met. This improbable to probable modification resulted in the calculation and recognition of incremental stock-based compensation expense of $3.5 million during the third quarter of 2018.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Equity Incentive Awards Activity</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock Options</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following is a summary of stock option activity for the nine months ended September 30, 2018 (in thousands, except per share data):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:73.183554%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.041116%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.041116%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Shares</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">(in thousands)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Price per Share</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,392 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">14.41 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Granted</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">842 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">43.13 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Exercised</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(290)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">16.45 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Canceled</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(59)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">26.10 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at September 30, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,885 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20.30 </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Units</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following is a summary of restricted stock unit activity for the nine months ended September 30, 2018 (in thousands, except per share data):</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:73.183554%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.041116%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.041116%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Shares</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">(in thousands)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted- Average Fair Value per Share at Grant Date </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">259 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.43 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Granted</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">146 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">42.76 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-30pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Vested</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(98)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.74 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Canceled</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">29.74 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at September 30, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">299 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">25.58 </span></td></tr></table></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As of September 30, 2018, outstanding restricted stock units included 159,000 granted in March 2017 with performance-based conditions to employees and executives. The restricted stock units vest upon the approval of the Company’s new drug application for ZX008 by the FDA, provided such approval occurs within five years following the grant date. Due to the uncertainties associated with the FDA approval process, approval is not yet probable, as such term is used for accounting purposes, prior to the occurrence of the event. Accordingly, no compensation expense has been recognized to date for these performance-based awards. </span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Valuation of Equity Awards</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of the stock options granted or modified during the periods indicated was estimated using the Black-Scholes option pricing model, based on the following assumptions:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:37.060206%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk free interest rate </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8% to 2.9% </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9% to 2.1% </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3% to 2.9% </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9% to 2.3% </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 to 6.1 years </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.1 years </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 to 6.1 years </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1 to 6.1 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">79.9% to 83.2% </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">75.1% to 75.5% </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">79.9% to 85.2% </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">75.1% to 76.6% </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:24pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of restricted stock units granted is determined based on the price of the Company's common stock on the date of grant.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation Expense</span></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the components of total stock-based compensation expense included in the condensed consolidated statements of operations (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;"> </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:37.060206%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of contract manufacturing </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">71 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,275 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">294 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,018 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,313 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,706 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">968 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,934 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,682 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,981 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,262 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,952 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,066 </span></td></tr></table></div> The Company has adopted certain equity incentive and stock purchase plans as described in the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. 20000 15000 30000 20000 0.90 0.10 3500000 <div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following is a summary of stock option activity for the nine months ended September 30, 2018 (in thousands, except per share data):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:73.183554%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.041116%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.041116%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Shares</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">(in thousands)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Weighted-</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Exercise</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Price per Share</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,392 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">14.41 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Granted</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">842 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">43.13 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Exercised</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(290)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">16.45 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Canceled</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(59)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">26.10 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at September 30, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,885 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20.30 </span></td></tr></table></div> 3392000 14.41 842000 43.13 290000 16.45 59000 26.10 3885000 20.30 <div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following is a summary of restricted stock unit activity for the nine months ended September 30, 2018 (in thousands, except per share data):</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:73.183554%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.041116%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.041116%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Shares</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">(in thousands)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted- Average Fair Value per Share at Grant Date </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">259 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.43 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Granted</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">146 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">42.76 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-30pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Vested</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(98)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.74 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;padding-right:-36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Canceled</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">29.74 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at September 30, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">299 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">25.58 </span></td></tr></table></div> 259000 10.43 146000 42.76 98000 10.74 8000 29.74 299000 25.58 159000 <div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The fair value of the stock options granted or modified during the periods indicated was estimated using the Black-Scholes option pricing model, based on the following assumptions:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:37.060206%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk free interest rate </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8% to 2.9% </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9% to 2.1% </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3% to 2.9% </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9% to 2.3% </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 to 6.1 years </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.1 years </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 to 6.1 years </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1 to 6.1 years </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">79.9% to 83.2% </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">75.1% to 75.5% </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">79.9% to 85.2% </span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">75.1% to 76.6% </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div> 0 0 0 0 <div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the components of total stock-based compensation expense included in the condensed consolidated statements of operations (in thousands):</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;"> </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:37.060206%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of contract manufacturing </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">71 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,275 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">294 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,018 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,313 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,706 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">968 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,934 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,682 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,981 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,262 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,952 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,066 </span></td></tr></table></div> 0 0 0 71000 3275000 294000 5018000 1313000 3706000 968000 6934000 2682000 6981000 1262000 11952000 4066000 Net Loss Per Share<div style="text-indent:24pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Basic net loss from continuing operations per share is calculated by dividing net loss from continuing operations by the weighted average number of shares outstanding for the period. Diluted net loss from continuing operations per share is calculated by dividing net loss from continuing operations by the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period if the effect is dilutive. The Company’s potentially dilutive shares of common stock include outstanding stock options, restricted stock units and warrants to purchase common stock.</span></div><div style="text-indent:24pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">A reconciliation of the numerators and denominators used in computing net loss from continuing operations per share is as follows (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:37.060206%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss from continuing operations </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(42,264)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(42,660)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(101,283)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(86,239)</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator: </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in per share calculation </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">39,242 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">25,431 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">36,485 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">25,024 </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss from continuing operations per share, basic and diluted </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.08)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.68)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.78)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.45)</span></td></tr></table></div><div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table presents the potential shares of common stock outstanding that were excluded from the computation of diluted net loss from continuing operations per share for the periods presented because including them would have been anti-dilutive (in thousands):</span></div><div style="margin-top:9pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:37.060206%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares subject to outstanding common stock options </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,957 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,121 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,752 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,879 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares subject to outstanding restricted stock units </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">303 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">271 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">287 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">228 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares subject to outstanding warrants to purchase common stock </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">28 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,251 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,522 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,288 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,643 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,074 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,629 </span></td></tr></table></div> Basic net loss from continuing operations per share is calculated by dividing net loss from continuing operations by the weighted average number of shares outstanding for the period. Diluted net loss from continuing operations per share is calculated by dividing net loss from continuing operations by the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period if the effect is dilutive. <div style="text-indent:24pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">A reconciliation of the numerators and denominators used in computing net loss from continuing operations per share is as follows (in thousands, except per share amounts):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:37.060206%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss from continuing operations </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(42,264)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(42,660)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(101,283)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(86,239)</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator: </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in per share calculation </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">39,242 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">25,431 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">36,485 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">25,024 </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss from continuing operations per share, basic and diluted </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.08)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.68)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.78)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.45)</span></td></tr></table></div> -42264000 -42660000 -101283000 -86239000 39242000 25431000 36485000 25024000 -1.08 -1.68 -2.78 -3.45 <div style="text-indent:24pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table presents the potential shares of common stock outstanding that were excluded from the computation of diluted net loss from continuing operations per share for the periods presented because including them would have been anti-dilutive (in thousands):</span></div><div style="margin-top:9pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:37.060206%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.684288%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares subject to outstanding common stock options </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,957 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,121 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,752 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,879 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares subject to outstanding restricted stock units </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">303 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">271 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">287 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">228 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares subject to outstanding warrants to purchase common stock </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">28 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,251 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">35 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,522 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,288 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,643 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,074 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,629 </span></td></tr></table></div> 3957000 4121000 3752000 3879000 303000 271000 287000 228000 28000 1251000 35000 1522000 4288000 5643000 4074000 5629000 United Kingdom (U.K.) Research and Development IncentivesThe Company carries out extensive research and development activities that benefit from the U.K.’s small and medium-sized enterprise (“SME”) research and development tax credit regime, whereby the Company may either receive an enhanced U.K. tax deduction on its eligible research and development activities or, when an SME entity is in a net operating loss position, elect to surrender net operating losses that arise from its eligible research and development activities in exchange for a cash<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> payment from the U.K. tax authorities. These refundable cash credits, which may be received without regard to actual tax liability, are not subject to accounting for income taxes and have been recorded as a component of other income. </span></div><div style="text-indent:24pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In December 2017, the Company filed a claim as an SME for a $3.0 million refundable cash credit for its 2015 tax year, which was received in July 2018. The Company recorded this amount as a component of other income for the nine months ended September 30, 2018. As of the date hereof, the Company has not filed claims for any refundable cash credit for its 2016 or 2017 tax years, nor has it recorded any balances related to claims for these years or for the 2018 tax year, as collectability is deemed not probable or reasonably assured.</span></div> 3000000.0 XML 13 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2018
Oct. 31, 2018
Document and Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q3  
Trading Symbol ZGNX  
Entity Registrant Name ZOGENIX, INC.  
Entity Central Index Key 0001375151  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   41,968,019
Entity Small Business false  
Entity Emerging Growth Company false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 163,038 $ 293,503
Marketable securities 376,087 0
Prepaid expenses 6,861 5,994
Other current assets 1,286 5,206
Total current assets 547,272 304,703
Property and equipment, net 244 245
Intangible assets 102,500 102,500
Goodwill 6,234 6,234
Other assets 3,380 3,931
Total assets 659,630 417,613
Current liabilities:    
Accounts payable 4,110 3,356
Accrued clinical trial expenses 10,674 8,657
Accrued compensation 5,039 6,616
Other accrued liabilities 2,413 1,842
Current portion of contingent consideration 32,500 0
Common stock warrant liabilities 607 512
Total current liabilities 55,343 20,983
Contingent consideration, net of current portion 47,600 76,900
Deferred income taxes 17,425 17,425
Other long-term liabilities 482 784
Total liabilities 120,850 116,092
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding 0 0
Common stock, $0.001 par value; 50,000 shares authorized; 35,827 and 34,808 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively 42 35
Additional paid-in capital 1,212,305 873,526
Accumulated deficit (673,521) (572,040)
Accumulated other comprehensive loss (46) 0
Total stockholders’ equity 538,780 301,521
Total liabilities and stockholders’ equity $ 659,630 $ 417,613
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Preferred stock par value (usd per share) $ 0.001 $ 0.001
Preferred stock authorized (shares) 10,000,000 10,000,000
Preferred stock issued (shares) 0 0
Preferred stock outstanding (shares) 0 0
Common stock par value (usd per share) $ 0.001 $ 0.001
Common stock authorized (shares) 50,000,000 50,000,000
Common stock issued (shares) 41,925,000 34,808,000
Common stock outstanding (shares) 41,925,000 34,808,000
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Revenue:        
Contract manufacturing revenue $ 0 $ 0 $ 0 $ 9,821
Costs and expenses:        
Cost of contract manufacturing 0 0 0 10,729
Research and development 27,608 21,178 77,329 49,369
Selling, general and administrative 11,016 6,073 27,663 18,129
Loss on contract termination 0 478 0 478
Asset impairment charges 0 196 0 1,116
Change in fair value of contingent consideration 5,700 10,500 3,200 11,600
Total costs and expenses 44,324 38,425 108,192 91,421
Loss from operations (44,324) (38,425) (108,192) (81,600)
Other income (expense):        
Interest income 2,133 121 3,995 332
Interest expense 0 (702) (6) (2,065)
Loss on extinguishment of debt 0 (3,378) 0 (3,378)
Change in fair value of common stock warrant liabilities (64) (380) (95) 360
Other (expense) income, net (9) 62 3,015 71
Total other income (expense) 2,060 (4,277) 6,909 (4,680)
Loss from continuing operations before income taxes (42,264) (42,702) (101,283) (86,280)
Income tax benefit 0 42 0 41
Net loss from continuing operations (42,264) (42,660) (101,283) (86,239)
Loss from discontinued operations, net of taxes 0 (134) (198) (870)
Net loss $ (42,264) $ (42,794) $ (101,481) $ (87,109)
Net loss per share, basic and diluted:        
Continuing operations (in dollars per share) $ (1.08) $ (1.68) $ (2.78) $ (3.45)
Discontinued operations (in dollars per share) 0 0 0 (0.03)
Total (in dollars per share) $ (1.08) $ (1.68) $ (2.78) $ (3.48)
Weighted average common shares used in the calculation of basic and diluted net loss per common share (shares) 39,242 25,431 36,485 25,024
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Statement of Comprehensive Income [Abstract]        
Net loss $ (42,264) $ (42,794) $ (101,481) $ (87,109)
Other comprehensive income (loss)        
Change in unrealized losses on marketable securities, net of tax (46) 0 (46) 0
Comprehensive loss $ (42,310) $ (42,794) $ (101,527) $ (87,109)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Operating activities:    
Net loss $ (101,481) $ (87,109)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 11,952 4,066
Depreciation and amortization 76 408
Amortization of debt issuance costs and debt discount 0 753
Net accretion and amortization of investments in marketable securities (521) 0
Loss on extinguishment of debt 0 3,378
Inventory write-down 0 2,232
Asset impairment charges 0 1,116
Change in fair value of common stock warrant liabilities 95 (360)
Change in fair value of contingent consideration 3,200 11,600
Changes in operating assets and liabilities:    
Trade accounts receivable 0 9,356
Inventory 0 2,583
Prepaid expenses and other current assets 1,429 4,996
Other assets 551 (2,413)
Accounts payable, accrued and other liabilities 1,463 4,204
Deferred revenue 0 (1,245)
Net cash used in operating activities (83,236) (46,435)
Investing activities:    
Purchases of marketable securities (375,612) 0
Purchases of property and equipment (75) (35)
Net cash used in investing activities (375,687) (35)
Financing activities:    
Proceeds from issuance of common stock under equity incentive plans 6,749 271
Taxes paid related to net share settlement of equity awards (1,426) 0
Proceeds from issuance of common stock under an at-the-market offering, net of issuance costs 323,135 19,378
Net cash provided by financing activities 328,458 19,649
Net decrease in cash and cash equivalents (130,465) (26,821)
Cash and cash equivalents, beginning of the period 293,503 91,551
Cash and cash equivalents, end of the period 163,038 64,730
Noncash financing activities    
Extinguishment of Endo working capital advance note payable through net settlement of balances owed to the Company $ 0 $ 7,000
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and Basis of Presentation
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Basis of Presentation Organization and Basis of Presentation
Zogenix, Inc., including its wholly-owned subsidiaries (the “Company”), is a pharmaceutical company developing and commercializing innovative central nervous system (“CNS”) therapies for people living with serious and life-threatening rare CNS disorders and medical conditions. The Company’s current primary area of therapeutic focus is rare, or “orphan” childhood-onset epilepsy disorders and its lead product candidate is ZX008. ZX008 is currently being developed for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut Syndrome. The Company operates in one business segment—the research, development and commercialization of pharmaceutical products and its headquarters are located in Emeryville, California.
Basis of Presentation
The accompanying condensed consolidated financial statements include the accounts of Zogenix, Inc. and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. In the opinion of management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. Certain reclassifications have been made to the prior period amounts to conform to the current year presentation. “Accrued clinical trial expenses” and “Other accrued liabilities”, which previously were reported as “Accrued expenses” on the condensed consolidated balance sheet, are now reported as separate line items. Additionally, previously reported “Interest expense, net” has been reclassified to present interest income and interest expense separately in the accompanying condensed consolidated statements of operations. The results of operations for any interim period are not necessarily indicative of results of operations for any future period. Certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted. Accordingly, these unaudited interim condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on March 6, 2018.
Future Funding Requirements
Excluding gains from two discrete business divestitures, the Company has incurred significant net losses and negative cash flows from operating activities since inception resulting in an accumulated deficit of $673.5 million at September 30, 2018. The Company expects to continue to incur significant operating losses and negative cash flows from operations to advance its product candidates through development and commercialization. Additionally, upon acceptance of the Company’s regulatory submissions for ZX008 by the U.S. Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”) and regulatory approval of ZX008 by the FDA or EMA, if at all, each a milestone event, the Company will owe milestone payments under an existing agreement in connection with the Company’s prior acquisition of ZX008. To date, the Company has relied primarily on the proceeds from equity offerings to finance its operations. See Note 6 for the Company's recent equity offerings.
Until the Company can generate a sufficient amount of revenue to finance its cash requirements, if ever, the Company may need to continue to rely on additional financing to achieve its business objectives. However, if such financing is not available at adequate levels when needed, the Company may be required to significantly delay, scale back or discontinue one or more of the product development programs or commercialization efforts or other aspects of its business plans, and its operating results and financial condition would be adversely affected.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Significant Accounting Policies
There have been no material changes to the Company’s significant accounting policies from those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, other than as set forth below.
Cash Equivalents and Marketable Securities
The Company considers cash equivalents to be only those investments which are highly liquid, readily convertible to cash and have an original maturity of three months or less at the date of purchase.
The Company invests its excess cash in marketable securities with high credit ratings that are classified as Level 1 and Level 2 within the fair value hierarchy. These marketable securities consists of money market funds and certificate of deposits, securities issued by the U.S. government and its agencies, corporate debt securities and commercial paper, which are all classified as “available-for-sale”. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and, therefore, classifies all securities with maturity dates beyond three months at the date of purchase as current assets on the condensed consolidated balance sheets. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the condensed consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on marketable securities are included in interest income (expense), net. The cost of securities sold is determined using the specific identification method.
The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and management’s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value.
Concentration of Credit Risk
Cash, cash equivalents and marketable securities are financial instruments that potentially subject the Company to concentration of credit risk. The Company invests its excess cash primarily in money market funds and certificate of deposits, securities issued by the U.S. government and its agencies, corporate debt securities and commercial paper. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe it is exposed to any significant credit risk related to these instruments. 
Accounting Pronouncements Recently Adopted
Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) and subsequent amendments to the initial guidance (collectively, “Topic 606”) amended the existing accounting standards for revenue recognition. The core principle of Topic 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. The Company adopted Topic 606 effective January 1, 2018 using the modified retrospective approach. The adoption of Topic 606 did not have a material impact on the Company’s condensed consolidated financial statements as the Company does not have any contracts with customers.
ASU 2016-15, Statement of Cash Flows (Topic 230) provides guidance on eight specific cash flow issues, thereby reducing the diversity in practice in how certain transactions are classified in the statement of cash flows. The amendments in this ASU are applied using a retrospective transition method to each period presented. The Company adopted ASU 2016-15
effective January 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.
ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business narrows the definition of a business and provides additional guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This accounting standards update is required to be applied prospectively to transactions occurring after the date of adoption. The Company adopted ASU 2017-09 effective January 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.
ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting provides guidance on determining changes to the terms and conditions of share-based payment awards and require an entity to apply modification accounting under Topic 718 unless all of the following conditions are met: (1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification; (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The amendments should be applied prospectively to an award modified on or after the adoption date. The Company adopted ASU 2017-09 effective January 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.
On December 22, 2017, the U.S. federal government enacted the Tax Cuts and Jobs Act (“the Act”). The Tax Act contains, among other things, significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% for tax years beginning after December 31, 2017, limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, implementing a territorial tax system, and requiring a mandatory one-time tax on U.S. owned undistributed foreign earnings and profits known as the transition tax. In December 2017, SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) to address the accounting implications of recently enacted U.S. federal tax reform. SAB 118 allows companies to record provisional amounts during a measurement period not to extend beyond one year of the enactment date to address ongoing guidance and tax interpretations that are expected over the next 12 months. The Company has adopted SAB 118 and currently considers its accounting of the impact of U.S. federal tax reform to be incomplete but continues to make a reasonable estimate of the effects on our existing deferred tax assets. The Company expects to complete the remainder of the analysis within the measurement period in accordance with SAB 118. Adjustments, if any, are not expected to impact the condensed consolidated statement of operations and comprehensive loss due to the full valuation allowance on the Company’s deferred tax assets.
ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting simplifies the accounting for share-based payment awards issued to nonemployees for goods and services, including fixing the estimated fair value of the stock award at the date of grant. ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The adoption of ASU 2018-07 requires a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year. ASU 2018-07 is effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company early adopted ASU 2018-07 effective July 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.
In August 2018, the SEC adopted amendments to certain disclosure requirements in Securities Act Release No. 33-10532, Disclosure Update and Simplification. These amendments eliminate, modify, or integrate into other SEC requirements certain disclosure rules. Among the amendments is the requirement to present an analysis of changes in stockholders’ equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments became effective for all filings made on or after November 5, 2018. In light of the anticipated timing of effectiveness of the amendments and expected proximity of effectiveness to the filing date for most filers’ quarterly reports, the SEC’s Division of Corporate Finance issued a Compliance and Disclosure Interpretation related to Exchange Act Forms, or CDI – Question 105.09, that provides transition guidance related to this disclosure requirement. CDI – Question 105.09 states that the SEC would not object if the filer’s first presentation of the changes in shareholders’ equity is included in its Form 10-Q for the quarter that begins after the effective date of the amendments. Except for the requirement to provide the annual disclosure
changes in stockholders’ equity for interim periods, which will be included beginning with the Company's quarterly report on Form 10-Q ending March 31, 2019, the Company has adopted all relevant disclosure requirements.
Accounting Pronouncements Issued But Not Yet Effective
ASU 2016-02, Leases (Topic 842) establishes a right-of-use model (“ROU”) that requires all lessees to recognize ROU assets and liabilities for leases with a duration greater than one year on the balance sheet as well as provide disclosures with respect to certain qualitative and quantitative information regarding the amount, timing and uncertainty of cash flows arising from leases. Both a ROU asset and liability will initially be measured at the present value of the future minimum lease payments over the lease term. Subsequent measurement, including the presentation of expenses and cash flows, will depend on the classification of the lease as either a finance or an operating lease. Initial costs directly attributable to negotiating and arranging the lease will be included in the asset. The new standard is effective for fiscal years beginning after December 15, 2018, and interim periods therein. Early adoption is permitted. Originally, entities were required to adopt ASU 2016-02 using a modified retrospective approach, which required prior periods to be presented under this new standard with various practical expedients allowed. In July 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption (January 1, 2019) while continuing to present all prior periods under previous lease accounting guidance. The Company intends to adopt the standard on January 1, 2019 by recognizing a cumulative effect adjustment to the opening balance of retained earnings and utilizing the practical expedient that allows the Company to not reassess whether an expired or existing contract contains a lease, the classification of leases or initial direct costs. The Company is in the process of inventorying and scoping its existing lease contracts. While the Company is currently evaluating the impact of adopting this accounting standard update on its condensed consolidated financial statements and related disclosures, the Company anticipates that ROU assets and corresponding liabilities will be recognized in its condensed consolidated balance sheets related to its lease arrangements. The adoption of these standards are also expected to impact the Company’s condensed consolidated financial statement disclosures.
ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. Under the amendments in ASU 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds its fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The updated guidance requires a prospective adoption. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the timing and impact of adopting this ASU on its condensed consolidated financial statements and related disclosures.
ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement modifies the disclosure requirements in Topic 820, Fair Value Measurement, by removing certain disclosure requirements related to the fair value hierarchy, modifying existing disclosure requirements related to measurement uncertainty and adding new disclosure requirements, such as disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and disclosing the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for public companies for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year. Early adoption is permitted for any removed or modified disclosures. The Company is currently evaluating the timing and impact of adopting this ASU on its condensed consolidated financial statements and related disclosures.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash, Cash Equivalents and Marketable Securities
 9 Months Ended
Sep. 30, 2018
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents, and Marketable Securities Cash, Cash Equivalents and Marketable SecuritiesThe following table summarizes the amortized cost and fair value of the Company's cash, cash equivalents and marketable securities as of September 30, 2018 (in thousands):
Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value 
(in thousands)
Current assets: 
Cash $4,747 $— $— $4,747 
Cash equivalents: 
Commercial paper 58,127 — — 58,127 
Corporate debt securities 1,624 — — 1,624 
Money market funds 97,686 — — 97,686 
Certificate of deposits 854 — — 854 
Total cash equivalents 158,291 — — 158,291 
Total cash and cash equivalents 163,038 — — 163,038 
Marketable securities: 
Commercial paper 174,769 1 (1)174,769 
Corporate debt securities 47,416 — (30)47,386 
Certificate of deposits 118,775 — — 118,775 
U.S. Treasuries 35,173 — (16)35,157 
Total marketable securities 376,133 1 (47)376,087 
Total cash, cash equivalents and marketable securities $539,171 $1 $(47)$539,125 
The following table summarizes the cost and fair value of marketable securities based on stated effective maturities as of September 30, 2018 (in thousands):
Amortized Cost Fair Value 
Due within one year $345,678 $345,644 
Due between one and two years 30,455 30,443 
Total $376,133 $376,087 
The Company did not hold any marketable securities as of December 31, 2017.
There have been no significant realized gains or losses on available-for-sale securities for the periods presented. Available-for-sale debt securities that were in a continuous loss position but were not deemed to be other than temporarily impaired were immaterial at September 30, 2018.
See Note 4 for further information regarding the fair value of the Company's financial instruments.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements
 9 Months Ended
Sep. 30, 2018
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The carrying amount of the Company’s financial instruments, including cash and cash equivalents, other current assets, accounts payable, accrued and other current liabilities approximate their fair value due to their short maturities.
Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
Level 1: 
Observable inputs such as quoted prices in active markets;
Level 2: 
Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3: 
Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
The following tables summarize assets and liabilities recognized or disclosed at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 (in thousands):
Level 1 Level 2 Level 3 Total 
September 30, 2018
Assets: 
Cash equivalents: 
Commercial paper $— $58,127 $— $58,127 
Corporate debt securities — 1,624 — 1,624 
Money market funds 97,686 — — 97,686 
Certificate of deposits — 854 — 854 
Marketable securities 
Commercial paper — 174,769 — 174,769 
Corporate debt securities — 47,386 — 47,386 
Certificate of deposits — 118,775 — 118,775 
U.S. Treasuries — 35,157 — 35,157 
Total assets(1) $97,686 $436,692 $— $534,378 
Liabilities: 
Common stock warrant liabilities(2) $— $— $607 $607 
Contingent consideration liabilities(3) — — 80,100 80,100 
Total liabilities $— $— $80,707 $80,707 

Level 1 Level 2 Level 3 Total 
December 31, 2017
Assets: 
Cash equivalents consisting of money market funds(1) $289,782 $— $— $289,782 
Total assets $289,782 $— $— $289,782 
Liabilities: 
Common stock warrant liabilities(2) $— $— $512 $512 
Contingent consideration liabilities(3) — — 76,900 76,900 
Total liabilities $— $— $77,412 $77,412 

(1) Fair value is determined by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry standard valuation models, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.
(2) Represents the fair value of common stock warrants outstanding that may require cash settlement under certain circumstances. The Company estimated the fair value of the warrant liabilities using the Black-Scholes valuation model. As of December 31, 2017 and September 30, 2018, common stock warrant liabilities relate to warrants issued in July 2011 in connection with a debt financing arrangement. The warrants entitle the holder to purchase up to 28,125 shares of common stock at an exercise price of $72.00 per share. The warrants will expire in July 2021.
(3) In connection with a prior acquisition, the Company may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. The Company estimated the fair value of the contingent consideration liabilities on the acquisition date using a probability-weighted income approach, which reflects the probability and timing of future payments. This fair value measurement is based on significant Level 3 inputs such as the anticipated timelines and probability of achieving development, regulatory approval or sales-based milestone events and projected revenues. The resulting probability-weighted cash flows are discounted at risk-adjusted rates. Subsequent to the acquisition date, at each reporting period prior to settlement, the Company revalues these liabilities by performing a review of the assumptions listed above and record increases or decreases in the fair value of these contingent consideration liabilities. In the absence of any significant changes in key assumptions, the quarterly determination of fair values of these contingent consideration liabilities would primarily reflect the passage of time and
risk-adjusted interest rates. Significant judgment is used in determining Level 3 inputs and fair value measurements as of the acquisition date and for each subsequent reporting period. Updates to assumptions could have a significant impact on the Company’s results of operations in any given period and actual results may differ from estimates. For example, significant increases in the probability of achieving a milestone or projected revenues would result in a significantly higher fair value measurement while significant decreases in the estimated probability of achieving a milestone or projected revenues would result in a significantly lower fair value measurement. Significant increases in the discount rate or in the anticipated timelines would result in a significantly lower fair value measurement while significant decreases in the discount rate or anticipated timelines would result in a significantly higher fair value measurement. The potential contingent consideration payments required upon achievement of development, regulatory approval and sales-based milestones related to the Company’s acquisition of ZX008 range from zero if none of the milestones are achieved to a maximum of $95.0 million (undiscounted). As of September 30, 2018, the Company has classified $32.5 million of the total contingent consideration liabilities of $80.1 million as current liabilities. The classification was based upon the Company’s reasonable expectation as to the timing of settlement of certain specified milestones.
The following table provides a reconciliation of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and nine months ended September 30, 2018 and 2017 (in thousands):

June 30, 2018Change in Fair Value September 30, 2018June 30, 2017Change in Fair Value September 30, 2017
Contingent consideration liabilities $74,400 $5,700 $80,100 $53,900 $10,500 $64,400 
Common stock warrant liabilities 543 64 607 69 380 449 

December 31, 2017Change in Fair Value September 30, 2018December 31, 2016Change in Fair Value September 30, 2017
Contingent consideration liabilities 76,900 $3,200 $80,100 $52,800 $11,600 $64,400 
Common stock warrant liabilities 512 95 607 809 (360)449 

The changes in fair value of the liabilities shown in the table above are recorded through change in fair value of contingent consideration liabilities within operating expense and the change in fair value of common stock warrant liabilities within other income (expense) in the condensed consolidated statements of operations.

There were no transfers between levels during the periods presented. See Note 3 for further information regarding the amortized cost of the Company's financial instruments.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Leases
The Company has two noncancellable operating leases consisting of administrative and research and development office space for its Emeryville, California headquarters and former headquarters in San Diego, California that expire in November 2022 and March 2020, respectively. The former headquarters has been subleased to an unrelated third party for the remainder of the Company’s original lease term. Future minimum lease payments under our non-cancellable operating leases at September 30, 2018, net of sublease income, were as follows (in thousands):
Gross Lease
Payments
Sublease
Income
Net Lease
Payments
2018 (remaining 3 months) $481 $(136)$345 
20191,955 (576)1,379 
20201,234 (148)1,086 
20211,004 — 1,004 
2022946 — 946 
Total $5,620 $(860)$4,760 
In October 2018, the Company executed a lease for new headquarters with its current landlord to move to a facility nearby its current headquarters in Emeryville, California. The lease has an initial term that expires on June 30, 2027 and provides for one five-year renewal option. Concurrent with the new lease, the landlord agreed to terminate the Company's existing lease once it completes the move to the new headquarters. The cash expected to be paid for rent over the term of the new lease of eight years is approximately $15.3 million beginning in June 2019, partially offset by a reduction in the commitments under its existing headquarter lease.
Legal Matters
The Company is not currently involved in any material legal proceedings. The Company may become involved in various legal proceedings and claims that arise in the ordinary course of business. Such matters are subject to uncertainty and there can be no assurance that such legal proceedings will not have a material adverse effect on its business, results of operations, financial position or cash flows.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Sale of Common Stock
 9 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Sale of Common Stock Sale of Common Stock
The Company has an at-the-market offering program (“ATM Program”) with Cantor Fitzgerald & Co. (“Cantor”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its common stock having an aggregate offering price of up to $75.0 million under a previously filed and effective registration statement on Form S-3 (File No. 333-220759) and a prospectus supplement filed in December 2017. Cantor is entitled to a commission at a fixed commission rate of up to 3% of the gross proceeds of the sales price of all common stock sold under the ATM program. The Company and Cantor may each terminate the ATM program at any time upon ten days’ prior notice.
In the second quarter of 2018, the Company sold a total of 740,417 shares of its common stock under the ATM program and received net proceeds of approximately $30.3 million, after deducting commissions and other offering expenses of $1.1 million.
In August 2018, the Company completed an underwritten public offering for the sale of 6,000,000 shares of its common stock. Net proceeds raised from the offering were approximately $292.9 million, after deducting underwriting discounts and commissions and other offering expenses of $19.1 million.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-Based Compensation
 9 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The Company has adopted certain equity incentive and stock purchase plans as described in the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
In March 2018, our board of directors approved an amendment and restatement of our non-employee director compensation policy, pursuant to which any non-employee director who is first elected to the board of directors is granted an option to purchase 20,000 shares of our common stock on the date of his or her initial election to the board of directors. In addition, on the date of each annual meeting of our stockholders, commencing with the 2018 annual meeting, each non-employee director is eligible to receive an option to purchase 15,000 shares of common stock. Prior to March 2018, under our non-employee director compensation policy, any non-employee director who was first elected to the board of directors was granted an option to purchase 30,000 shares of our common stock on the date of his or her initial election to the board of directors. In addition, on the date of each annual meeting of our stockholders, each non-employee director was eligible to receive an option to purchase 20,000 shares of common stock.
Performance Stock Options
In October 2015, the Company granted employees certain performance-based stock options for retention purposes. The stock options would vest upon satisfaction of a specified regulatory milestone within three years of the date of grant. In 2017, management determined the achievement of the performance condition was no longer probable and the cumulative compensation expense previously recognized was reversed. In September 2018, these awards were modified to allow for 90% of such options outstanding at the modification date to vest immediately. The remaining 10% of the awards were canceled in October 2018 since the performance condition was not met. This improbable to probable modification resulted in the calculation and recognition of incremental stock-based compensation expense of $3.5 million during the third quarter of 2018.
Equity Incentive Awards Activity

Stock Options
The following is a summary of stock option activity for the nine months ended September 30, 2018 (in thousands, except per share data):
Shares
(in thousands)
Weighted-
Average
Exercise
Price per Share
Outstanding at December 31, 20173,392 $14.41 
Granted
842 43.13 
Exercised
(290)16.45 
Canceled
(59)26.10 
Outstanding at September 30, 20183,885 $20.30 

Restricted Stock Units
The following is a summary of restricted stock unit activity for the nine months ended September 30, 2018 (in thousands, except per share data):
Shares
(in thousands)
Weighted- Average Fair Value per Share at Grant Date 
Outstanding at December 31, 2017259 $10.43 
Granted
146 42.76 
Vested
(98)10.74 
Canceled
(8)29.74 
Outstanding at September 30, 2018299 $25.58 
As of September 30, 2018, outstanding restricted stock units included 159,000 granted in March 2017 with performance-based conditions to employees and executives. The restricted stock units vest upon the approval of the Company’s new drug application for ZX008 by the FDA, provided such approval occurs within five years following the grant date. Due to the uncertainties associated with the FDA approval process, approval is not yet probable, as such term is used for accounting purposes, prior to the occurrence of the event. Accordingly, no compensation expense has been recognized to date for these performance-based awards.
Valuation of Equity Awards
The fair value of the stock options granted or modified during the periods indicated was estimated using the Black-Scholes option pricing model, based on the following assumptions:

Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Risk free interest rate 2.8% to 2.9% 1.9% to 2.1% 2.3% to 2.9% 1.9% to 2.3% 
Expected term 3.5 to 6.1 years 6.1 years 3.5 to 6.1 years 5.1 to 6.1 years 
Expected volatility 79.9% to 83.2% 75.1% to 75.5% 79.9% to 85.2% 75.1% to 76.6% 
Expected dividend yield — %— %— %— %
The fair value of restricted stock units granted is determined based on the price of the Company's common stock on the date of grant.
Stock-Based Compensation Expense
The following table summarizes the components of total stock-based compensation expense included in the condensed consolidated statements of operations (in thousands):
 
Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Cost of contract manufacturing $— $— $— $71 
Research and development 3,275 294 5,018 1,313 
Selling, general and administrative 3,706 968 6,934 2,682 
Total $6,981 $1,262 $11,952 $4,066 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss Per Share
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Net Loss per Share Net Loss Per Share
Basic net loss from continuing operations per share is calculated by dividing net loss from continuing operations by the weighted average number of shares outstanding for the period. Diluted net loss from continuing operations per share is calculated by dividing net loss from continuing operations by the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period if the effect is dilutive. The Company’s potentially dilutive shares of common stock include outstanding stock options, restricted stock units and warrants to purchase common stock.
A reconciliation of the numerators and denominators used in computing net loss from continuing operations per share is as follows (in thousands, except per share amounts):
Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Numerator: 
Net loss from continuing operations $(42,264)$(42,660)$(101,283)$(86,239)
Denominator: 
Shares used in per share calculation 39,242 25,431 36,485 25,024 
Net loss from continuing operations per share, basic and diluted $(1.08)$(1.68)$(2.78)$(3.45)
The following table presents the potential shares of common stock outstanding that were excluded from the computation of diluted net loss from continuing operations per share for the periods presented because including them would have been anti-dilutive (in thousands):
Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Shares subject to outstanding common stock options 3,957 4,121 3,752 3,879 
Shares subject to outstanding restricted stock units 303 271 287 228 
Shares subject to outstanding warrants to purchase common stock 28 1,251 35 1,522 
Total 4,288 5,643 4,074 5,629 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
United Kingdom (U.K.) Research and Development Incentives
 9 Months Ended
Sep. 30, 2018
Other Income and Expenses [Abstract]  
United Kingdom (U.K.) Research and Development Incentives United Kingdom (U.K.) Research and Development IncentivesThe Company carries out extensive research and development activities that benefit from the U.K.’s small and medium-sized enterprise (“SME”) research and development tax credit regime, whereby the Company may either receive an enhanced U.K. tax deduction on its eligible research and development activities or, when an SME entity is in a net operating loss position, elect to surrender net operating losses that arise from its eligible research and development activities in exchange for a cash
payment from the U.K. tax authorities. These refundable cash credits, which may be received without regard to actual tax liability, are not subject to accounting for income taxes and have been recorded as a component of other income.
In December 2017, the Company filed a claim as an SME for a $3.0 million refundable cash credit for its 2015 tax year, which was received in July 2018. The Company recorded this amount as a component of other income for the nine months ended September 30, 2018. As of the date hereof, the Company has not filed claims for any refundable cash credit for its 2016 or 2017 tax years, nor has it recorded any balances related to claims for these years or for the 2018 tax year, as collectability is deemed not probable or reasonably assured.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Cash Equivalents and Marketable Securities
Cash Equivalents and Marketable Securities
The Company considers cash equivalents to be only those investments which are highly liquid, readily convertible to cash and have an original maturity of three months or less at the date of purchase.
The Company invests its excess cash in marketable securities with high credit ratings that are classified as Level 1 and Level 2 within the fair value hierarchy. These marketable securities consists of money market funds and certificate of deposits, securities issued by the U.S. government and its agencies, corporate debt securities and commercial paper, which are all classified as “available-for-sale”. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and, therefore, classifies all securities with maturity dates beyond three months at the date of purchase as current assets on the condensed consolidated balance sheets. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the condensed consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on marketable securities are included in interest income (expense), net. The cost of securities sold is determined using the specific identification method.
The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and management’s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value.
Concentration of Credit Risk Concentration of Credit RiskCash, cash equivalents and marketable securities are financial instruments that potentially subject the Company to concentration of credit risk. The Company invests its excess cash primarily in money market funds and certificate of deposits, securities issued by the U.S. government and its agencies, corporate debt securities and commercial paper. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe it is exposed to any significant credit risk related to these instruments.
Recent Accounting Pronouncements
Accounting Pronouncements Recently Adopted
Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) and subsequent amendments to the initial guidance (collectively, “Topic 606”) amended the existing accounting standards for revenue recognition. The core principle of Topic 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. The Company adopted Topic 606 effective January 1, 2018 using the modified retrospective approach. The adoption of Topic 606 did not have a material impact on the Company’s condensed consolidated financial statements as the Company does not have any contracts with customers.
ASU 2016-15, Statement of Cash Flows (Topic 230) provides guidance on eight specific cash flow issues, thereby reducing the diversity in practice in how certain transactions are classified in the statement of cash flows. The amendments in this ASU are applied using a retrospective transition method to each period presented. The Company adopted ASU 2016-15
effective January 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.
ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business narrows the definition of a business and provides additional guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This accounting standards update is required to be applied prospectively to transactions occurring after the date of adoption. The Company adopted ASU 2017-09 effective January 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.
ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting provides guidance on determining changes to the terms and conditions of share-based payment awards and require an entity to apply modification accounting under Topic 718 unless all of the following conditions are met: (1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification; (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The amendments should be applied prospectively to an award modified on or after the adoption date. The Company adopted ASU 2017-09 effective January 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.
On December 22, 2017, the U.S. federal government enacted the Tax Cuts and Jobs Act (“the Act”). The Tax Act contains, among other things, significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% for tax years beginning after December 31, 2017, limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, implementing a territorial tax system, and requiring a mandatory one-time tax on U.S. owned undistributed foreign earnings and profits known as the transition tax. In December 2017, SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) to address the accounting implications of recently enacted U.S. federal tax reform. SAB 118 allows companies to record provisional amounts during a measurement period not to extend beyond one year of the enactment date to address ongoing guidance and tax interpretations that are expected over the next 12 months. The Company has adopted SAB 118 and currently considers its accounting of the impact of U.S. federal tax reform to be incomplete but continues to make a reasonable estimate of the effects on our existing deferred tax assets. The Company expects to complete the remainder of the analysis within the measurement period in accordance with SAB 118. Adjustments, if any, are not expected to impact the condensed consolidated statement of operations and comprehensive loss due to the full valuation allowance on the Company’s deferred tax assets.
ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting simplifies the accounting for share-based payment awards issued to nonemployees for goods and services, including fixing the estimated fair value of the stock award at the date of grant. ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The adoption of ASU 2018-07 requires a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year. ASU 2018-07 is effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company early adopted ASU 2018-07 effective July 1, 2018. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.
In August 2018, the SEC adopted amendments to certain disclosure requirements in Securities Act Release No. 33-10532, Disclosure Update and Simplification. These amendments eliminate, modify, or integrate into other SEC requirements certain disclosure rules. Among the amendments is the requirement to present an analysis of changes in stockholders’ equity in the interim financial statements included in quarterly reports on Form 10-Q. The analysis, which can be presented as a footnote or separate statement, is required for the current and comparative quarter and year-to-date interim periods. The amendments became effective for all filings made on or after November 5, 2018. In light of the anticipated timing of effectiveness of the amendments and expected proximity of effectiveness to the filing date for most filers’ quarterly reports, the SEC’s Division of Corporate Finance issued a Compliance and Disclosure Interpretation related to Exchange Act Forms, or CDI – Question 105.09, that provides transition guidance related to this disclosure requirement. CDI – Question 105.09 states that the SEC would not object if the filer’s first presentation of the changes in shareholders’ equity is included in its Form 10-Q for the quarter that begins after the effective date of the amendments. Except for the requirement to provide the annual disclosure
changes in stockholders’ equity for interim periods, which will be included beginning with the Company's quarterly report on Form 10-Q ending March 31, 2019, the Company has adopted all relevant disclosure requirements.
Accounting Pronouncements Issued But Not Yet Effective
ASU 2016-02, Leases (Topic 842) establishes a right-of-use model (“ROU”) that requires all lessees to recognize ROU assets and liabilities for leases with a duration greater than one year on the balance sheet as well as provide disclosures with respect to certain qualitative and quantitative information regarding the amount, timing and uncertainty of cash flows arising from leases. Both a ROU asset and liability will initially be measured at the present value of the future minimum lease payments over the lease term. Subsequent measurement, including the presentation of expenses and cash flows, will depend on the classification of the lease as either a finance or an operating lease. Initial costs directly attributable to negotiating and arranging the lease will be included in the asset. The new standard is effective for fiscal years beginning after December 15, 2018, and interim periods therein. Early adoption is permitted. Originally, entities were required to adopt ASU 2016-02 using a modified retrospective approach, which required prior periods to be presented under this new standard with various practical expedients allowed. In July 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which now allows entities the option of recognizing the cumulative effect of applying the new standard as an adjustment to the opening balance of retained earnings in the year of adoption (January 1, 2019) while continuing to present all prior periods under previous lease accounting guidance. The Company intends to adopt the standard on January 1, 2019 by recognizing a cumulative effect adjustment to the opening balance of retained earnings and utilizing the practical expedient that allows the Company to not reassess whether an expired or existing contract contains a lease, the classification of leases or initial direct costs. The Company is in the process of inventorying and scoping its existing lease contracts. While the Company is currently evaluating the impact of adopting this accounting standard update on its condensed consolidated financial statements and related disclosures, the Company anticipates that ROU assets and corresponding liabilities will be recognized in its condensed consolidated balance sheets related to its lease arrangements. The adoption of these standards are also expected to impact the Company’s condensed consolidated financial statement disclosures.
ASU 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. Under the amendments in ASU 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds its fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The updated guidance requires a prospective adoption. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the timing and impact of adopting this ASU on its condensed consolidated financial statements and related disclosures.
ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement modifies the disclosure requirements in Topic 820, Fair Value Measurement, by removing certain disclosure requirements related to the fair value hierarchy, modifying existing disclosure requirements related to measurement uncertainty and adding new disclosure requirements, such as disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and disclosing the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for public companies for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year. Early adoption is permitted for any removed or modified disclosures. The Company is currently evaluating the timing and impact of adopting this ASU on its condensed consolidated financial statements and related disclosures.
Fair Value Measurements The carrying amount of the Company’s financial instruments, including cash and cash equivalents, other current assets, accounts payable, accrued and other current liabilities approximate their fair value due to their short maturities.
Stock-based Compensation The Company has adopted certain equity incentive and stock purchase plans as described in the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
Net Loss per Share Basic net loss from continuing operations per share is calculated by dividing net loss from continuing operations by the weighted average number of shares outstanding for the period. Diluted net loss from continuing operations per share is calculated by dividing net loss from continuing operations by the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period if the effect is dilutive.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash, Cash Equivalents and Marketable Securities (Tables)
 9 Months Ended
Sep. 30, 2018
Cash and Cash Equivalents [Abstract]  
Amortized Cost and Fair Value of Cash, Cash Equivalents and Marketable Securities The following table summarizes the amortized cost and fair value of the Company's cash, cash equivalents and marketable securities as of September 30, 2018 (in thousands):
Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value 
(in thousands)
Current assets: 
Cash $4,747 $— $— $4,747 
Cash equivalents: 
Commercial paper 58,127 — — 58,127 
Corporate debt securities 1,624 — — 1,624 
Money market funds 97,686 — — 97,686 
Certificate of deposits 854 — — 854 
Total cash equivalents 158,291 — — 158,291 
Total cash and cash equivalents 163,038 — — 163,038 
Marketable securities: 
Commercial paper 174,769 1 (1)174,769 
Corporate debt securities 47,416 — (30)47,386 
Certificate of deposits 118,775 — — 118,775 
U.S. Treasuries 35,173 — (16)35,157 
Total marketable securities 376,133 1 (47)376,087 
Total cash, cash equivalents and marketable securities $539,171 $1 $(47)$539,125 
Cost and Fair Value of Marketable Securities
The following table summarizes the cost and fair value of marketable securities based on stated effective maturities as of September 30, 2018 (in thousands):
Amortized Cost Fair Value 
Due within one year $345,678 $345,644 
Due between one and two years 30,455 30,443 
Total $376,133 $376,087 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2018
Fair Value Disclosures [Abstract]  
Liabilities Measured at Fair Value on Recurring Basis The following tables summarize assets and liabilities recognized or disclosed at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 (in thousands):
Level 1 Level 2 Level 3 Total 
September 30, 2018
Assets: 
Cash equivalents: 
Commercial paper $— $58,127 $— $58,127 
Corporate debt securities — 1,624 — 1,624 
Money market funds 97,686 — — 97,686 
Certificate of deposits — 854 — 854 
Marketable securities 
Commercial paper — 174,769 — 174,769 
Corporate debt securities — 47,386 — 47,386 
Certificate of deposits — 118,775 — 118,775 
U.S. Treasuries — 35,157 — 35,157 
Total assets(1) $97,686 $436,692 $— $534,378 
Liabilities: 
Common stock warrant liabilities(2) $— $— $607 $607 
Contingent consideration liabilities(3) — — 80,100 80,100 
Total liabilities $— $— $80,707 $80,707 

Level 1 Level 2 Level 3 Total 
December 31, 2017
Assets: 
Cash equivalents consisting of money market funds(1) $289,782 $— $— $289,782 
Total assets $289,782 $— $— $289,782 
Liabilities: 
Common stock warrant liabilities(2) $— $— $512 $512 
Contingent consideration liabilities(3) — — 76,900 76,900 
Total liabilities $— $— $77,412 $77,412 

(1) Fair value is determined by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry standard valuation models, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.
(2) Represents the fair value of common stock warrants outstanding that may require cash settlement under certain circumstances. The Company estimated the fair value of the warrant liabilities using the Black-Scholes valuation model. As of December 31, 2017 and September 30, 2018, common stock warrant liabilities relate to warrants issued in July 2011 in connection with a debt financing arrangement. The warrants entitle the holder to purchase up to 28,125 shares of common stock at an exercise price of $72.00 per share. The warrants will expire in July 2021.
(3) In connection with a prior acquisition, the Company may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. The Company estimated the fair value of the contingent consideration liabilities on the acquisition date using a probability-weighted income approach, which reflects the probability and timing of future payments. This fair value measurement is based on significant Level 3 inputs such as the anticipated timelines and probability of achieving development, regulatory approval or sales-based milestone events and projected revenues. The resulting probability-weighted cash flows are discounted at risk-adjusted rates. Subsequent to the acquisition date, at each reporting period prior to settlement, the Company revalues these liabilities by performing a review of the assumptions listed above and record increases or decreases in the fair value of these contingent consideration liabilities. In the absence of any significant changes in key assumptions, the quarterly determination of fair values of these contingent consideration liabilities would primarily reflect the passage of time and
risk-adjusted interest rates. Significant judgment is used in determining Level 3 inputs and fair value measurements as of the acquisition date and for each subsequent reporting period. Updates to assumptions could have a significant impact on the Company’s results of operations in any given period and actual results may differ from estimates. For example, significant increases in the probability of achieving a milestone or projected revenues would result in a significantly higher fair value measurement while significant decreases in the estimated probability of achieving a milestone or projected revenues would result in a significantly lower fair value measurement. Significant increases in the discount rate or in the anticipated timelines would result in a significantly lower fair value measurement while significant decreases in the discount rate or anticipated timelines would result in a significantly higher fair value measurement. The potential contingent consideration payments required upon achievement of development, regulatory approval and sales-based milestones related to the Company’s acquisition of ZX008 range from zero if none of the milestones are achieved to a maximum of $95.0 million (undiscounted). As of September 30, 2018, the Company has classified $32.5 million of the total contingent consideration liabilities of $80.1 million as current liabilities. The classification was based upon the Company’s reasonable expectation as to the timing of settlement of certain specified milestones
Assets Measured at Fair Value on Recurring Basis The following tables summarize assets and liabilities recognized or disclosed at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 (in thousands):
Level 1 Level 2 Level 3 Total 
September 30, 2018
Assets: 
Cash equivalents: 
Commercial paper $— $58,127 $— $58,127 
Corporate debt securities — 1,624 — 1,624 
Money market funds 97,686 — — 97,686 
Certificate of deposits — 854 — 854 
Marketable securities 
Commercial paper — 174,769 — 174,769 
Corporate debt securities — 47,386 — 47,386 
Certificate of deposits — 118,775 — 118,775 
U.S. Treasuries — 35,157 — 35,157 
Total assets(1) $97,686 $436,692 $— $534,378 
Liabilities: 
Common stock warrant liabilities(2) $— $— $607 $607 
Contingent consideration liabilities(3) — — 80,100 80,100 
Total liabilities $— $— $80,707 $80,707 

Level 1 Level 2 Level 3 Total 
December 31, 2017
Assets: 
Cash equivalents consisting of money market funds(1) $289,782 $— $— $289,782 
Total assets $289,782 $— $— $289,782 
Liabilities: 
Common stock warrant liabilities(2) $— $— $512 $512 
Contingent consideration liabilities(3) — — 76,900 76,900 
Total liabilities $— $— $77,412 $77,412 

(1) Fair value is determined by taking into consideration valuations obtained from third-party pricing services. The third-party pricing services utilize industry standard valuation models, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.
(2) Represents the fair value of common stock warrants outstanding that may require cash settlement under certain circumstances. The Company estimated the fair value of the warrant liabilities using the Black-Scholes valuation model. As of December 31, 2017 and September 30, 2018, common stock warrant liabilities relate to warrants issued in July 2011 in connection with a debt financing arrangement. The warrants entitle the holder to purchase up to 28,125 shares of common stock at an exercise price of $72.00 per share. The warrants will expire in July 2021.
(3) In connection with a prior acquisition, the Company may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. The Company estimated the fair value of the contingent consideration liabilities on the acquisition date using a probability-weighted income approach, which reflects the probability and timing of future payments. This fair value measurement is based on significant Level 3 inputs such as the anticipated timelines and probability of achieving development, regulatory approval or sales-based milestone events and projected revenues. The resulting probability-weighted cash flows are discounted at risk-adjusted rates. Subsequent to the acquisition date, at each reporting period prior to settlement, the Company revalues these liabilities by performing a review of the assumptions listed above and record increases or decreases in the fair value of these contingent consideration liabilities. In the absence of any significant changes in key assumptions, the quarterly determination of fair values of these contingent consideration liabilities would primarily reflect the passage of time and
risk-adjusted interest rates. Significant judgment is used in determining Level 3 inputs and fair value measurements as of the acquisition date and for each subsequent reporting period. Updates to assumptions could have a significant impact on the Company’s results of operations in any given period and actual results may differ from estimates. For example, significant increases in the probability of achieving a milestone or projected revenues would result in a significantly higher fair value measurement while significant decreases in the estimated probability of achieving a milestone or projected revenues would result in a significantly lower fair value measurement. Significant increases in the discount rate or in the anticipated timelines would result in a significantly lower fair value measurement while significant decreases in the discount rate or anticipated timelines would result in a significantly higher fair value measurement. The potential contingent consideration payments required upon achievement of development, regulatory approval and sales-based milestones related to the Company’s acquisition of ZX008 range from zero if none of the milestones are achieved to a maximum of $95.0 million (undiscounted). As of September 30, 2018, the Company has classified $32.5 million of the total contingent consideration liabilities of $80.1 million as current liabilities. The classification was based upon the Company’s reasonable expectation as to the timing of settlement of certain specified milestones
Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)
The following table provides a reconciliation of liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and nine months ended September 30, 2018 and 2017 (in thousands):

June 30, 2018Change in Fair Value September 30, 2018June 30, 2017Change in Fair Value September 30, 2017
Contingent consideration liabilities $74,400 $5,700 $80,100 $53,900 $10,500 $64,400 
Common stock warrant liabilities 543 64 607 69 380 449 

December 31, 2017Change in Fair Value September 30, 2018December 31, 2016Change in Fair Value September 30, 2017
Contingent consideration liabilities 76,900 $3,200 $80,100 $52,800 $11,600 $64,400 
Common stock warrant liabilities 512 95 607 809 (360)449 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies (Tables)
 9 Months Ended
Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Payments Under Non-cancelable Operating Leases Future minimum lease payments under our non-cancellable operating leases at September 30, 2018, net of sublease income, were as follows (in thousands):
Gross Lease
Payments
Sublease
Income
Net Lease
Payments
2018 (remaining 3 months) $481 $(136)$345 
20191,955 (576)1,379 
20201,234 (148)1,086 
20211,004 — 1,004 
2022946 — 946 
Total $5,620 $(860)$4,760 
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of Stock Option Activity
The following is a summary of stock option activity for the nine months ended September 30, 2018 (in thousands, except per share data):
Shares
(in thousands)
Weighted-
Average
Exercise
Price per Share
Outstanding at December 31, 20173,392 $14.41 
Granted
842 43.13 
Exercised
(290)16.45 
Canceled
(59)26.10 
Outstanding at September 30, 20183,885 $20.30 
Schedule of Restricted Stock Unit Activity
The following is a summary of restricted stock unit activity for the nine months ended September 30, 2018 (in thousands, except per share data):
Shares
(in thousands)
Weighted- Average Fair Value per Share at Grant Date 
Outstanding at December 31, 2017259 $10.43 
Granted
146 42.76 
Vested
(98)10.74 
Canceled
(8)29.74 
Outstanding at September 30, 2018299 $25.58 
Assumptions used in the Black-Scholes Option-Pricing Model
The fair value of the stock options granted or modified during the periods indicated was estimated using the Black-Scholes option pricing model, based on the following assumptions:

Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Risk free interest rate 2.8% to 2.9% 1.9% to 2.1% 2.3% to 2.9% 1.9% to 2.3% 
Expected term 3.5 to 6.1 years 6.1 years 3.5 to 6.1 years 5.1 to 6.1 years 
Expected volatility 79.9% to 83.2% 75.1% to 75.5% 79.9% to 85.2% 75.1% to 76.6% 
Expected dividend yield — %— %— %— %
Stock-Based Compensation Expense
The following table summarizes the components of total stock-based compensation expense included in the condensed consolidated statements of operations (in thousands):
 
Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Cost of contract manufacturing $— $— $— $71 
Research and development 3,275 294 5,018 1,313 
Selling, general and administrative 3,706 968 6,934 2,682 
Total $6,981 $1,262 $11,952 $4,066 
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss Per Share (Tables)
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Basic and Diluted Net Loss Per Share
A reconciliation of the numerators and denominators used in computing net loss from continuing operations per share is as follows (in thousands, except per share amounts):
Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Numerator: 
Net loss from continuing operations $(42,264)$(42,660)$(101,283)$(86,239)
Denominator: 
Shares used in per share calculation 39,242 25,431 36,485 25,024 
Net loss from continuing operations per share, basic and diluted $(1.08)$(1.68)$(2.78)$(3.45)
Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share
The following table presents the potential shares of common stock outstanding that were excluded from the computation of diluted net loss from continuing operations per share for the periods presented because including them would have been anti-dilutive (in thousands):
Three Months Ended September 30, Nine Months Ended September 30, 
2018201720182017
Shares subject to outstanding common stock options 3,957 4,121 3,752 3,879 
Shares subject to outstanding restricted stock units 303 271 287 228 
Shares subject to outstanding warrants to purchase common stock 28 1,251 35 1,522 
Total 4,288 5,643 4,074 5,629 
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and Basis of Presentation - Narrative (Details) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accumulated deficit $ 673,521 $ 572,040
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Sep. 30, 2017
Dec. 31, 2016
Cash and Cash Equivalents [Line Items]        
Cash $ 4,747      
Cash equivalents 158,291      
Total cash and cash equivalents 163,038 $ 293,503 $ 64,730 $ 91,551
Marketable securities, amortized cost 376,133      
Marketable securities, gross unrealized gains 1      
Marketable securities, gross unrealized losses (47)      
Marketable securities, estimated fair value 376,087      
Total cash, cash equivalents and marketable securities 539,171      
Total cash, cash equivalents and marketable securities 539,125      
Amortized Cost        
Due within one year, amortized cost 345,678      
Due between one and two years, amortized cost 30,455      
Marketable securities, amortized cost 376,133      
Fair Value        
Due within one year, estimated fair value 345,644      
Due between one and two years, estimated fair value 30,443      
Marketable securities, estimated fair value 376,087      
Commercial paper        
Cash and Cash Equivalents [Line Items]        
Cash equivalents 58,127      
Marketable securities, amortized cost 174,769      
Marketable securities, gross unrealized gains 1      
Marketable securities, gross unrealized losses (1)      
Marketable securities, estimated fair value 174,769      
Corporate debt securities        
Cash and Cash Equivalents [Line Items]        
Cash equivalents 1,624      
Marketable securities, amortized cost 47,416      
Marketable securities, gross unrealized gains 0      
Marketable securities, gross unrealized losses (30)      
Marketable securities, estimated fair value 47,386      
Money market funds        
Cash and Cash Equivalents [Line Items]        
Cash equivalents 97,686      
Certificate of deposits        
Cash and Cash Equivalents [Line Items]        
Cash equivalents 854      
Marketable securities, amortized cost 118,775      
Marketable securities, gross unrealized gains 0      
Marketable securities, gross unrealized losses 0      
Marketable securities, estimated fair value 118,775      
U.S. Treasuries        
Cash and Cash Equivalents [Line Items]        
Marketable securities, amortized cost 35,173      
Marketable securities, gross unrealized gains 0      
Marketable securities, gross unrealized losses (16)      
Marketable securities, estimated fair value $ 35,157      
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
 9 Months Ended
Sep. 30, 2018
Dec. 31, 2017
Sep. 30, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Short-term fixed income securities $ 376,087,000    
Total assets 534,378,000    
Liabilities measured at fair value on a recurring basis $ 80,707,000 $ 77,412,000  
Shares of common stock exercisable through warrants 28,125    
Warrants exercise price per share (usd per share) $ 72.00    
Fair value of contingent consideration $ 32,500,000 0  
Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Total assets 97,686,000    
Liabilities measured at fair value on a recurring basis 0 0  
Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Total assets 436,692,000    
Liabilities measured at fair value on a recurring basis 0 0  
Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Total assets 0    
Liabilities measured at fair value on a recurring basis 80,707,000 77,412,000  
Common stock warrant liabilities      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities measured at fair value on a recurring basis 607,000 512,000  
Common stock warrant liabilities | Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities measured at fair value on a recurring basis 0 0  
Common stock warrant liabilities | Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities measured at fair value on a recurring basis 0 0  
Common stock warrant liabilities | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Total assets     $ 449,000
Liabilities measured at fair value on a recurring basis 607,000 512,000  
Contingent consideration liabilities      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities measured at fair value on a recurring basis 80,100,000 76,900,000  
Contingent consideration liabilities | Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities measured at fair value on a recurring basis 0 0  
Contingent consideration liabilities | Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities measured at fair value on a recurring basis 0 0  
Contingent consideration liabilities | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Liabilities measured at fair value on a recurring basis   76,900,000  
Commercial paper      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 58,127,000    
Short-term fixed income securities 174,769,000    
Commercial paper | Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 0    
Short-term fixed income securities 0    
Commercial paper | Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 58,127,000    
Short-term fixed income securities 174,769,000    
Commercial paper | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 0    
Short-term fixed income securities 0    
Corporate debt securities      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 1,624,000    
Short-term fixed income securities 47,386,000    
Corporate debt securities | Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 0    
Short-term fixed income securities 0    
Corporate debt securities | Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 1,624,000    
Short-term fixed income securities 47,386,000    
Corporate debt securities | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 0    
Short-term fixed income securities 0    
Money market funds      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 97,686,000 289,782,000  
Money market funds | Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 97,686,000 289,782,000  
Money market funds | Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 0 0  
Money market funds | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 0 $ 0  
Certificate of deposits      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 854,000    
Short-term fixed income securities 118,775,000    
Certificate of deposits | Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 0    
Short-term fixed income securities 0    
Certificate of deposits | Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 854,000    
Short-term fixed income securities 118,775,000    
Certificate of deposits | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash Equivalents 0    
Short-term fixed income securities 0    
U.S. Treasuries      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Short-term fixed income securities 35,157,000    
U.S. Treasuries | Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Short-term fixed income securities 0    
U.S. Treasuries | Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Short-term fixed income securities 35,157,000    
U.S. Treasuries | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Short-term fixed income securities 0    
ZX008      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Potential contingent consideration payment, minimum 0    
Potential contingent consideration payment, maximum 95,000,000.0    
Fair value of contingent consideration 32,500,000    
Total contingent consideration $ 80,100,000    
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Details) - Level 3 - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Contingent consideration liabilities        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Beginning Balance $ 74,400 $ 53,900 $ 76,900 $ 52,800
Changes in fair value 5,700 10,500 3,200 11,600
Ending Balance 80,100 64,400 80,100 64,400
Common stock warrant liabilities        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Beginning Balance 543 69 512 809
Changes in fair value 64 380 95 (360)
Ending Balance $ 607 $ 449 $ 607 $ 449
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2019
USD ($)
Oct. 31, 2018
lease
Sep. 30, 2018
lease
Subsequent Event [Line Items]      
Number of Noncancelable Leases     2
Subsequent event      
Subsequent Event [Line Items]      
Number of lease renewal options   1  
Length of each lease renewal   5 years  
Term of new lease   8 years  
Expected      
Subsequent Event [Line Items]      
Expected payment for rent | $ $ 15.3    
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies - Future Minimum Lease Payments (Details)
$ in Thousands
Sep. 30, 2018
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2018 (remaining 6 months) gross lease payment due $ 481
2019 gross lease payment due 1,955
2020 gross lease payment due 1,234
2021 gross lease payment due 1,004
2022 gross lease payment due 946
Total gross lease payment due 5,620
2018 (remaining 6 months) sublease income (136)
2019 sublease income (576)
2020 sublease income (148)
2021 sublease income 0
2022 sublease income 0
Total sublease income (860)
2018 (remaining 6 months) net lease payments 345
2019 net lease payments 1,379
2020 net lease payments 1,086
2021 net lease payments 1,004
2022 net lease payments 946
Total net lease payments $ 4,760
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Sale of Common Stock (Details) - Common Stock - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2018
Jun. 30, 2018
Sep. 30, 2018
Class of Stock [Line Items]      
Aggregate offering price     $ 75,000,000.0
Commission rate (percent)     3.00%
Stock issued (in shares) 6,000,000 740,417  
Proceeds from stock issuance $ 292,900,000 $ 30,300,000  
Underwriting discounts and commissions and other offering expenses $ 19,100,000 $ 1,100,000  
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-Based Compensation - Options Activity (Details)
shares in Thousands
 9 Months Ended
Sep. 30, 2018
$ / shares
shares
Shares (in thousands)  
December 31, 2017 (in shares) | shares 3,392
Granted (in shares) | shares 842
Exercised (in shares) | shares (290)
Canceled (in shares) | shares (59)
March 31, 2018 (in shares) | shares 3,885
Weighted- Average Exercise Price per Share  
Outstanding weighted average exercise price, beginning balance (in usd per share) | $ / shares $ 14.41
Granted weighted average exercise price (in usd per share | $ / shares 43.13
Exercised weighted average exercise price (in usd per share | $ / shares 16.45
Canceled weighted average exercise price (in usd per share | $ / shares 26.10
Outstanding weighted average exercise price, ending balance (in usd per share | $ / shares $ 20.30
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-Based Compensation - Restricted Stock Unit Activity (Details) - Restricted stock units
shares in Thousands
 9 Months Ended
Sep. 30, 2018
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding at December 31, 2017 (in shares) | shares 259
Granted (in shares) | shares 146
Vested (in shares) | shares (98)
Canceled (in shares) | shares (8)
Outstanding at March 31, 2018 (in shares) | shares 299
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Nonvested at December 31, 2017 - Weighted average fair value per share at grant date (in usd per share) | $ / shares $ 10.43
Granted - Weighted average fair value per share at grant date (in usd per share) | $ / shares 42.76
Vested - Weighted average fair value per share at grant date (in usd per share) | $ / shares 10.74
Canceled - Weighted average fair value per share at grant date (in usd per share) | $ / shares 29.74
Nonvested at March 31, 2018 - Weighted average fair value per share at grant date (in usd per share) | $ / shares $ 25.58
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-Based Compensation - Assumptions used in Black-Scholes Option-Pricing Model (Detail) - Stock Options
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Risk free interest rate, minimum 2.80% 1.90% 2.30% 1.90%
Risk free interest rate, maximum 2.90% 2.10% 2.90% 2.30%
Expected volatility, minimum 79.90% 75.10% 79.90% 75.10%
Expected volatility, maximum 83.20% 75.50% 85.20% 76.60%
Expected dividend yield 0.00% 0.00% 0.00% 0.00%
Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expected term 3 years 6 months 6 years 1 month 6 days 3 years 6 months 5 years 1 month 6 days
Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expected term 6 years 1 month 6 days 6 years 1 month 6 days 6 years 1 month 6 days 6 years 1 month 6 days
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Stock-based compensation expense $ 6,981 $ 1,262 $ 11,952 $ 4,066
Cost of contract manufacturing        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Stock-based compensation expense 0 0 0 71
Research and development        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Stock-based compensation expense 3,275 294 5,018 1,313
Selling, general and administrative        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Stock-based compensation expense $ 3,706 $ 968 $ 6,934 $ 2,682
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-Based Compensation - Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Mar. 31, 2018
Feb. 28, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock-based compensation expense $ 6,981 $ 1,262 $ 11,952 $ 4,066      
Performance stock options              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Percentage of outstanding options that vested (percent) 90.00%   90.00%        
Percentage of outstanding options that were canceled (percent) 10.00%   10.00%        
Stock-based compensation expense $ 3,500            
Restricted stock units              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Outstanding RSUs at March 31, 2018 (in shares) 299,000   299,000       259,000
Non-employee Director              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of options granted upon initial election to board (shares)         20,000 30,000  
Additional number of options available for grant annually (shares)         15,000 20,000  
Employees and Executives | Restricted stock units              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Outstanding RSUs at March 31, 2018 (in shares) 159,000   159,000        
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss Per Share - Reconciliation of Numerator and Denominators in Computing Net Loss per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Earnings Per Share [Abstract]        
Net loss from continuing operations $ (42,264) $ (42,660) $ (101,283) $ (86,239)
Shares used in per share calculation (in shares) 39,242 25,431 36,485 25,024
Net loss from continuing operations per share, basic and diluted (in dollars per share) $ (1.08) $ (1.68) $ (2.78) $ (3.45)
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss Per Share - Antidilutive Securities (Details) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive securities excluded from computation of earnings per share amount 4,288 5,643 4,074 5,629
Shares subject to outstanding common stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive securities excluded from computation of earnings per share amount 3,957 4,121 3,752 3,879
Shares subject to outstanding restricted stock units        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive securities excluded from computation of earnings per share amount 303 271 287 228
Shares subject to outstanding warrants to purchase common stock        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive securities excluded from computation of earnings per share amount 28 1,251 35 1,522
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
United Kingdom (U.K.) Research and Development Incentives (Details)
$ in Millions
Dec. 31, 2017
USD ($)
Other Income and Expenses [Abstract]  
Claim for refundable cash credit $ 3.0
EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 126 208 1 false 32 0 false 5 false false R1.htm 0001001 - Document - Document and Entity Information Sheet http://www.zogenix.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.zogenix.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 2101101 - Disclosure - Organization and Basis of Presentation Sheet http://www.zogenix.com/role/OrganizationandBasisofPresentation Organization and Basis of Presentation Notes 7 false false R8.htm 2103102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.zogenix.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 2105103 - Disclosure - Cash, Cash Equivalents and Marketable Securities Sheet http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecurities Cash, Cash Equivalents and Marketable Securities Notes 9 false false R10.htm 2108104 - Disclosure - Fair Value Measurements Sheet http://www.zogenix.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 2112105 - Disclosure - Commitments and Contingencies Sheet http://www.zogenix.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 11 false false R12.htm 2116106 - Disclosure - Sale of Common Stock Sheet http://www.zogenix.com/role/SaleofCommonStock Sale of Common Stock Notes 12 false false R13.htm 2118107 - Disclosure - Stock-Based Compensation Sheet http://www.zogenix.com/role/StockBasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 2125108 - Disclosure - Net Loss Per Share Sheet http://www.zogenix.com/role/NetLossPerShare Net Loss Per Share Notes 14 false false R15.htm 2129109 - Disclosure - United Kingdom (U.K.) Research and Development Incentives Sheet http://www.zogenix.com/role/UnitedKingdomUKResearchandDevelopmentIncentives United Kingdom (U.K.) Research and Development Incentives Notes 15 false false R16.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.zogenix.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.zogenix.com/role/SummaryofSignificantAccountingPolicies 16 false false R17.htm 2306301 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables) Sheet http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesTables Cash, Cash Equivalents and Marketable Securities (Tables) Tables http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecurities 17 false false R18.htm 2309302 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.zogenix.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.zogenix.com/role/FairValueMeasurements 18 false false R19.htm 2313303 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.zogenix.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://www.zogenix.com/role/CommitmentsandContingencies 19 false false R20.htm 2319304 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.zogenix.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.zogenix.com/role/StockBasedCompensation 20 false false R21.htm 2326305 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.zogenix.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.zogenix.com/role/NetLossPerShare 21 false false R22.htm 2402401 - Disclosure - Organization and Basis of Presentation - Narrative (Details) Sheet http://www.zogenix.com/role/OrganizationandBasisofPresentationNarrativeDetails Organization and Basis of Presentation - Narrative (Details) Details 22 false false R23.htm 2407402 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Details) Sheet http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails Cash, Cash Equivalents and Marketable Securities (Details) Details http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesTables 23 false false R24.htm 2410403 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 24 false false R25.htm 2411404 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Details) Sheet http://www.zogenix.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueUsingSignificantUnobservableInputsDetails Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Details) Details 25 false false R26.htm 2414405 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.zogenix.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.zogenix.com/role/CommitmentsandContingenciesTables 26 false false R27.htm 2415406 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Details) Sheet http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails Commitments and Contingencies - Future Minimum Lease Payments (Details) Details 27 false false R28.htm 2417407 - Disclosure - Sale of Common Stock (Details) Sheet http://www.zogenix.com/role/SaleofCommonStockDetails Sale of Common Stock (Details) Details http://www.zogenix.com/role/SaleofCommonStock 28 false false R29.htm 2420408 - Disclosure - Stock-Based Compensation - Options Activity (Details) Sheet http://www.zogenix.com/role/StockBasedCompensationOptionsActivityDetails Stock-Based Compensation - Options Activity (Details) Details 29 false false R30.htm 2421409 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details) Sheet http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails Stock-Based Compensation - Restricted Stock Unit Activity (Details) Details 30 false false R31.htm 2422410 - Disclosure - Stock-Based Compensation - Assumptions used in Black-Scholes Option-Pricing Model (Detail) Sheet http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail Stock-Based Compensation - Assumptions used in Black-Scholes Option-Pricing Model (Detail) Details 31 false false R32.htm 2423411 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail) Sheet http://www.zogenix.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail Stock-Based Compensation - Stock-Based Compensation Expense (Detail) Details 32 false false R33.htm 2424412 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 33 false false R34.htm 2427413 - Disclosure - Net Loss Per Share - Reconciliation of Numerator and Denominators in Computing Net Loss per Share (Details) Sheet http://www.zogenix.com/role/NetLossPerShareReconciliationofNumeratorandDenominatorsinComputingNetLossperShareDetails Net Loss Per Share - Reconciliation of Numerator and Denominators in Computing Net Loss per Share (Details) Details 34 false false R35.htm 2428414 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details) Sheet http://www.zogenix.com/role/NetLossPerShareAntidilutiveSecuritiesDetails Net Loss Per Share - Antidilutive Securities (Details) Details 35 false false R36.htm 2430415 - Disclosure - United Kingdom (U.K.) Research and Development Incentives (Details) Sheet http://www.zogenix.com/role/UnitedKingdomUKResearchandDevelopmentIncentivesDetails United Kingdom (U.K.) Research and Development Incentives (Details) Details http://www.zogenix.com/role/UnitedKingdomUKResearchandDevelopmentIncentives 36 false false All Reports Book All Reports zgnx-20180930.htm ex10120180930.htm ex31120180930.htm ex31220180930.htm ex32120180930.htm ex32220180930.htm zgnx-20180930.xsd zgnx-20180930_cal.xml zgnx-20180930_def.xml zgnx-20180930_lab.xml zgnx-20180930_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "zgnx-20180930.htm": { "axisCustom": 0, "axisStandard": 13, "contextCount": 126, "dts": { "calculationLink": { "local": [ "zgnx-20180930_cal.xml" ] }, "definitionLink": { "local": [ "zgnx-20180930_def.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml" ] }, "inline": { "local": [ "zgnx-20180930.htm" ] }, "labelLink": { "local": [ "zgnx-20180930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "zgnx-20180930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml" ] }, "schema": { "local": [ "zgnx-20180930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" ] } }, "elementCount": 312, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 41, "http://xbrl.sec.gov/dei/2018-01-31": 11, "total": 52 }, "keyCustom": 26, "keyStandard": 182, "memberCustom": 5, "memberStandard": 21, "nsprefix": "zgnx", "nsuri": "http://www.zogenix.com/20180930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information", "role": "http://www.zogenix.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108104 - Disclosure - Fair Value Measurements", "role": "http://www.zogenix.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112105 - Disclosure - Commitments and Contingencies", "role": "http://www.zogenix.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116106 - Disclosure - Sale of Common Stock", "role": "http://www.zogenix.com/role/SaleofCommonStock", "shortName": "Sale of Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118107 - Disclosure - Stock-Based Compensation", "role": "http://www.zogenix.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125108 - Disclosure - Net Loss Per Share", "role": "http://www.zogenix.com/role/NetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129109 - Disclosure - United Kingdom (U.K.) Research and Development Incentives", "role": "http://www.zogenix.com/role/UnitedKingdomUKResearchandDevelopmentIncentives", "shortName": "United Kingdom (U.K.) Research and Development Incentives", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.zogenix.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables)", "role": "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesTables", "shortName": "Cash, Cash Equivalents and Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.zogenix.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313303 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.zogenix.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "icb70afe3c5b14fafa7a6d240a7ae5f00_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "icb70afe3c5b14fafa7a6d240a7ae5f00_I20180930", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319304 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.zogenix.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2326305 - Disclosure - Net Loss Per Share (Tables)", "role": "http://www.zogenix.com/role/NetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "icb70afe3c5b14fafa7a6d240a7ae5f00_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Organization and Basis of Presentation - Narrative (Details)", "role": "http://www.zogenix.com/role/OrganizationandBasisofPresentationNarrativeDetails", "shortName": "Organization and Basis of Presentation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "icb70afe3c5b14fafa7a6d240a7ae5f00_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Details)", "role": "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails", "shortName": "Cash, Cash Equivalents and Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "icb70afe3c5b14fafa7a6d240a7ae5f00_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "icb70afe3c5b14fafa7a6d240a7ae5f00_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "icb70afe3c5b14fafa7a6d240a7ae5f00_I20180930", "decimals": "-3", "lang": null, "name": "zgnx:CashEquivalentsAndDebtSecuritiesAvailableforsale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i39b505156beb4fd6a03d1bdccae80ff8_I20180630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Details)", "role": "http://www.zogenix.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueUsingSignificantUnobservableInputsDetails", "shortName": "Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i39b505156beb4fd6a03d1bdccae80ff8_I20180630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "icb70afe3c5b14fafa7a6d240a7ae5f00_I20180930", "decimals": "INF", "first": true, "lang": null, "name": "zgnx:NumberofNoncancelableLeases", "reportCount": 1, "unique": true, "unitRef": "lease", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414405 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.zogenix.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "icb70afe3c5b14fafa7a6d240a7ae5f00_I20180930", "decimals": "INF", "first": true, "lang": null, "name": "zgnx:NumberofNoncancelableLeases", "reportCount": 1, "unique": true, "unitRef": "lease", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "icb70afe3c5b14fafa7a6d240a7ae5f00_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415406 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Details)", "role": "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails", "shortName": "Commitments and Contingencies - Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "icb70afe3c5b14fafa7a6d240a7ae5f00_I20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i71b21ad7b35c475ca4a0373b58dee30f_D20180101-20180930", "decimals": "INF", "first": true, "lang": null, "name": "zgnx:SaleOfStockAggregateOfferPrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417407 - Disclosure - Sale of Common Stock (Details)", "role": "http://www.zogenix.com/role/SaleofCommonStockDetails", "shortName": "Sale of Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i71b21ad7b35c475ca4a0373b58dee30f_D20180101-20180930", "decimals": "INF", "first": true, "lang": null, "name": "zgnx:SaleOfStockAggregateOfferPrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i58b5eef0a2c2492784a56b3800d04b87_I20171231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420408 - Disclosure - Stock-Based Compensation - Options Activity (Details)", "role": "http://www.zogenix.com/role/StockBasedCompensationOptionsActivityDetails", "shortName": "Stock-Based Compensation - Options Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i58b5eef0a2c2492784a56b3800d04b87_I20171231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i6e818381e16c454b9a872a483c84e2a0_I20171231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421409 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)", "role": "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails", "shortName": "Stock-Based Compensation - Restricted Stock Unit Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "id3564366fd72402487d8ac94bd8c9692_D20180101-20180930", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i7e8e747ba449457e9f0bc7508a687590_D20180701-20180930", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422410 - Disclosure - Stock-Based Compensation - Assumptions used in Black-Scholes Option-Pricing Model (Detail)", "role": "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail", "shortName": "Stock-Based Compensation - Assumptions used in Black-Scholes Option-Pricing Model (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i7e8e747ba449457e9f0bc7508a687590_D20180701-20180930", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i301bb29c572c4b6fb03c13ee1f7ee9ab_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423411 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)", "role": "http://www.zogenix.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail", "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "contextRef": "ifc8a7cf852e24903985cdfbf61a7d7b2_D20180701-20180930", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i301bb29c572c4b6fb03c13ee1f7ee9ab_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424412 - Disclosure - Stock-Based Compensation - Additional Information (Detail)", "role": "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i2c21af8cafbc4b3380a0daa94915caa6_D20180701-20180930", "decimals": "-5", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i301bb29c572c4b6fb03c13ee1f7ee9ab_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427413 - Disclosure - Net Loss Per Share - Reconciliation of Numerator and Denominators in Computing Net Loss per Share (Details)", "role": "http://www.zogenix.com/role/NetLossPerShareReconciliationofNumeratorandDenominatorsinComputingNetLossperShareDetails", "shortName": "Net Loss Per Share - Reconciliation of Numerator and Denominators in Computing Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i301bb29c572c4b6fb03c13ee1f7ee9ab_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428414 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details)", "role": "http://www.zogenix.com/role/NetLossPerShareAntidilutiveSecuritiesDetails", "shortName": "Net Loss Per Share - Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i301bb29c572c4b6fb03c13ee1f7ee9ab_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i58b5eef0a2c2492784a56b3800d04b87_I20171231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430415 - Disclosure - United Kingdom (U.K.) Research and Development Incentives (Details)", "role": "http://www.zogenix.com/role/UnitedKingdomUKResearchandDevelopmentIncentivesDetails", "shortName": "United Kingdom (U.K.) Research and Development Incentives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i58b5eef0a2c2492784a56b3800d04b87_I20171231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i301bb29c572c4b6fb03c13ee1f7ee9ab_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i301bb29c572c4b6fb03c13ee1f7ee9ab_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i301bb29c572c4b6fb03c13ee1f7ee9ab_D20180701-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "role": "http://www.zogenix.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i301bb29c572c4b6fb03c13ee1f7ee9ab_D20180701-20180930", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Basis of Presentation", "role": "http://www.zogenix.com/role/OrganizationandBasisofPresentation", "shortName": "Organization and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.zogenix.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105103 - Disclosure - Cash, Cash Equivalents and Marketable Securities", "role": "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecurities", "shortName": "Cash, Cash Equivalents and Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "iee5a02bbebad49aba55ae03b858c920d_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 32, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.zogenix.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.zogenix.com/role/DocumentandEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.zogenix.com/role/DocumentandEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.zogenix.com/role/DocumentandEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.zogenix.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.zogenix.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.zogenix.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.zogenix.com/role/DocumentandEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.zogenix.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.zogenix.com/role/DocumentandEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.zogenix.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.zogenix.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.zogenix.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r39", "r75" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r67" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Net accretion and amortization of investments in marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r40", "r41", "r42" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r21" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r135", "r142" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Underwriting discounts and commissions and other offering expenses" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SaleofCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r154", "r174", "r178" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.zogenix.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r66", "r209" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt issuance costs and debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r82" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive securities excluded from computation of earnings per share amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r82" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r82" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r66", "r121" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Asset impairment charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r97", "r221", "r232" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r12", "r38" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r106" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Marketable securities, gross unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r107" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Marketable securities, gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r104" ], "calculation": { "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "terseLabel": "Marketable securities, amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]", "terseLabel": "Fair\u00a0Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost", "terseLabel": "Due within one year, amortized cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value", "terseLabel": "Due within one year, estimated fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": { "auth_ref": [ "r108", "r109", "r229" ], "calculation": { "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value", "totalLabel": "Marketable securities, estimated fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": { "auth_ref": [ "r108", "r109", "r229" ], "calculation": { "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost", "totalLabel": "Marketable securities, amortized cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r101", "r105" ], "calculation": { "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "zgnx_CashCashEquivalentsAndShorttermInvestmentsFairValue", "weight": 1.0 }, "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "zgnx_CashEquivalentsAndDebtSecuritiesAvailableforsale", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Marketable securities, estimated fair value", "verboseLabel": "Short-term fixed income securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails", "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r103" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r155", "r175" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail", "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Certificate of deposits" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails", "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r185", "r186" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r65", "r192" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r191" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Potential contingent consideration payment, maximum" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "auth_ref": [ "r191" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "terseLabel": "Potential contingent consideration payment, minimum" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r187", "r188", "r190" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Total contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r187", "r189" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Current portion of contingent consideration", "verboseLabel": "Fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r187", "r189" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration, net of current portion" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r27" ], "calculation": { "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r27", "r68" ], "calculation": { "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0 }, "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents, end of the period", "periodStartLabel": "Cash and cash equivalents, beginning of the period", "terseLabel": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails", "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "zgnx_CashEquivalentsAndDebtSecuritiesAvailableforsale", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]", "terseLabel": "Cash and Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r16", "r69", "r73", "r98" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash Equivalents and Marketable Securities" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r27" ], "calculation": { "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "totalLabel": "Total cash, cash equivalents and marketable securities" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": { "auth_ref": [ "r99", "r110" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.", "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]", "terseLabel": "Cash, Cash Equivalents, and Marketable Securities" } } }, "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r27" ], "calculation": { "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SaleofCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails", "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r34", "r126", "r224", "r236" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r125", "r127" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SaleofCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value (usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock issued (shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r20", "r135" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock outstanding (shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 50,000 shares authorized; 35,827 and 34,808 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r44", "r46", "r47" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r88", "r230" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r149", "r151" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails", "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r51" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of contract manufacturing" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of contract manufacturing" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r182", "r183" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r66", "r95" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r198" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Change in fair value of common stock warrant liabilities" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r143", "r179" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareBasicAndDiluted", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation, when the per share amount is the same.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic and Diluted Share", "terseLabel": "Discontinued operations (in dollars per share)" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Net loss per share, basic and diluted:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r80" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "totalLabel": "Total (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r73", "r82", "r83", "r84" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/NetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SaleofCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r66", "r131" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Change in fair value of common stock warrant liabilities" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r199", "r200", "r201", "r202", "r205", "r206" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r199", "r200", "r201" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Assets Measured at Fair Value on Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r203", "r206" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueUsingSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r203", "r206" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueUsingSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r200", "r206" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r149", "r150", "r151", "r201", "r216" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.zogenix.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueUsingSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r204", "r206" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.zogenix.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueUsingSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r149", "r150", "r151", "r201", "r217" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r149", "r150", "r151", "r201", "r218" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r149", "r150", "r151", "r201", "r219" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.zogenix.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueUsingSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r199", "r200", "r201" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Liabilities Measured at Fair Value on Recurring Basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r203", "r206" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.zogenix.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueUsingSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r203", "r206" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)", "verboseLabel": "Changes in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueUsingSignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r203" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueUsingSignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.zogenix.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueUsingSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnContractTermination": { "auth_ref": [ "r67", "r124" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.", "label": "Gain (Loss) on Contract Termination", "negatedLabel": "Loss on contract termination" } } }, "localname": "GainLossOnContractTermination", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r66", "r129", "r130" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of debt", "terseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r116", "r117" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r66", "r120" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "verboseLabel": "Asset impairment charges" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r50", "r67", "r81", "r193" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net loss from continuing operations", "totalLabel": "Net loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.zogenix.com/role/NetLossPerShareReconciliationofNumeratorandDenominatorsinComputingNetLossperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r77" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Loss from continuing operations before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareBasicAndDiluted", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share", "terseLabel": "Continuing operations (in dollars per share)", "verboseLabel": "Net loss from continuing operations per share, basic and diluted (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.zogenix.com/role/NetLossPerShareReconciliationofNumeratorandDenominatorsinComputingNetLossperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r5", "r6", "r194" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "terseLabel": "Loss from discontinued operations, net of taxes" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r74", "r96", "r184" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReceivable": { "auth_ref": [ "r26", "r231" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.", "label": "Income Taxes Receivable", "terseLabel": "Claim for refundable cash credit" } } }, "localname": "IncomeTaxReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/UnitedKingdomUKResearchandDevelopmentIncentivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r65" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r65" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r65" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r65" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r65" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r65" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r118", "r119" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r48", "r94", "r208", "r209", "r227" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeDomesticDeposits": { "auth_ref": [ "r226" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Interest earned on deposits in United States money market accounts and other United States interest earning accounts.", "label": "Interest Income, Domestic Deposits", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeDomesticDeposits", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r52", "r112", "r113", "r114" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Inventory write-down" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Cost and Fair Value of Marketable Securities" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Length of each lease renewal" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of new lease" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r30" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r222", "r234" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r200" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "verboseLabel": "Liabilities measured at fair value on a recurring basis" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds", "verboseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails", "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r62" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r62" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r62", "r64", "r67" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r43", "r45", "r49", "r67", "r83", "r225", "r237" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.zogenix.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.zogenix.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Noncash financing activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r54" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NotesReduction": { "auth_ref": [ "r70", "r71", "r72" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.", "label": "Notes Reduction", "terseLabel": "Extinguishment of Endo working capital advance note payable through net settlement of balances owed to the Company" } } }, "localname": "NotesReduction", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r210", "r211" ], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total gross lease payment due" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals": { "auth_ref": [ "r212" ], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contractually required future rental payments receivable on noncancelable subleasing arrangements.", "label": "Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals", "negatedTotalLabel": "Total sublease income" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r210", "r211" ], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2022 gross lease payment due" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r210", "r211" ], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2021 gross lease payment due" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r210", "r211" ], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2020 gross lease payment due" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r210", "r211" ], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2019 gross lease payment due" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Remainder of Fiscal Year", "terseLabel": "2018 (remaining 6 months) gross lease payment due" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r7", "r197" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/OrganizationandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r15", "r31" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r194", "r195", "r196" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Change in unrealized losses on marketable securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r148", "r180" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "United Kingdom (U.K.) Research and Development Incentives" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/UnitedKingdomUKResearchandDevelopmentIncentives" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r55" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Payments for Rent", "terseLabel": "Expected payment for rent" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r61", "r152" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.", "label": "Payments Related to Tax Withholding for Share-based Compensation", "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r57", "r58", "r102" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r59" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares or units awarded to employees for meeting certain performance targets.", "label": "Performance Shares [Member]", "terseLabel": "Performance stock options" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par value (usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock authorized (shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock issued (shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock outstanding (shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r19" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r9", "r11", "r115" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r60" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock under an at-the-market offering, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r60", "r176" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based compensation arrangement. Issuance includes, but is not limited to, exercise of stock options and similar instruments.", "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options", "terseLabel": "Proceeds from issuance of common stock under equity incentive plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r18", "r122", "r235" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r181", "r238" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units", "verboseLabel": "Shares subject to outstanding restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/NetLossPerShareAntidilutiveSecuritiesDetails", "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r142", "r233" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zogenix.com/role/OrganizationandBasisofPresentationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r145", "r146", "r147" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Contract manufacturing revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The reporting scenario used to indicate financial results forecast for a future period.", "label": "Scenario, Forecast [Member]", "terseLabel": "Expected" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r82" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]", "terseLabel": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Amortized Cost and Fair Value of Cash, Cash Equivalents and Marketable Securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r83" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Basic and Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r154", "r173", "r178" ], "lang": { "en-US": { "role": { "documentation": "Schedule that sets forth the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r154", "r173", "r178" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Minimum Payments Under Non-cancelable Operating Leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r155", "r175" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail", "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock Unit Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r158", "r168", "r169" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Assumptions used in the Black-Scholes Option-Pricing Model" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r35", "r76", "r132", "r133", "r134", "r136", "r137", "r138", "r139", "r140", "r141", "r142" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SaleofCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r53", "r111" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r56" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r65" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Canceled - Weighted average fair value per share at grant date (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted - Weighted average fair value per share at grant date (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at March 31, 2018 (in shares)", "periodStartLabel": "Outstanding at December 31, 2017 (in shares)", "terseLabel": "Outstanding RSUs at March 31, 2018 (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested at March 31, 2018 - Weighted average fair value per share at grant date (in usd per share)", "periodStartLabel": "Nonvested at December 31, 2017 - Weighted average fair value per share at grant date (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r166" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r166" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested - Weighted average fair value per share at grant date (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail", "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Canceled weighted average exercise price (in usd per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r160", "r175" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "March 31, 2018 (in shares)", "periodStartLabel": "December 31, 2017 (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Shares (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding weighted average exercise price, ending balance (in usd per share", "periodStartLabel": "Outstanding weighted average exercise price, beginning balance (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- Average Exercise Price per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r153", "r156" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail", "http://www.zogenix.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised weighted average exercise price (in usd per share" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted weighted average exercise price (in usd per share" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r73", "r155", "r157" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r171", "r177" ], "lang": { "en-US": { "role": { "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAssumptionsusedinBlackScholesOptionPricingModelDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r36", "r135" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SaleofCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statements of Comprehensive Income (Loss)" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r19", "r20", "r135", "r142" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SaleofCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r19", "r20", "r135", "r142", "r161" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r19", "r20", "r135", "r142" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Proceeds from stock issuance" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SaleofCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "verboseLabel": "Shares subject to outstanding common stock options" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r23", "r24", "r100" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Sale of Common Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SaleofCommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r149", "r151", "r223" ], "lang": { "en-US": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasuries" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails", "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r86", "r87", "r89", "r90", "r91", "r92", "r93" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "verboseLabel": "Shares subject to outstanding warrants to purchase common stock" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [ "r78" ], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Common stock warrant liabilities" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average common shares used in the calculation of basic and diluted net loss per common share (shares)", "verboseLabel": "Shares used in per share calculation (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.zogenix.com/role/NetLossPerShareReconciliationofNumeratorandDenominatorsinComputingNetLossperShareDetails" ], "xbrltype": "sharesItemType" }, "zgnx_AccruedClinicalExpenseCurrent": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "label": "AccruedClinicalExpenseCurrent", "terseLabel": "Accrued clinical trial expenses" } } }, "localname": "AccruedClinicalExpenseCurrent", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "zgnx_AggregateNumberOfCommonStockSharesExercisableFromWarrantsIssued": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "AggregateNumberOfCommonStockSharesExercisableFromWarrantsIssued", "terseLabel": "Shares of common stock exercisable through warrants" } } }, "localname": "AggregateNumberOfCommonStockSharesExercisableFromWarrantsIssued", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "sharesItemType" }, "zgnx_CashCashEquivalentsAndShorttermInvestmentsFairValue": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "", "label": "Cash, Cash Equivalents, and Short-term Investments, Fair Value", "totalLabel": "Total cash, cash equivalents and marketable securities" } } }, "localname": "CashCashEquivalentsAndShorttermInvestmentsFairValue", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_CashEquivalentsAndDebtSecuritiesAvailableforsale": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "", "label": "Cash Equivalents and Debt Securities, Available-for-sale", "totalLabel": "Total assets" } } }, "localname": "CashEquivalentsAndDebtSecuritiesAvailableforsale", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_CommonStockWarrantExercisePricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CommonStockWarrantExercisePricePerShare", "terseLabel": "Warrants exercise price per share (usd per share)" } } }, "localname": "CommonStockWarrantExercisePricePerShare", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "perShareItemType" }, "zgnx_CommonStockWarrantLiabilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CommonStockWarrantLiability [Member]", "terseLabel": "Common stock warrant liabilities" } } }, "localname": "CommonStockWarrantLiabilityMember", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.zogenix.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueUsingSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "zgnx_ContingentPurchaseConsiderationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "ContingentPurchaseConsideration [Member]", "verboseLabel": "Contingent consideration liabilities" } } }, "localname": "ContingentPurchaseConsiderationMember", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.zogenix.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueUsingSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "zgnx_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYearsAmortizedCost": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through second fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Two Years, Amortized Cost", "terseLabel": "Due between one and two years, amortized cost" } } }, "localname": "DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYearsAmortizedCost", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYearsFairValue": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through second fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Two Years, Fair Value", "terseLabel": "Due between one and two years, estimated fair value" } } }, "localname": "DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYearsFairValue", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CashCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and Entity Information [Abstract]", "label": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.zogenix.com/20180930", "xbrltype": "stringItemType" }, "zgnx_EmployeesandExecutivesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "EmployeesandExecutives [Member]", "terseLabel": "Employees and Executives" } } }, "localname": "EmployeesandExecutivesMember", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "zgnx_LesseeOperatingLeaseNumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Number of Renewal Options", "label": "Lessee, Operating Lease, Number of Renewal Options", "terseLabel": "Number of lease renewal options" } } }, "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "zgnx_NonemployeeDirectorMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NonemployeeDirector [Member]", "terseLabel": "Non-employee Director" } } }, "localname": "NonemployeeDirectorMember", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "zgnx_NumberofNoncancelableLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NumberofNoncancelableLeases", "terseLabel": "Number of Noncancelable Leases" } } }, "localname": "NumberofNoncancelableLeases", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "zgnx_OperatingLeasesFutureMinimumPaymentsDueNet": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "label": "OperatingLeasesFutureMinimumPaymentsDueNet", "totalLabel": "Total net lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueNet", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_OperatingLeasesFutureMinimumPaymentsDueNetRemainderofFiscalYear": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "zgnx_OperatingLeasesFutureMinimumPaymentsDueNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "label": "OperatingLeasesFutureMinimumPaymentsDueNetRemainderofFiscalYear", "terseLabel": "2018 (remaining 6 months) net lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueNetRemainderofFiscalYear", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_OperatingLeasesFutureMinimumPaymentsNetDueinFiveYears": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "zgnx_OperatingLeasesFutureMinimumPaymentsDueNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "label": "OperatingLeasesFutureMinimumPaymentsNetDueinFiveYears", "terseLabel": "2022 net lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsNetDueinFiveYears", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_OperatingLeasesFutureMinimumPaymentsNetDueinFourYears": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "zgnx_OperatingLeasesFutureMinimumPaymentsDueNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "label": "OperatingLeasesFutureMinimumPaymentsNetDueinFourYears", "terseLabel": "2021 net lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsNetDueinFourYears", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_OperatingLeasesFutureMinimumPaymentsNetDueinThreeYears": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "zgnx_OperatingLeasesFutureMinimumPaymentsDueNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "label": "OperatingLeasesFutureMinimumPaymentsNetDueinThreeYears", "terseLabel": "2020 net lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsNetDueinThreeYears", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_OperatingLeasesFutureMinimumPaymentsNetDueinTwoYears": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "zgnx_OperatingLeasesFutureMinimumPaymentsDueNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "label": "OperatingLeasesFutureMinimumPaymentsNetDueinTwoYears", "terseLabel": "2019 net lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsNetDueinTwoYears", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_OperatingLeasesFutureMinimumSubleaseIncomeDueinFiveYears": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "label": "OperatingLeasesFutureMinimumSubleaseIncomeDueinFiveYears", "negatedTerseLabel": "2022 sublease income" } } }, "localname": "OperatingLeasesFutureMinimumSubleaseIncomeDueinFiveYears", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_OperatingLeasesFutureMinimumSubleaseIncomeDueinFourYears": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "label": "OperatingLeasesFutureMinimumSubleaseIncomeDueinFourYears", "negatedTerseLabel": "2021 sublease income" } } }, "localname": "OperatingLeasesFutureMinimumSubleaseIncomeDueinFourYears", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_OperatingLeasesFutureMinimumSubleaseIncomeDueinThreeYears": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "label": "OperatingLeasesFutureMinimumSubleaseIncomeDueinThreeYears", "negatedTerseLabel": "2020 sublease income" } } }, "localname": "OperatingLeasesFutureMinimumSubleaseIncomeDueinThreeYears", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_OperatingLeasesFutureMinimumSubleaseIncomeDueinTwoYears": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "label": "OperatingLeasesFutureMinimumSubleaseIncomeDueinTwoYears", "negatedTerseLabel": "2019 sublease income" } } }, "localname": "OperatingLeasesFutureMinimumSubleaseIncomeDueinTwoYears", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_OperatingLeasesFutureMinimumSubleaseIncomeRemainderofFiscalYear": { "auth_ref": [], "calculation": { "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "label": "OperatingLeasesFutureMinimumSubleaseIncomeRemainderofFiscalYear", "negatedTerseLabel": "2018 (remaining 6 months) sublease income" } } }, "localname": "OperatingLeasesFutureMinimumSubleaseIncomeRemainderofFiscalYear", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_SaleOfStockAggregateOfferPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sale of Stock, Aggregate Offer Price", "label": "Sale of Stock, Aggregate Offer Price", "terseLabel": "Aggregate offering price" } } }, "localname": "SaleOfStockAggregateOfferPrice", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/SaleofCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "zgnx_SaleOfStockCommissionPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of Stock, Commission, Percent", "label": "Sale of Stock, Commission, Percent", "terseLabel": "Commission rate (percent)" } } }, "localname": "SaleOfStockCommissionPercent", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/SaleofCommonStockDetails" ], "xbrltype": "percentItemType" }, "zgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCanceledPercentageOfSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Canceled, Percentage of Shares Outstanding", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Canceled, Percentage of Shares Outstanding", "terseLabel": "Percentage of outstanding options that were canceled (percent)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCanceledPercentageOfSharesOutstanding", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "zgnx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPercentageOfSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Percentage of Shares Outstanding", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Percentage of Shares Outstanding", "terseLabel": "Percentage of outstanding options that vested (percent)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedPercentageOfSharesOutstanding", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "zgnx_SharebasedCompensationArrangementbySharebasedPaymentAwardAdditionalNumberofSharesAvailableforGrantAnnually": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SharebasedCompensationArrangementbySharebasedPaymentAwardAdditionalNumberofSharesAvailableforGrantAnnually", "terseLabel": "Additional number of options available for grant annually (shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAdditionalNumberofSharesAvailableforGrantAnnually", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "zgnx_SharebasedCompensationArrangementbySharebasedPaymentAwardInitialNumberofSharesGranted": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SharebasedCompensationArrangementbySharebasedPaymentAwardInitialNumberofSharesGranted", "terseLabel": "Number of options granted upon initial election to board (shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardInitialNumberofSharesGranted", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "zgnx_ZX008Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "ZX008 [Member]", "terseLabel": "ZX008" } } }, "localname": "ZX008Member", "nsuri": "http://www.zogenix.com/20180930", "presentation": [ "http://www.zogenix.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=SL66093879-108312" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=SL66093883-108312" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4542-108314" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=114001942&loc=d3e12317-112629" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=114001942&loc=d3e12355-112629" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208855" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "19A", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=107668666&loc=SL79513924-113897" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r239": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r7": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "305", "URI": "http://asc.fasb.org/topic&trid=2122426" } }, "version": "2.0" } ZIP 56 0001375151-18-000085-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001375151-18-000085-xbrl.zip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end